Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
ACYL AND SULFONYL DERIVATIVES OF 6 9-DISUBSTITUTED 2-
(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS
ANTIPROLIFERATIVE AGENTS
The present invention relates to acyl and sulfonyl derivatives of 6,9-
disubstituted 2-
(trans-1,4-diaminocyclohexyl)-purines and methods of using the same as
antiproliferative
agents or to prevent apoptosis.
Background
Cell division, in both normal and neoplastic cells, is a tightly controlled
event which
occurs by defined stages. Quiescent cells which are not actively dividing, are
in the Go phase,
as are those terminally differentiated or in a state of temporary arrest. The
first phase is the
first gap (Gl) phase during which the cell prepares to synthesize DNA. In late
Gl phase at
what is termed a restriction point or R point, the cell commits to entering S
phase during
which DNA synthesis occurs. Upon completion of S phase, the cell enters the
second gap (G2)
phase during which the cell prepares to divide, which is followed by mitosis,
or M phase.
Initial experiments in cell cycle regulation revealed the existence of a
protein called
"Maturation Promoting Factor" (MPF), a heterodimer with kinase activity.
Later, comparison
of subsequently identified proteins and their underlying genes revealed a
family of yeast genes
known as cell division control (cdc) genes are identified. Further experiments
demonstrated
that some of the cdc genes encode kinases, and are later called cyclin-
dependent kinases
(cdks). As the result of this reclassification, some cell cycle proteins have
dual designations,
such as cdkl which is also known as cdc2. The kinase component of the MPF is
now
identified as p34odoz and the regulatory subunit of MPF is now called cyclin
B. Cyclins are
first identified as proteins whose levels oscillated during the cell cycle and
are specifically
degraded at mitosis. To date, animal cyclins A-I and cdks 1-8 have been
identified. .To.further
complicate nomenclature, subtypes of cyclins and cdks have been identified,
such as cyclins
B1 and B2. (For a review on cdks, see D.O. Morgan, Annu. Rev. Cell Dev. Biol.
13, 261-291,
1997).
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
2
Subsequent research on cell regulation has demonstrated that the stages of
cellular
division are achieved in part by modulation cyclins and cyclin-dependent
kinases (cdks).
Cyclins sequentially regulate cdks and are characterized by a 100 amino acid
homology region
termed the "cyclin box" which is involved in binding a protein kinase partner.
Cdks are
closely related in sequence and size (35-40 kDa) and are defined as protein
kinases activated
by bound cyclin regulatory subunits. Cdks contain a conserved active-site
cleft of
approximately 300 amino acids that is characteristic of all eukaryotic protein
kinases. Thus,
both the cyclins and cdks appear to be highly conserved protein families.
Isolation of individual cyclins and cdks has enabled further identification of
the roles
and interactions of each component in cell cycle phase transitions. Excess
levels of cdks
persist throughout the cell cycle. Activation of cdks occurs upon cyclin
synthesis and binding
to the catalytic cdk subunit, the result of which is stimulation of the cdk
serine/threonine
kinase activity. Complete cdk activation requires phosphorylation on a
conserved threonine
residue located in the T-loop by a cyclin-dependent kinase activating kinase
(CAK).
Since their initial discover, cyclins and cdks also interact with other
transcription
factors and proteins involved in a broad range of cellular pathways. Cdk7 has
been identified
as a component in transcription factor IIH (TFIIH), which contains the RNA
polymerase II C-
terminal domain (CTD) kinase activity. More recently, cdk8, which partners
with cyclin C,
has also been discovered to phosphorylate the CTD of RNA polymerase II, but
does not
appear to possess CAK activity. Thus, it is clear that cdks participate in a
broad range of
cellular functions in addition to cell cycle regulation.
Inactivation of the cdk-cyclin complex can result from the phosphorylation of
a
threonine and/or tyrosine residue in the ATP-binding site of the cdk or from
binding of one of
a number of endogenous inhibitor proteins.
In Gl phase, D-type cyclins bind to several different cdks, including cdk2,
cdk4, cdk5
and cdk6, but are most commonly associated with cdk4 and cdk6. D-type cyclins
are thought
to act as growth factor sensors, which link cell cycle progression to external
cues. Cyclin E-
cdk2 complexes appear in the mammalian cell cycle after the D-type cyclin-cdk
complexes.
Cyclin E synthesis is tightly regulated and occurs in late Gl and early S
phase. The cyclin E-
cdk2 complex is essential for the cell to begin DNA replication.
The Gl cyclins, cyclin-D and cyclin-E, are transiently produced proteins, with
a half-
life of about 20 minutes. The short half-life is thought to result from a PEST
sequence in the
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
3
C-terminal regions of these proteins, the degradation of which appears to be
mediated by the
ubiquitination pathway.
The G2 cyclins, cyclin-A and cyclin-B, are stable throughout interphase and
specifically destroyed at mitosis through an ubiquitination pathway. Both
cyclin A and cyclin
B2 appear to be degraded only when complexed with their cdk partner [cyclinA-
cdk2 and
cyclin A/B-cdkl (cdc2)]. However, cyclin B 1 destruction is connected with the
integrity of
the mitotic apparatus at the end of metaphase. If the spindle is incorrectly
assembled, or
chromosomes incorrectly aligned, then cyclin B1 destruction is prevented.
Retinoblastoma protein (Rb), a 105 kDa nuclear phosphoprotein, is a substrate
of
cyclin-cdk complexes of cdks-2, -4 and -6 in Gl phase and functions as one of
the major
checkpoint controls in the cell cycle via carefully orchestrated
phosphorylation and
dephosphorylation. In Go/Gl, Rb exists in a hypophosphorylated state. As the
cell progresses
into late Gl, Rb becomes hyperphosphorylated by D-cyclin complexes, which
inactivates Rb
and drives the cell into S phase resulting in cell cycle progression and cell
division. This state
of hyperphosphorylation of Rb remains in G2. During late M phase, Rb is
dephosphorylated,
thus returning to the hypophosphorylated state. A high cellular level of p 16
results in
inactivation of cdk4 because p16 binds cyclinD/cdk4 and cyclin D/cdk6
complexes.
Phosphorylation of the Rb protein alters its binding characteristics; in the
hypophosphorylated
state, Rb binds to and sequesters specific transcription factors, such as E2F,
the binding of
which prevents the exit from the Gl phase. Once cdks hyperphosphorylate Rb,
the
transcription factors are released which can then activate transcription of
genes necessary for
S phase progression, for example, thymdine kinase, myc, myb, dihydrofolate
reductase, and
DNA polymerase-a.
Localization of cyclin-CDK complexes is also very suggestive about the role
each
complex plays in the pathway. Nuclear cyclins A and E bind to p107 and p130,
possibly
because they are in the nucleus. Mammalian cyclin B 1 accumulates in the
cytoplasm in G2
phase and translocates into the nucleus at the beginning of mitosis. Cyclin B
associates with
the spindle apparatus, in particular with the spindle caps, and it is thought
that the cyclin B-
cdc2 kinase may be involved in the formation of the spindle through
phosphorylating
components of the mitotic apparatus. In addition, cyclin Bl is part of a
feedback mechanism
ensuring correct assembly of the metaphase mitotic apparatus. Human cyclin B2
is almost
exclusively associated with the membrane compartment, and in particular the
Golgi apparatus.
Cyclin B2-cdc2 is involved in the disassembly of the Golgi apparatus when
cells enter mitosis.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
4
The p34 doz/cyclin B kinase is a key mitotic factor that is highly conserved
and is
thought to be involved in cell cycle transitions in all eukaryotic cells.
Histone Hl is a substrate
for p34 d 2/cyclin B; histone H1 is selectively phosphorylated on specific
sites in mitosis,
which is thought to be important for chromatin condensation. p34 a 2 /cyclin B
complex also
phosphorylates lamin, which is responsible for nuclear lamina breakdown.
Nuclear lamina is
made up of a polymer of lamin subsunits that are hyperphosphorylated at
mitosis, and this
phosphorylation is responsible for their disassembly. Lamins are part of the
intermediate
filament family of proteins, and p34cdc2/cyclin B phosphorylates a subset of
the sites
phosphorylated at mitosis on the cytoplasmic intermediate filament subunits,
vimentin and
desmin. Thus, p34odc2/cyclin B complex is involved in the re-organization of
the cell
architecture at mitosis.
In addition, p34cd2/cyclin B is involved in the re-organization of
microfilaments,
through phosphorylation of non-muscle caldesmon, an 83 kDa protein that binds
to actin and
calmodulin, and inhibits actomyosin ATPase activity. At mitosis, caldesmon is
phosphorylated by p34 d 2/cyclin B, which weakens its affinity for actin and
causes it to
dissociate from microfilaments.
p34cdo2/cyclin B is implicated in actomyosin filament regulation, by
phosphorylating
the myosin in the contractile ring, which divides the cell into two
(cytokinesis). In metaphase,
the myosin II regulatory light chain (MLC) is phosphorylated on two main sites
at the N-
terminus. Once phosphorylated, the myosin is prevented from interacting with
actin. At
anaphase, these two sites are dephosphorylated.
The p34doz/cyclin B kinase also plays a role in reorganization of the membrane
compartment at mitosis. For example, p34odo2/cyclin B phosphorylates rablAp
and rab4p.
When rab4p is phosphorylated by p34odc2/cyclin B, it dissociates from the
membrane
compartment.
At mitosis, most forms of transcription are inhibited. Again, p34odo2/cyclin B
plays a
role by inhibiting pol III-mediated transcription by phosphorylating TFIIIB.
Given that pol I,
pol II and pol III-mediated transcription share several common factors, such
as TATA-binding
protein (TBA), it is likely that p34dc2 /cyclin B is involved in down-
regulating all forms of
transcription at mitosis.
Given the importance of cyclin/cdk complexes in triggering cell cycle
division, they
are under tight feedback mechanisms. CDK-inhibitor proteins (CDIs) are small
proteins that
bind and inactivate specific cyclin-CDK complexes, or monomeric CDKs. These
inhibitors
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
can be grouped into two families based on sequence and functional
similarities. The INK4
family includes p15'Nx4s, p16", p18 and p19 that specifically bind cdk4 and
cdk6. Both
p16'NK4 and p15INK4B contain four ankyrin repeats and, in addition to sharing
significant
homology, are encoded by adjacent genes on the 9p121ocus.
5 The gene for p 16rNK4 (MTS 1) is recognized as a potential tumor suppressor
gene, as it
is rearranged, deleted or mutated in a large number of tumor cell lines, and
in some primary
tumors. In one study of hereditary melanoma, about half the families had
germline mutations
in the p161NK4 gene. Rb is a repressor of p161NK4. Inactivation of cellular
Rb, either by
mutation or viral antigens, correlates with increased levels of p16INK4.
p16M4, p15INK4B
and p 18 inhibit binding of cyclin D and cdk4 and cdk6 complexes to bind to
the Rb protein.
The second family of CDIs is the Kip/Cip family that includes p21c;pi,w.aF-i,
p27K'pi
and p57K'p2. P27'P1 is present in proliferating cells in a latent or masked
form. Upon
stimulation, p27K1P1 is unmasked binds to and inhibits cyclin-CDK4/6
complexes. The
Kip/Cip family proteins have strong homology in the N-terminus, the region
that binds the
cyclin-cdk complexes. The Kip/Cip family proteins preferentially bind to and
inhibit cyclin-
cdk complexes involved in the Gl and S phase complexes over those involved in
the M phase.
p21 (also known as WAF1, Cipl and Sdil) is induced by p53 and forms a ternary
complex with proliferating cell nuclear antigen (PCNA), a subunit of DNA
polymerase S in
several cyclin-CDK2 complexes, including cyclins A, DI and E. p21WAF-1
expression in
growing, quiescent and senescent cells correlates with a role as a negative
regulator of S phase
entry. p21wAF-1 mRNA is upregulated as cells become senescent or quiescent,
and after
serum stimulation of quiescent cells, and decreases as cells enter S phase.
P21 inactivates
cyclin E-cdk2, cyclin-A-cdk2, and cyclins D1-, D2- and D3 cdk4 complexes.
Genetic analysis of numerous human tumors reveals a disproportionate number of
altered cell cycle proteins, and it is this aberration that is thought to
cause abnormal cell cycle.
For example, cyclin Dl is the bcl-1/PRAD1 proto-oncogene that is either
overexpressed or
deregulated in a variety of human tumors. The cyclin D1/CCND1 gene, located at
chromosome 11q13, is amplified in a number of cancers, mainly breast and non-
small cell
lung carcinomas. This correlates with the observation that overexpression of
cyclin Dl is a
common feature in the tumors with this specific 11q13 amplicon. The gene for
p16 is
rearranged, deleted or mutated in a large number of tumor cell lines, and in
some primary
tumors. Mutations in cdk4, specifically an Arg24Cys mutation, have been
identified in two
unrelated hereditary melanoma families. This mutation was found in 11/11 of
the melanoma
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
6
patients, 2/17 unaffecteds and 0/5 spouses. Zuo, L., et al., Nature Genetics
12(1996):97-99.
This mutation has a specific effect on the p161Nx4a binding domain of cdk4,
but has no affect
on the ability to bind to cyclin D and form a functional kinase. As a result
of this mutation,
the resulting cyclin D/cdk4 complex is resistant to normal physiological
inhibition by
p 16INx4a Other studies have demonstrated that about half the familial
melanoma kindreds
show evidence of linkage to the region of chromosome 9p2l that contains the p
16INK4a gene.
The types of p 161NK4a mutations identified include a nonsense mutation,
splice donor mutation,
an unidentified mutation that prevents p 161NK4a transcription, and 3 missense
mutants that are
unable to bind to cdk4 or cdk6. Overexpression of cdk4 as result of gene
amplification has
been identified in a study of 32 glioma cell lines. He, J., et al., Cancer
Res. 54, 5804-5807
(1994). This alteration was observed among the ten cases having intact p16
genes. Genetic
analysis of glioma cell lines revealed that 24 of 32 glioma cell lines had one
of two alternative
genetic alterations, each of which indicates that increased cdk4 kinase
activity is important to
glial tumor development. Cdk4 maps to the long ann of chromosome 12 and is
found
overexpressed in certain tumors because of its amplification as a component of
an amplicon
that includes other relevant genes, such as SAS and MDM2. All of the above
conditions lead
to activation of cdk4. Overexpression of cyclins B 1 and E in leukemic and
solid tumor cell
lines, as well as altered patterns of cyclin E expression in breast cancer has
also been reported.
Cellular hyperproliferation occurs in a number of disease states. The most
common
hyperproliferative diseases are neoplasms, which are typically named according
to the original
source of the hyperproliferative tissue. Neoplasms are defined as new growths
of animal or
plant tissue that resemble more or less the tissue from which it arises, but
serve no physiologic
function, and are benign, potentially malignant or malignant in character.
Neoplasms arise as
the result of loss of normal controls, leading to unregulated growth.
Neoplastic cells may lack
differentiation and acquire the ability to invade local tissues, that is
metastasize. Neoplasms
may develop in any type of tissue of any organ at any age. The incidence, and
mortality rate,
of neoplasms generally increases with age, with certain neoplasms having peak
incidence
between the ages of 60 and 80 (e.g. prostate, stomach and colon). However,
other neoplasms
have a peak incidence from birth to 10 years of age (e.g. acute lymphoblastic
leukemia). Diet,
exposure to carcinogens, particularly use of tobacco, and familial
predisposition also affect
incidence of particular neoplasms.
Neoplastic cells differ from normal cells in a number of important aspects,
including
loss of differentiation, increased invasiveness and decreased drug
sensitivity. Another
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
7
iniportant difference is the unchecked growth of cells, which is thought to
result from loss of
normal cellular control mechanisms of these cells are either deactivated,
bypassed or
otherwise disregarded, leaving the neoplastic cells to proliferate without
regard to the normal
controlling mechanisms.
Neoplasm is an abnormal mass of tissue, the growth of which exceeds and is
uncoordinated
with that of the normal tissue, and persists in the same excessive manner
after cessation of the
stimuli that evoked the change.
Neoplasms are classified as either benign or malignant. Benign neoplasms
exhibit
slow, localized growth that is usually circumscribed due to their
encapsulation by a fibrous
connective tissue capsule. Whereas benign neoplasms rarely cause the death of
the organism,
untreated malignant neoplasms have a high probability of killing the organism.
Malignant
neoplasms are generally nonencapsulated, and usually exhibit more rapid growth
rate.
Malignant neoplasms often invade surrounding tissues and vessels and spread to
distant body
sites. Malignant neoplasms are generically described as "cancer" or as
"tumors", the later term
which denotes swelling.
Myeloproliferative disorders are a group of disorders characterized by
abnormal
proliferation by one or more hematopoietic cell lines or connective tissue
elements. Four
disorders are normally included as myeloproliferative disorders: polycythemia
vera (primary
polycythemia; Vaquez' Disease), myelofibrosis (agnogenic myeloid metaplasia),
chronic
myelogenous leukemia and primary (essential) thrombocythemia. Acute leukemia,
especially
erythroleukemia, and paroxysmal noctemal hemoglobinuria are also classified as
myeloproliferative disorders. Each of these disorders is identified according
to its predominaint
feature or site of proliferation. Although each results from proliferation of
different cells,
each has been shown to be caused by a clonal proliferation arising at the
level of a pluripotent
stem cell, which causes varying degrees of abnormal proliferation of
erythroid, myeloid, and
megakaryocytic precursors in the bone marrow. All myeloproliferative disorders
have a
tendency to terminate in acute leukemia.
Leukemias are malignant neoplasms of the blood-forming tissues. At least two
viruses
are associated with causing leukemias in humans, the Epstein-Barr virus is
associated with
Burkitt's lymphoma and the human T-cell lymphotropic virus, also called human
acute
leukemia/lymphoma virus (HTLV-1) has been linked to some T cell leukemias and
lymphomas. Exposure, especially prolonged exposure to chemical agents, such as
benzene
and some antineoplastics, or to ionizing radiation, genetic predisposition
(e.g. Down's
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
8
syndrome) and some familial disorders (e.g. Fanconi's anemia) result in
predispositions to
leukemias.
Development of leukemias appears to occur through a single cell cycle through
two or
more steps with subsequent proliferation and clonal expansion. Leukemias are
currently
classified according to their cellular maturity; acute leukemias are
predominantly
undifferentiated cell populations and chronic leukemias are more mature cell
forms. Acute
leukemias are further divided into lymphoblastic (ALL, also known as acute
lymphocytic
leukemia) and myeloid (AML, also known as acute myelocytic, myelogenous,
myeloblastic,
myelomonoblastic) types. They may be further classified by morphologic and
cytochemical
appearance according to the French-American-British (FAB) classification or
according to
type and degree of differentiation. Chronic leukemias are classified as either
lymphocytic
(CLL) or myelocytic (CML). CLL is characterized by the appearance of mature
lymphocytes
in the blood, bone marrow and lymphoid organs. CML is characterized by the
predominance
of granulocytic cells of all stages of differentiation in blood, bone marrow,
liver, spleen and
other organs.
Myelodysplastic Syndrome (MDS) is characterized as a clonal proliferative
disorder in
which a normal or hypercellular bone marrow is associated with an ineffective
and
dysmyelopoiesis. Hemapoietic cells which may proliferate include erythroid,
myeloid and
megakaryocytic forms. MDS is a relative new designation of group of disorders
known as
Preleukemia, Refractory Anemias, Ph-Chromosome-Negative Chronic Myelocytic
Leukemia,
Chronic Myelomonocytic Leukemia and Agnogenic Myeloid Metaplasia. The FAB
system
provides further classification of Myelofibrosis.
Lymphomas are a heterogeneous group of neoplasms arising in the
reticuloendothelial
and lymphatic systems. The major types of lymphomas are Hodgkin's disease and
non-
Hodgkin's lymphoma, as well as the rarer Burkitt's lymphoma and mycosis
fungoides.
Hodgkin's disease is a chronic disease with lymphoreticular proliferation of
unknown cause
that may present in localized or disseminated form, and is further classified
according to four
histopathologic profiles. Non-Hodgkin's lymphomas are a heterogeneous group of
diseases consisting of neoplastic proliferation of lymphoid cells that usually
disseminate
throughout the body. The former terms, lymphosarcoma and reticulum cell
sarcoma, are now
being replaced with terms that reflect that cell of origin and biology of the
disease. The
Rappaport classification is based on the histopathology; on the degree of the
differentiation of
the tumor and on whether the growth pattern is diffuse or nodular. The Lukes
and Collins
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
9
classification is based upon the cell of origin, specifically whether it is T
cell or B cell derived,
histiocytic (or monocytic) origin or unclassifiable. The International Panel
Working
Formulation of the National Cancer Institute categorizes non-Hodgkin's
lymphomas using the
above classifications.
Burkitt's lymphoma is a highly undifferentiated B cell lymphoma that tends to
involve
sites other than the lymph nodes and reticulendoethlial system. Burkitt's
lymphoma, unlike
other lymphomas, has a specific geographic distribution, which suggests an
unidentified insect
vector and an infectious agent. Evidence points to the herpes like Epstein-
Barr virus.
Mycosis fungoides is an uncommon chronic T cell lymphoma primarily affecting
the
skin and occasionally internal organs.
Plasma cell dyscrasias (PCDs), or monoclonal gammopathy, are disorders
characterized by the disproportionate proliferation of one clone of cells
normally engaged in
immunoglobulin (Ig) synthesis, and the presence of a structurally and
electrophoretically
homogeneous IG or polypeptide subunit in serum or urine. The disorders may be
primarily
asymptomatic to progressive, overt neoplasms (e.g., multiple myeloma). The
disorder results
from disproportionate proliferation of one clone producing a specific Ig: IgG,
IgM, IgA, IgD
or IgE.
Multiple myeloma, also known as plasma cell myeloma or myelomatosis, is a
progressive neoplastic disease characterized by marrow plasma cell tumors and
overproduction of an intact monoclonal Ig (IgG, IgA, IgD or IgE) or Bence
Jones protein,
which is free monoclonal K or k light chains. Diffuse osteoporosis or discrete
osteolytic
lesions arise due to replacement by expanding plasma cell tumors or an
osteoclast-activating
factor secreted by malignant plasma cells.
Macroglobulinemia, or primary or Waldenstrom's macroglobulinemia, is a plasma
cell
dyscrasia involving B cells that normally synthesize and secrete IgM.
Macrogolbulinemia is
distinct from myeloma and other PCDs, and resembles a lymphomatous disease.
Many
patients have symptoms of hyperviscosity; fatigue, weakness, skin and mucosal
bleeding and
so forth.
Heavy chain diseases are neoplastic plasma cell dyscrasias characterized by
the
overproduction of homogenous y, a, , and S Ig heavy chains. These disorders
result in
incomplete monoclonal Igs. The clinical picture is more like lymphoma than
multiple
myeloma.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
Hypersplenism is a syndrome in which circulating cytopenia is associated with
splenomegaly. Treatment of patients with hypersplenism requires therapy for
the underlying
disease, not splenectomy. Lymphoproliferative and myeloproliferative diseases
are some, but
not the sole, causes of hypersplenism. Myeloproliferative disorders causing
hypersplenism
5 include polycythemia vera, myelofibrosis with myeloid metaplasia, chronic
myelogenous
leukemia and essential thrombocythemia. Chronic lymphocytic leukemia and the
lymphomas
(including Hodkin's disease) are specific lymphoproliferative disorders that
may cause
hypersplenism.
Lung tissue is the site for both benign and malignant primary tumors, as well
as the
10 site of metastasis from cancers of many other organs and tissues. Cigarette
smoking causes
an overwhelming percentage of lung cancers, estimated at over ninety percent
of the cases in
men and about seventy percent of the cases in women, exposure to occupational
agents such
as asbestos, radiation, arsenic, chromates, nickel, chloromethyl ethers,
poison gas, and coke
oven emissions is also associated with lung cancer. The most common types of
lung cancer
are squamous cell, small and large cell and adenocarcinoma.
About ninety-five percent of the stomach cancers are carcinoma; less common
are
lymphoinas and leiomyosarcomas. Gastric carcinomas are classified according to
gross
appearance; protruding, penetrating (the tumor has a sharp, well-circumscribed
border and
may be ulcerated) spreading or miscellaneous, which has characteristics of two
of the other
types.
Pancreatic cancers may be exocrine tumors, which are mostly adenocarcinomas
arising
from duct cells rather than the acinar cells, or endocrine tumors, which
include insulinoama,
Gastrin-producing pancreatic tumors involving cells of the non-(3-type or in
the duodenal wall
can cause Zollinger-Ellison Syndrome, a syndrome marked by hypergastrinemeia.
Sometimes
other endocrine abnormalities, particularly with the parathyroids, or
pituitary and adrenal
glands cause polyglandular disorder known as multiple endocrine neoplasia
(MEN). Non-(3
islet cell tumors may cause a syndrome known as Vipoma Syndrome, which is
characterized
by prolonged massive watery diarrhea.
Neoplasms of the bowel include tumors of the small intestine, tumors of the
large
intestine, cancer of the colon and rectum. Benign small intestine tumors
include may arise
from jejunal and ileal neoplasms, including leiomyomas, lipomas,
neurofibromas, and
fibromas. Malignant small intestine tumors, such as adenocarcinomas, are
uncommon, and
typically arise in the proximal jejunum. Patients with Crohn's disease of the
small intestine
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
11
are more prone to such adenocarcinomas rather than patients with Crohn's
disease of the
colon. In patients with Crohn's disease, the tumors tend to occur distally in
the bypassed or
inflamed loops of the bowel. Carcinoid tumors typically arise in the small
bowel, especially
the ileum, and in about half the cases, multiple tumors exist. Kaposi's
sarcoma, which occurs
frequently in transplant recipients and AIDS patients, have gastrointestinal
involvement in
about half the cases. Lesions may occur anywhere in the GI tract, but are
usually found in the
stomach, small intestine, or distal colon.
Tumors of the large bowel include polyps of the colon and rectum. Polyps are a
mass
of tissue that arises from the bowel wall and protrudes into the lumen. Polyps
are classified
on the basis of their histology, as tubular adenomas, tubulovillous adenomas,
villous
adenomas, hyperplastic polyps, hamartomas, juvenile polyps, polypoid
carcinomas,
pseudopolyps, lipomas, leiomyomas and even rarer tumors.
Malignant tumors may also arise in the anorectum. These are epidermoid
(squamous
cells) carcinoma of the anorectum which comprise about three to five percent
of rectal and
anal cancers.
In Western countries, cancer of the colon and rectum are second to lung cancer
in
accounting for more new cases each year. In the USA, about 75,000 people died
of these
cancers in 1989; about 70 % occurred in the rectuin and sigmoid colon, and 95%
are
adenocarcinomas.
Neoplasms of the liver include benign neoplasms, which are relatively common
but
often undetected, and malignant neoplasms. Hepatocellular adenoma is the most
important
benign liver neoplasm. Asymptomatic small hemangiomas occur in one to five
percent of
adults. Bile duct adenomas and other mesenchymal neoplasms also occur, but are
relatively
rare. Malignant neoplasms of the liver are the most common form of hepatic
tumor, and the
liver is a frequent site of bloodborne metastases, usually from lung, breast,
colon, pancreas
and stomach primary tumors. The incidence of hepatocellular carcinoma is
linked with
chronic hepatitis B virus in certain parts of Africa and Southeast Asia. In
North America,
Europe and other areas of low prevalence, most of the patients have underlying
cirrhosis.
Fibrolamellar carcinoma is a distant variant of hepatocellular carcinoma with
characteristic
morphology of malignant hepatocytes enmeshed in lamellar fibrous tissue.
Fibrolamellar
carcinoma usually affects relatively young adults, and has no association with
preexisting
cirrhosis, chronic hepatitis B virus infection or other known risk factors.
Other primary
malignancies of the liver include cholangiocarcinoma (a tumor arising from
intrahepatic
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
12
biliary epitlielium), hepatoblastoma (which is one of the most common cancers
in infants) and
angiosarcoma (which is associated with industrial exposure to vinyl chloride).
Leukemia and
related disorders may involve hepatic tissues, thought the result of
infiltration with abnonnal
cells.
Multiple Endocrine Neoplasia (MEN) Syndromes are a group of genetically
distinct
familial diseases involving adenomatous hyperplasia and malignant tumor
formation in
several endocrine glands. Three distinct syndromes have been identified. Type
I(MEN-I) is
characterized by tumors of the parathyroid glands, pancreatic islets, and the
pituitary. Type II
(MEN-II) is characterized by medullary carcinoma of the thyroid,
pheochromocytoma and
hperparthyroidism. Type III (MEN-III) is characterized by multiple mucosal
neuromas,
medullary carcinoma of the thyroid, and pheochromocytoma.
Carcinoid syndrome is usually caused by metastatic intestinal carcinoid tumors
that
secrete excessive amount of vasoactive substances, including serotonin,
bradykinin, histamine,
prostaglandins and polypeptide hormones. Abnormal levels of these substances
cause a
variety of symptoms, often episodic cutanteous flushing, cyanosis, abdominal
cramps,
diarrhea, and valvular heart disease.
Neoplasms of the bone and joints may be benign or malignant. Benign tumors of
the
bone include osteochondromas (osteocartilaginous exostoses), which are the
most common
benign bone tumors in children between ages 10 to 20, benign chondromas (which
are located
within the bone), which occur most commonly in children and young adults
between the ages
10 to 30, chondroblastoma (which arises in an epiphysis), which is rare, but
most common in
children between the ages of 10 to 20, chondromyxofibromas, osteoid osteoma,
giant cell
tumors and fibromatous lesions. Primary malignant tumors of the bone include
osteogenic
sarcoma (osteosarcoma), which is the second most common primary bone tumor,
fibrosarcomas, malignant fibrous histiocytoma, chondrosarcomas, mesenchymal
chondrosarcoma, Ewing's tumor (Ewing's sarcoma), malignant lymphoma of bone,
multiple
myeloma, malignant giant cell tumor.
Primary cancers of other tissues may metastasize to bone tissue. The most
common
are carcinomas arising in the breast, lung, prostate, kidney, and thyroid.
Central nervous system (CNS) neoplasms are generally classified according to
the
organ. Primary intracranial neoplasms are subdivided into six classes: tumors
of (1) the skull;
(2) the meninges; (3) the cranial nerves; (4) the neuroglia and ependyma; (5)
pituitary or
pineal gland; (6) congenital origin. Skull neoplasms include osteoma,
hemangioma,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
13
granuloma, xanthoma, and osteitis deformans. The meninges neoplasms include
meningioma,
sarcoma, and glomatosis. The cranial nerve neoplasms include glioma of the
optic nerve, and
schwannoma of the 8th and 5th cranial nerves. The neuroglia neoplasms include
gliomas and
ependymomas. The pituitary or pineal body neoplasms include pituitary adenoina
and
pinealoma. The congenital origin neoplams include craniopharyngioma, chordoma,
germinoma, teratoma, dermoid cyst, agioma and hemangioblastoma.
Spinal cord neoplasms are lesions that compress the spinal cord or its roots,
arising
from the cord parenchyma, roots, meninges, or vertebrae. Primary spinal cord
neoplasms are
much less common than intracranial tumors. Metastatic lesions are common and
may arise
from carcinomas of the lung, breast, prostate, kidney, thyroid or lymphoma.
Genitourinary neoplasms occur at any age and in both sexes; however, they
account
for about 30% of cancer in the male and 4% in the female. Adenocarcinoma of
the prostate
accounts for a significant number of malignancies in men over 50. Prostate
adenocarcinoma
is thought to be hormone related and its pathology is typically glandular.
Carcinoma of the
kidney, adenocarcinoma, is only about one to two percent of adult cancers, but
most solid
kidney tumors are malignant. Wilms' tumors, an embryonal adnomyosarcoma of the
kidneys,
occurs fetally and is often not diagnosed for several years. Renal pelvis and
ureter neoplasms
are histologically similar. Urinary bladder neoplasms may be induced by known
urinary
carcinogens such as aniline dyes, and the most common is transitional cell
carcinoma, less
common is squamous cell carcinoma. Rarer genitourinary neoplasms include
carcinoma of
the urethra, and penis. Neoplasms of the testis account for the majority of
solid malignancies
in males under 30. Most malignant testicular tumors arise from the primordial
germ cell and
are classified according the cell type involved.
Breast cancer is the most common cancer in women. In the USA, the cumulative
risk
for women of all ages of developing breast cancer is about 10%, but that of
dying from the
disease is only about 3.6%. However, the risk increases with age, a family
history of breast
cancer, exposure to radiation, and even diet is implicated in higher risk.
Breast cancers are routinely typed for estrogen- and progesterone-receptor
analysis.
About two thirds of the patients have estrogen-receptor positive (ER+) breast
tumors. Tumors
which are progesterone positive are thought to have functional estrogen
receptor and the
presence of both receptors gives a greater likelihood of favorable response to
endocrine
treatnient than the presence of just one receptor. Endocrine therapy, usually
tamoxifen, is
preferred in estrogen receptor-positive tumors. Estrogens and androgens are
also effective,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
14
but less favored due to undesirable side effects induced by higher levels of
these hormones
than other forms of endocrine treatment. Breast cancer may metastasize to
almost any organ
in the body, but most common sites of metastasis are the lung, liver, bone,
lymph nodes and
skin.
Lobular carcinoma in situ (LCIS) or lobular neoplasia, is most frequently
found in
premenopausal women. Ductal carcinoma in situ (DCIS) occurs in both pre- and
postmenopausal women. DCIS forms a palpable mass. LCIS and DCIS account for
about
90% of all breast cancers. The rarer forms, medullary and tubular lesions,
have a somewhat
better prognosis.
The most common gynecologic neoplasms are endometrial carcinomas, which ranks
fourth in frequency after breast, colorectal and lung cancers in women.
Endometrial
carcinomas are characterized by their clinical staging, ranging from in situ
at stage 0, to
metastasis to distant organs at stage IVB. Endometrial carcinomas typically
produce estrogen
and the current treatment approaches are surgery and progesterone therapy.
Ovarian cancers account for about 18% of all gynecologic neoplasms. About 80%
of
malignant ovarian cancers arise from the ovarian epithelium and are classified
according to
their histology. Tumors may also arise from germ cells or stroma.
Vulvar carcinoma accounts for about 3-4% of all gynecologic neoplasms. Vulvar
carcinoma usually occurs after menopause, and about 90% are squamous cell
carcinomas.
About 4% are basal cell carcinomas and the rest include intraepithelial
carcinomas,
adenocarcinoma of Bartholin's gland, fibrosarcoma and melanoma.
Vaginal carcinoma accounts for about 1% of gynecologic malignancies, with a
peak
incidence from about ages 45 to 65. About 95% of vaginal carcinomas are
squamous cell
carcinoma. Primary carcinoma of the oviduct is rare and typically spread
directly or by the
lymphatics.
Trophoblastic disease or neoplams of trophoblastic origin, can follow intra-
or
extrauterine pregnancy. A degenerating pregancy results in a hydatidiform mole
of which
about 80% are benign.
Neoplasms may arise in the ear canal and affect hearing. Ceruminomas also
arise, are
typically malignant despite appearing benign histologically and are treated by
surgical
removal. Basal cell and squamous cell carcinomas frequently develop on the
external ear as
the result from regular sun exposure, and are also typically treated by
surgical removal. The
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
middle ear may be the site of squamous cell carcinomas. Nonchromaffin
paragangliomas may
arise in the temporal bone.
The most cominon malignant tumor in the nose and paranasal sinuses is squamous
cell
carcinoma; less common are adenoid cystic and mucoepidermod carcinomas,
malignant mixed
5 tumors, adenocarcinomas, lymphomas, fibrosarcomas, osteosarcomas,
chondrosarcomas, and
melanomas.
Squamous cell carcinoma of the nasopharynx is more commonly observed in
children
and young adults.
The most common malignancies of the upper respiratory tract are squamous cell
10 carcinomas of the tonsil and of the larynx. Both are more common in males
and are
associated with tobacco smoking and ethanol ingestion; about 85 % of patients
with cancer of
the head or neck have a history of ethanol and tobacco consumption
In the head and neck, about 90% of the cancers are squamous cell (epidermoid)
carcinoma. Melanomas, lymphomas and sarcomas are relatively rare forms of
primary head
15 and neck cancers. Cancers of the head and neck are classified according to
the size and site of
involvement of the primary neoplasm; number and size of metastases to the
cervical lymph
nodes and evidence of distant metastases.
Ophthalmologic cancers may arise in the skin of the eyelids and may be benign
or
neoplastic. Common benign growths are xanthelasmas, which form yellow-white
flat plaques
of lipid material subcutaneously. Basal cell carcinomas are more common;
treatment is
typically surgical removal or radiation therapy. Other less common malignant
tumors are
squamous cell or meibomian gland carcinomas and other types of melanomas. The
most
common primary ocular malignancy is malignant melanoma of the choroid.
Tumors also arise in the skin tissue, and include benign tumors such as moles,
lipomas
and the like, as well as malignant tumors. About 40-50% of malignant melanomas
arise from
melanocytes in moles. Malignant skin cancers are either basal cell or squamous
cell
carcinomas and frequently arise in sun-exposed areas of skin. They are the
most common
malignancies, and the incidence is rising. Less common malignancies include
malignant
melanoma, Paget's disease of the nipple or estramammary Patent's, Kaposi's
sarcoma (KS),
and cutaneous T cell lymphoma (mycosis fungiodes). The incidence of KS is
increasing as
the result of the increased incidence of AIDS. KS arises in about one third of
patients with
AIDS.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
16
Oral cancers account for about 5% of cancers in men and 2% of cancers in
women.
The most common form of oral cancer is squamous cell carcinoma. Incidence
increases with
age and risk factors, particularly tobacco and alcohol consumption.
Surgery is oldest effective form of treatment of neoplasms. Success is largely
achieved if the neoplasm is detected in its early stages and has not
metastasized. Radiation is
also important therapy, and is the favored therapy of many neoplasms such as
Hodgkin's
disease, early stage non-Hodgkin's lymphomas, squamous cell carcinoma of the
head and
neck. Radiation has proven very successful as an adjunct to surgery and
antineoplastic drugs.
Antineoplastic drugs are also useful in the treatment of neoplasms, and are
classified
according to their mechanism of action. Antineoplastic drugs frequently target
fundamental
biological processes necessary for cell replication or growth. Numerous
combinations,
typically of antineoplastic drugs with differing mechanisms of action, have
proven to be
particularly effective therapy, permit lower doses and frequently minimize
negative side
effects. The combinations of drugs with different mechansisms of action need
to be evaluated
for optimal doses and schedules of administration. For instance, the sequence
of
administration of the cyclin-dependent kinase inhibitor, flavopiridol, with a
number of
different chemotherapeutic agents determines whether the combination will have
a synergistic
or an antagonistic effect on tumor cell proliferation (Bible, K.C. and
Kaufinann, S.H., Cancer
Res. 57, 3375-3380, 1997).
Alkylating agents, such as mechlorethamin and cyclophosphamide, alkylate DNA,
and
restrict DNA replication.
Antimetabolites that are directed to disrupting necessary cell division
pathways
include:
Folate antagonists bind to dehydrofolate reductase and interfer with
pyrimidine
synthesis. Folate antagonists are S-phase specific. Methotrexate is a very
commonly used
antineoplastic folate antagonist.
Purine antagonists block de novo purine synthesis and are S-phase specific. 6-
mercaptopurine is an example of a purine antagonist.
Pyrimidine antagonists interfere with thymidylate synthase to reduce thymidine
production and are S-phase specific. A frequently used pyrimidine antagonist
is 5-
fluorouracil.
Cytarabine inhibits DNA polymerase and is S-phase specific.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
17
Plant alkyloids include vincas, such as vinblastine and vincristine, and
podophyllotoxins, such as etoposide. Plant alkyloids are effective in the
metaphase and
inhibit mitosis by a variety of mechanisms including altering microtubular
proteins.
Antibiotics include doxorubicin and daunomycin, which intercalate between DNA
strands to inhibit the uncoiling of DNA, bleomycin, which causes incisions in
DNA strands,
and mitomycin, which inhibits DNA synthesis by acting as bifunctional
alkylator.
Nitrosureas include carmustine and lomustine and alkylate DNA or cause
carbamoylate amino acids in proteins.
Inorganic ions, such as cisplatin, cause inter- and intracalation of DNA
strands to
inhibit the uncoiling of DNA.
Taxanes, such as taxol and taxotere, prevent cells from dividing by promoting
the
assembly and preventing the disassembly of microtubules.
DNA topoisomerase I inhibitors, including campothecin analogs like irinotecan,
inhibit
cell growth by interfering with DNA sysnthesis.
Biologic Response Modifiers, such as the interferons, have antiproliferative
effects,
but their specific role is not known. Interferons include a(leukocyte)
interferon, ~i
(fibroblast) interferon and y (lymphocyte) interferon.
Enzymes, such as asparaginase, are also used alter metabolic pathways
important in
cancerous cells. Asparaginase depletes the cell of asparagine, on which
leukemic cells
depend.
Hormones and their analogs, such as tamoxifen, flutamide, and progesterone,
have non-
specific effects but are useful to treat certain neoplams which are known to
be hormone
responsive, especially breast, ovarian and prostate neoplasms. Tamoxifen,
frequently used in
the treatment of breast neoplasms, places cells at rest, and binds to the
estrogen receptor.
Flutamide, frequently used in the treatment of prostate neoplasms, binds the
androgen
receptor.
Cytokinins are naturally occurring and artificial plant growth regulators.
Natural
cytokinins tend to be non-specific inhibitors of various protein kinases. The
molecular
mechanisms by which cytokinins regulate cell growth and division are still
being determined.
Studies have indicated that cytokinins may increase accessibility of the DNA
template,
activate RNA polymerases, affect polyadenylation and secondary structure of
mRNA and
stimulate formation and activity of polyribosomes. Cytokinins are thought to
affect cell
division by interacting with regulatory proteins of the cell cycle. Both
cytokinins and cyclin-
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
18
dependent kinases (cdks) act at multiple and similar control points of cell
cycle, for example,
at the Gl/S and G2/M transitions and S and M phases.
Olomoucine, [6-(benzylamino)-2-[(2-hydroxyethyl)amino]-9-methylpurine], was
first
discovered as an herbicide. More recently, it has been discovered that
Olomoucine is an
artificial cytokinin, which specifically inhibit some cdks, including
p34odo2/cyclin B kinases, at
micromolar concentration, but has no effect on other major protein kinases
such as cAMP-
and cGMP-dependent kinases, and protein kinase C. Olomoucine has recently been
shown to
have good selectivity for the CDKlcyclin protein kinases, but only has
moderate inhibitory
activity, with an IC50 of about 7 M for CDK2. Vesely, J., et al., Eur. J.
Biochem., 1994, 224,
771-786. A 2.4 A crystal structure of olomucine revealed that the purine
portion of
olomoucine binds in the conserved ATP binding pocket, while the benzylamino
group extends
into a region of the active site unique to the cdk2 kinases.
Roscovitine, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine,
is a
recently synthesized purine that has been shown to have selectivity towards
some cyclin-
dependent kinases and to have 10-fold more active on cdk than olomoucine.
Meijer, L., et al.,
Eur. J. Biochem., 243:527-536(1997) and PCT/FR96/01905. Meijer et al report
that most
kinases are not significantly inhibited by roscovitine. However, cdc 2/cyclin
B, cdk 2/cyclin
A, cdk 2/cyclin E and cdk 5/p35 are substantially inhibited with IC50 values
of 0.65 , 0.7, 0.7
and 0.2 M, respectively. In contrast, cdk 4/cyclin D1 and cdk 6/cyclin D2 had
IC50 values of
greater than 100 M.
Havlicek, L., et al., J. Med. Chem. (1997)40:408-412 report that Roscovitine,
and
related analogs substituted in the 2, 6 andlor 9 positions, inhibit p34ca
a/cyclin B kinases. None
of the analogs had superior IC50 values over the (R) enantiomer of
Roscovitine, which had an
IC50 value of 0.2 M. The (S) enantiomer had an IC50 value of 0.8 M; the
racemic mixture
(R/S) had an IC50 value of 0.65 M. These authors conclude that the N6-benzyl
substituent of
Roscovitine was superior over the isopentenyl or cyclohexylmethyl
substituents.
The National Cancer Institute (NCI) is a US Government-run organization
directed at
the discovery and development of novel therapuetic oncology products. In 1985,
the NCI
established a new cancer screening strategy involving human tumor cell lines
in an in vitro
assay as the primary cancer screen. A total of sixty human tumor cell lines,
derived from
seven cancer types (lung, colon, melanoma, renal, ovarian, brain and leukemia)
are selected
for inclusion in the NCI panel. Grever, M.R., et al., Seminars in Oncolo~y,
19:1992:622-638.
The protocols used in the assays have also been reported in the literature.
American Type
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
19
Tissue Collection (ATCC) acts as a depository for these and other tumor cell
lines. Useful
human tumor cell lines include the following:
MCF7: human breast adenocarcinoma, hormone-dependent;
MDA-MB-231: human breast adenocarcinoma, hormone-independent;
MDA-MB-435: human breast adenocarcinoma, hormone-independent
HT-29: human colon adenocarcinoma, moderately well differentiated grade II;
HCT-15: human colon adenocarcinoma;
Colo-205: human colon adenocarcinoma;
A549: human non-small cell lung carcinoma;
DMS-114: human small cell lung carcinoma;
NCI-H460: human non-small cell lung carcinoma;
PC-3: human prostate adenocarcinoma, hormone-independent;
DU 145: human prostate carcinoma, hormone-independent;
HL-60: human acute promyelocytic leukemia;
Jurkat: human acute T-cell leukemia; and
Molt-4: human acute lymphoblastic leukemia.
Skehan, P., et al., J. Natl. Cancer Inst. 82: 1107-1112, 1990 sets forth
useful protocol for using
such tumor cell lines for screening antineoplastic drugs.
Meijer, et al., supra, report that roscovitine inhibits the proliferation of
the NCI
disease-oriented in vitro screen, i.e., 60 human tumour cell lines comprising
nine tumour types
(leukemia, non-small cell lung cancer, colon cancer, central nervous system
cancer,
melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer)
mammalian cell lines
with an average IC50 value of 16 M. The results of individual tumour lines
are not reported.
Two distinct cdk inhibitors, flavopiridol and olomoucine, suppress the death
of
neuronal PC12 cells and sympathetic neurons in two model systems of neuronal
survival. Park
et al., J. Biol. Chem. 271(14):8161-8169 (1996). The concentration of each
required to
promote survival correlated with the amount required to inhibit proliferation.
Neuronal
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
apoptosis is an important aspect of both nervous system development and a
component of
neuronal injury and disease.
The PC 12 cell line was initially derived from a rat adrenal medullary
pheochromocytoma. When grown in serum-containing medium, PC12 cells divide and
5 resemble precursors of adrenal chromaffm cells and sympathetic neurons. Upon
addition of
nerve growth factor (NGF), PC12 cells attain the phenotypic properties of
sympathetic
neurons. Upon removal of either serum or seruin and NGF, both naive and
neuronally
differentiated PC 12 cells undergo apoptosis, which is also analogous of
sympathetic neurons.
The role of cell cycle regulation in apoptosis may be explained that
withdrawal of
10 NGF or serum results in uncoordinated cell cycle progression of naive PC12
cells.
Differentiated or sympathetic neurons are hypothesized to attempt
inappropriate re-entry of
the cell cycle.
Changes in the activity of cdks and cyclins are observed during apoptosis of
many
different cell types. Camptothecin- or araC-induced apoptosis of HL60 cells is
associated
15 with elevated cdc2 activity and cyclin E-associated kinase activity.
Camptothecin-induced
apoptosis of RKO cells is associated with an increase in expression of cyclin
D1.
Camptothecin causes apoptotic death of rat cerebral cortical neurons. Morris
and
Geller, J. Cell Biol. 134:757-770(1996). Camptothecin-treated nonproliferating
neuronally
differentiated PC12 cells die within 6 days after treatment, and cultured rat
sympathetic
20 neurons die within 5 days after treatment, even in the presence of NGF.
Park et al., J.
Neurosci. 17(4):1256-1270(1997). However, administration of either both, or
individual
olomoucine or flavopiridol, resulted in approximately 30% cell death at day 6.
Maximal
protection of PC 12 cells, or rat sympathetic neurons, from death was observed
at 1 M
flavopiridol and 200 M olomoucine, which are the minimum concentrations that
fully inhibit
DNA synthesis by proliferating PC12 cells. Administration of iso-olomoucine,
an inactive
analog of olomoucine, failed to prevent the cell death of camptothecin-treated
neuronal cells.
Olomoucine and flavopiridol appear to partially suppress neurite generation.
Park et
al. J. Biol. Chem. 271(14):8161-8169 (1996).
Flavopiridol and olomoucine were also shown to protect against camptothecin-
induced
cortical neuronal death. Park et al., J. Neurosci. 17(4):1256-1270(1997). The
IC50 values of
flavopiridol and olomoucine were 0.1 M and 100 M, respectively.
Administration of iso-
olomoucine failed to prevent the cell death of camptothecin-treated neuronal
cells.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
21
There are several implications of the above observations. It is well
recognized that
patients treated with radiation or antineoplastic agents experience
undesirable side effects,
including developing new neoplasms or undesirable cellular apoptosis. For
example, some
patients treated with high-dose araC for refractory leukemia develop a
cerebellar toxicity
syndrome, characterized by loss of Purkinj e neurons. Winkelman and Hinges,
Ann Neurol.
14:520-527(1983) and Vogel and Horouipian, Cancer 71:1303-1308(1993). Patients
treated
with cis-platinum have been reported to develop periperal neuropathies.
Wallach, et al., J.
Fla. Med. Assoc. 79:821-822(1992) and Mansfield and Castillo, AJNR Am. J.
Neuroradiol.
15:1178-1180(1994). In view of these observations, either co-administration or
sole
administration of the present compounds in the treatment of neoplasms would
reduce or
preclude cellular apoptosis, in particular, neuronal damage caused by
treatment with
antineoplastic agents or radiation.
Cerebrovascular disease is the most common cause of neuologic disability in
Western
countries. The major specific types of cerebrovascular disease are cerebral
insufficiency due
to transient disturbances of blood flow, infarction, hemmorrhage, and
arteriovenous
malformation. Stroke generally denotes ischemic lesions. Undesirable neuronal
apoptosis
occurs in cerebrovascular disease.
Inhibition of cyclin-dependent kinases would also have therapeutic value in
treating
additional hyperproliferative disorders (see Meijer, et al., Pharmacol. Ther.
82, 279-284, 1999
for a review). Neointimal formation in vascular injury, such as occurs in
angioplasty
procedures, represents a hyperproliferative disorder (non-neoplastic) in which
cell cycle
inhibitors would have a therapeutic benefit. Flavopiridol has been shown to
inhibit SMC
growth in vitro and in vivo, suggesting potential for other CDK inhibitors in
this area (Ruef et
al., Circulation 100, 659-665, 1999). Atherosclerosis represents another
widespread form of
vascular injury. It has been shown that the CDK inhibitor, p27Kipl, and cyclin
E are
upregulated in human atherosclerotic tissue (Ihling et al., Atherosclerosis
144, 7-14, 1999).
One of the implications of this study is that cell cycle control is altered in
the regions of
chronic inflammation associated with atherosclerosis.
Autoimmune disorders such as rheumatoid arthritis, Type I diabetes,
inflammatory
bowel disorder and allograft rejection may represent additional areas where
reducing rapid
cell proliferation by CDK inhibition would have therapeutic benefit. Lesion
cellularity is a
common component associated with these chronic inflammatory disorders. For
instance,
jejunal hyperplasia is associated with Type I diabetes, and is present in
Streptozoticin treated
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
22
rats (an animal model for Type I diabetes). Diabetic crypt enterocytes
exhibited increased
tyrosine kinase, ornithine decarboxylase (ODC), and cdkl actvities when
compared with
control rats. Treatment with an ODC inhibitor, difluoromethylornithine,
prevented j ejunal
hyperplasia, and reduced the proliferation associated activities mentioned
above (Parekh et al.,
J. Invest. Med. 47, 397-404, 1999).
Inhibitors of CDKs may also have utility as antivirals. For instance, the CDK
inhibitors olomoucine and roscovitine inhibited the replication of herpes
simplex virus
(Schang et al., J. Virol. 72, 5626-5637, 1998).
Summary of the Invention
The present invention provides a method of inhibiting cell cycle progression
by
administration of an antiproliferative compound for Formula (I). More
specifically, the
present invention provides a method of inhibiting the activity of cyclin-
dependent kinase
complexes, including cdkl/cyclin B, cdk2/cyclin E, and cdk4/cyclin Dl.
The present invention also provides a method of preventing apoptosis in cells
by
administration of a compound for Formula (I). A preferred method of the
invention is
preventing apoptosis of neuronal cells by administration of a compound for
Formula (I). A
particularly preferred method of the present invention is preventing apoptosis
of neuronal cells
induced by antineoplastic agents or resulting from cerebrovascular disease.
Another preferred
embodiment of the present invention is the method of preventing apoptosis
induced by oxygen
depletion. A more preferred invention provides a method of preventing
apoptosis induced
cerebrovascular disease. Another preferred invention provides a method of
preventing
apoptosis induced by stroke or infarction.
The present invention provides a method of inhibiting the development of
neoplasms
by administration of a compound for Formula (I). The present invention
provides a method
for treating a patient afflicted with a neoplastic disease state comprising
administering a
compound of the Formula (I). It is preferred that the amount administered is a
therapeutically
effective amount of a compound of the formula. A preferred method of the
present invention
administers a single compound of the formula provided. Alternatively, a
preferred method of
the present invention administers an amount of a compound of the formula in
conjunction
with other antineoplastic agents.
A "hyperproliferative disorder" refers to a disease condition characterized by
rapid, or
uncontrolled cell division. Hyperproliferative disorders include neoplastic
diseases and non-
neoplastic diseases.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
23
"Neoplastic disease" refers to an abnormal state or condition characterized by
rapid or
uncontrolled proliferation of a cells or tissue that serves no useful biologic
purpose, but grows
at the expense of the healthy organism. Neoplastic diseases include leukemias,
carcinomas
and adenocarcinomas, sarcomas, melanomas, and mixed types of neoplasms.
Leukemias include, but are not limited to, acute lymphoblastic, chronic
lymphocytic,
acute myeloblastic and chronic myelocytic leukemias.
Carcinomas and adenocarcinomas include, but are not limited to, those of the
cervis,
breast, prostate, esophagus, stomacll, small intestines, colon, ovary and
lungs.
Sarcomas include, but are not limited to, oesteromas, osteosarcoma, lipoma,
lipsarcoma, hemangiomas and hemangiosarcoma.
Melanomas include, but are not limited to, amelanotic and melanotic melanomas.
Mixed types of neoplasms include, but are not limited to, carcinosarcoma,
lymphoid
tissue type, folicullar reticulum, cell sarcoma and Hodgkins Disease.
"Non-neoplastic diseases" refer to an abnormal state or condition
characterized by
rapid or uncontrolled proliferation of cells or tissue that otherwise serve a
useful biologic
purpose. Non-neoplastic diseases include restenosis and autoimmune diseases.
Autoimmune
diseases include, but are not limited to, atherosclerosis, rheumatoid
arthritis, Type I diabetes,
inflammatory bowel disorder and allograft rejection.
The term "therapeutically effective amount" of a compound of the formula
refers to an
amount that is effective, upon single or multiple dose administration to the
patient, in
controlling, slowing, reducing, or preventing cellular division or cellular
proliferation, or the
growth of the neoplasm or metastases of the neoplasm or preventing apoptosis.
A
therapeutically effective amount of a compound of the formula will vary
according to the age
and weight of the patient, renal function of the patient, bioavailability of
the compound
administered, type of neoplasm to be treated, the combination of other
antineoplastic agents,
and other criteria well known to those skilled in the art using standard
clinical and laboratory
tests and procedures. A therapeutically effective amount of a compound of the
formula will
vary according to the type of cell susceptible to apoptosis, the location of
the neoplasm or site
of hyperproliferation, or infarct.
"Controlling the growth" of the neoplasm refers to slowing, interrupting,
arresting or
stopping the growth of the neoplasm or metastases of the neoplasm. The term
"controlling the
growth" of the neoplasm also refers to killing the neoplasia or metastases of
the neoplasm, as
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
24
well as prophylatic treatment of a patient who is at risk of developing a
hyperproliferative
disease, or is at risk of undergoing, developing neuroal apoptosis.
An effective amount of a compound of the formula is that amount which is
effective,
upon single or multiple dose administration to a patient in providing a
reduction of cellular
proliferation, or in preventing apoptosis. An "antineoplastic effect" refers
to the slowing,
interrupting, preventing or destruction of further growth of neoplastic cells.
An "antiapoptotic
effect" refers to the slowing, interrupting, preventing of apoptosis of
neuronal cells.
An effective antineoplastic amount of a compound of the formula can be readily
determined by an attending diagnostician, as one skilled in the art, by the
use of known
techniques and by observing results obtained under analogous circumstances. In
determining
the effective amount, a number of factors are considered by the attending
diagnostician,
including but not limited to, the species of mammal; its size, age and general
health; the
specific disease involved; the degree of or involvement or the severity of the
disease; the
response of the individual patient; the particular compound of the formula
administered; the
mode of administration; the bioavailability characteristics of the preparation
administered; the
dose regimen selected; the use of concomitant medication; and other relevant
circumstances.
A f-urther embodiment of the present invention includes a method for the
prophylactic
treatment of a patient at risk of developing a hyperproliferative disease,
such as a neoplastic or
non-neoplastic, disease comprising administering a prophylactically effective
antineoplastic
amount of a compound of the formula. A patient at risk of developing a
neoplastic disease
refers to a patient who, because of an identified genetic predisposition to
neoplasms, had or
currently have neoplasms, exposure of carcinogenic agents, diet, age or has
other risk factors
associated with the development of neoplastic disease states. Preferred
patients at risk of
developing a neoplastic disease state include patients who are positive for
oncogenic viruses,
are in remission from prior treatment of neoplasm(s), use tobacco products or
have previously
been exposed to carcinogens such as asbestos, or are positive for various
neoplastic genetic
markers.
Oncogenic viruses are those viruses associated with cancers. For example, Rous
sarcoma of chickens, Shope rabbit papilloma, murine leukemia viruses are
animal viruses
recognized as having a role in development of various cancers. Human
papillomaviras is
associated with genital cancer. Molluscum contagiosum virus is associated with
molluscum
contagiosum tumors. The JC virus, a human papovirus, is associated with
disorders of
reticulendothelial system such as leukemia and lymphoma. Human retroviruses
such as
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
human T-cell lymphotropic viruses (HTLV) types 1 and 2 are associated with
some human
leukemias and lymphomas. Human immunodeficiency viruses (HIV) types 1 and 2
are the
causes of AIDS. Epstein-Barr virus has been associated with various
malignancies, including
nasopharyngeal carcinoma, African Burkitt's lymphoma and lymphomas in
5 immunosuppressed organ transplant recipients.
Genetic markers such as mutations, rearrangements and the like in BRCA 1, bcl-
1/PRAD1, cyclin D1/CCND1, p16, cdk4, especially an Arg24Cys mutation,
p16INK4a. Genetic
markers are associated with predispositions to various neoplasms. For example,
alterations in
the BRCA 1 gene are associated with a higher risk for breast and ovarian
cancer. Other
10 genetic markers include alterations in the MMSC1 gene, which interacts with
the MMCA1
brain and prostate cancer gene, in the CtIP gene, which is linked to the
BRACAI gene in
breast and ovarian cancer, binds to the BRCA1 gene and is linked to the E1A
oncogene
pathway, and in the MKK3 gene, which is a cell cycle control gene that acts as
a tumor
suppressor in lung cancer by activating apoptosis. Patients at risk of
developing a neoplastic
15 disease state also include patients who overexpress various cell cycle
proteins, including cdk4,
cyclins B 1 and E. Patients at risk of developing a neoplastic disease state
include those with
elevated levels of tumor markers. Known tumor markers include prostate
specific antigen
(PSA) and plasma insulin-like growth factor-1 (IGF- 1), which are markers for
prostate cancer.
Nuclear matrix proteins (NMPs) are associated with the presence of cancer,
particularly
20 bladder and colon cancers.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds according to the formula (I),
Ra
N N
H~
N N
" ~
HNN N
~2
(I) NH2
wherein
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
26
Z is selected from the group consisting of -S(O)2- and -C(O)-;
when Z is -S(O)Z-, Ra is selected from the group consisting of -Rl and -
N(R1)(R3), or
when Z is -C(O)-, Ra is selected from the group consisting of -Rl, -OR1, -
N(Rl)(R3)
and -SRl,
where
Rl is selected from the group consisting of
-C1-C11 alkyl, wherein each carbon may be optionally substituted with one, two
or three X substituents,
-C3-Clo cycloalkyl, wherein each carbon may be optionally substituted with
one or two X substituents,
-(CH2)nQp(CH2)õW, wherein each carbon of -(CH2)ri may be optionally
substituted with one or two X substituents,
Q is O, S, or NR3,
n is independently an integer 0-6,
p is independently an integer 0 or 1,
W is independently selected from the group consisting of hydrogen, C3-
C10 cycloalkyl, -(C3-Clo cycloalkyl)-aromatic, and one of the following
aromatic or heteroaromatic rings:
x
B \ \ ~ B
x Xo/ x
B X
x \
/
O
where B is -0-, -S-, -NR6-, where each carbon of the aromatic or
heteroaromatic ring
may be independently substituted by a nitrogen atom, and each carbon of the
aromatic
ring may be independently substituted with an X substituent;
and -(CHZ)nCHWa,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
27
where each X substituent is independently selected from the group consisting
of
hydrogen, halogen, methylenedioxy, -Cl-C8 alkyl, -C3-Clo cycloalkyl,
substituted or
unsubstituted phenyl, -C1-C8 alkoxy, -SR3, -OH, =O, -CY3, -OCY3, -C02R3, -CN, -
CO-NR4R5, -NO2, -COR3, -NR4R5, -NH-C(O)-R3, -NH-C(O)-(C1-C6 alkyl)-
aromatic, and -NH-C(O)-(C1-C6 alkyl)-heteroaromatic;
where each Y is independently selected from the group consisting of hydrogen
and halogen;
where each R3 is independently selected from the group consisting of
hydrogen, and Cl-C8 alkyl, where Cl-C8 alkyl may be straight or branched,
saturated or unsaturated;
where each R4 and R5 is independently selected from the group consisting of
hydrogen, and Cl-C6 alkyl, where C1-C6 alkyl may be straight or branched,
saturated or unsaturated, where which each carbon of C1-C6 alkyl is optionally
substituted with an X substituent, or where R4 and R5 taken together with the
nitrogen to which they are attached, form a heterocyclic ring of three to
seven
atoms including the nitrogen atom;
where -NR6- is selected from the group consisting of an unsubstituted N, an N
substituted with -hydrogen, -(C1-C6 alkyl), -C3-Clo cycloalkyl, -S(O)2-(Ci-C6
alkyl), -S(O)2-(C3-Clo cycloalkyl), -C(O)R3, -C(O)-(Co-C6 alkyl)-aromatic, and
-S(O)2-(Co-C6 alkyl)-aromatic, wherein each carbon of the aromatic ring may
be optionally substituted with an X substituent; and
where phenyl is substituted with one to five substituents independently
selected
from the group consisting of hydrogen, halogen, methylenedioxy, -CI-Cg alkyl,
-C3-Clo cycloalkyl, -Cl-C8 alkoxy, -OH, -CY3, -OCY3, -C02R3, -CN, -NO2, -
COR3, -NR4R5, -SR3, -CO-NR4R5, and -NH-C(O)-R3; and
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
28
R2 is selected from the group consisting of cyclopentyl, cyclopentenyl, and
isopropyl;
and
the pharmaceutically acceptable salts, optical isomers, solvates and hydrates
thereof
A preferred aspect of the present invention provides compounds of formula (Ia)
(ZRa
H" N N ~ N
~ \>
N~N N
H"
~2
(Ia) NH2
where Z, Ra, and R2 are as defined hereinabove.
Another preferred aspect of the present invention provides compounds of
formula (I)
or formula (Ia) wherein R2 is cyclopentyl.
Another preferred aspect of the present invention provides compounds of
formula (Ia)
wherein Z is -C(O)-.
Another preferred aspect of the present invention provides compounds of
formula (Ia)
wherein Z is -S(O)Z-.
A more preferred aspect of the present invention provides compounds of formula
(Ia)
wherein Z is -C(O)- and Ra is -OR1 or -N(R1)(R3).
Another more preferred aspect of the present invention provides compounds of
formula (Ia) wherein Z is -C(O)- and Ra is -SR1.
Another more preferred aspect of the present invention provides compounds of
formula (Ia) wherein Z is -C(O)- and Ra is -OR1.
Still another more preferred aspect of the present invention provides
compounds of
formula (Ia) wherein Z is -C(O)- and Ra is -N(RI)(R3).
A special embodiment of the present invention provides compounds of formula
(I) or
formula (Ia) wherein Rl is -(CHZ)nQp(CHZ)nW.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
29
Another special embodiment of the present invention provides compounds of
formula
(Ia) wherein Z is -C(O)-, Ra is -N(Rl)(R3) and Rl is -(CHZ)nQp(CHZ)nW.
A preferred special embodiment of the present invention provides compounds of
formula (Ia) wherein Z is -C(O)-, Ra is -N(R1)(R3), Rl is -(CH2)õQp(CH2)nW and
W is
X
\ B \ \ \ B
X / Xo/ X
B X
or
O
where B is -0-, -S-, -NR6-, where each carbon of the aromatic or
heteroaromatic ring may be
independently substituted by a nitrogen atom, and each carbon of the aromatic
ring may be
independently substituted with an X substituent.
Another preferred special embodiment of the present invention provides
compounds of
formula (Ia) wherein Z is -C(O)-, Ra is -N(Rl)(R3), Rl is -(CH2)nQp(CH2)nW and
W is
phenyl, each carbon of which may be independently substituted with an X
substituent.
Preferred compounds of the present invention include:
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine- l -
carboxylic acid (4-fluoro-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (3-trifluoromethyl-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (2-methoxy-phenyl)-amide;
trans-4-[2-(4-.Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (3-chloro-phenyl)-amide;
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (2-bromo-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexyla.inino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (2-chloro-phenyl)-amide;
5 trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (4-trifluoromethoxy-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (4-chloro-2-trifluoromethyl-phenyl)-amide;
trans-4-[2-(4-Aniino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino] -
piperidine-l-
10 carboxylic acid (4-chloro-3-trifluoromethyl-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino] -
piperidine-l-
carboxylic acid (4-methyl-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (4-methylsulfanyl-phenyl)-amide;
15 trans-4-[2-(4-.Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid biphenyl-2-yl-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (4-isopropyl-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
20 carboxylic acid (4-ethoxy-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclop entyl-9H-purin-6-ylamino] -pip
eridine-l-
carboxylic acid (2-fluoro-5-trifluoromethyl-phenyl)-amide;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (4-fluoro-2-trifluoromethyl-phenyl)-amide; and
25 trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-,9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl)-amide and
pharmaceutically acceptable salts, optical isomers, solvates and hydrates
thereof.
Other preferred compounds of the present invention include:
30 trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid butyl ester;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid ethyl ester;
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
31
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid 4-nitro-benzyl ester;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid allyl ester;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6=ylamino]-
piperidine-l-
carboxylic acid 2-nitro-phenyl ester;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine- l -
carboxylic acid 4,5-dimethoxy-2-nitro-benzyl ester;
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid prop-2-ynyl ester; and
trans- 4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid 4-methoxycarbonyl-phenyl ester; and
pharmaceutically acceptable salts, optical isomers, solvates and hydrates
thereof.
Still other preferred compounds of the present invention include:
trans-l-{4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
y1 } -2-phenoxy- ethanone;
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
yl } -2-phenyl sulfanyl-ethanone;
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
yl}-2-(4-chloro-phenoxy)-ethanone;
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylainino]-
piperidin-1-
yl } -2-b enzyloxy-ethanone;
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-1-
yl } -2-phenyl-butan-1-one;
trans-(E)-1-{4-[2-(4-Ainino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-
1-yl}-3-(3-trifluoromethyl-phenyl)-propenone; and
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
yl } -1-cyclobutyl-methanone; and
pharmaceutically acceptable salts, optical isomers, solvates or hydrates
thereof.
Most preferred compounds of the present invention include:
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
yl } -2-phenoxy-ethanone;
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
32
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
yl } -2-phenylsulfanyl-ethanone;
trans-l- {4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-l-
yl}-2-(4-chloro-phenoxy)-ethanone; and
trans-l-{4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidin-1-
yl}-2-benzyloxy-ethanone; and
pharmaceutically acceptable salts, optical isomers, solvates and hydrates
thereof.
Other most preferred compounds of the present invention include:
trans- 4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid 4-metlloxycarbonyl-phenyl ester; and
trans-4-[2-(4-Amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]-
piperidine-l-
carboxylic acid 2-nitro-phenyl ester; and
a pharmaceutically acceptable salts, optical isomers, solvates and hydrates
thereof.
The term "Co-C6 alkyl" refers to a single bond, or a C1-C6 alkyl.
The term "Cl-C6 alkyl" refers to a saturated or unsaturated, straight or
branched chain
hydrocarbyl radical of from one to six carbon atoms. An unsaturated C1-C6
alkyl may contain
one or more double or triple bond between two adjacent carbon atoms, and
requires at least
two carbon atoms in the alkyl chain. A C1-C6 alkyl includes, but is not
limited to, the
following: methyl, ethyl, propyl, isopropyl, 1-propenyl, propynyl, 2-propenyl,
n-butyl,
isobutyl, 2-methyl-2-propenyl, 2-butynyl, 3-butynyl, tertiary butyl, sec-
butyl, 1-butenyl, 2-
butenyl, and 3-butenyl, pentyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-
pentynyl, 3-pentynyl, 4-
pentynyl, prenyl, neopentyl, hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-
hexenyl, 2-hexynyl, 3-
hexynyl, 4-hexynyl, 5-hexynyl. A Ci-C6 alkyl includes smaller subsets of alkyl
radicals, such
as a C1-C4 alkyl, a C1-C3 alkyl, and a C1-C2 alkyl, as well as a C5-C6 alkyl.
The term "C1-C8 alkyl" refers to a saturated or unsaturated, straight or
branched chain
hydrocarbyl radical of from one to eight carbon atoms. A Cl-C8 alkyl may be
saturated or
unsaturated. An unsaturated C1-C8 alkyl may contain one or more double or
triple bond
between two adjacent carbon atoms. A Cl-Cg alkyl includes, but is not limited
to, the
following: methyl, ethyl, propyl, isopropyl, 1-propenyl, propynyl, 2-propenyl,
n-butyl,
isobutyl, 2-methyl-2-propenyl, 2-butynyl, 3-butynyl, tertiary butyl, sec-
butyl, 1-butenyl, 2-
butenyl, and 3-butenyl, pentyl, 2-pentenyl, 3-pentenyl, 4-pentenyl,, 2-
pentynyl, 3-pentynyl, 4-
pentynyl, prenyl, neopentyl, hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-
hexenyl, 2-hexynyl, 3-
hexynyl, 4-hexynyl, 5-hexynyl, heptyl, heptenyl, heptynyl, octyl, octenyl and
octynyl. A Cl-
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
33
C8 alkyl includes smaller subsets of alkyl radicals, such as a C1-C4 alkyl, a
Cl-C3 alkyl, a C1-
C2 alkyl, as well as a C5-C8 alkyl, a C5-C7 alkyl, and a C6-C8 alkyl.
The term "Cl-C11 alkyl" refers to a saturated or unsaturated, straight or
branched chain
hydrocarbyl radical of from one to eleven carbon atoms. A C1-C11 alkyl may be
saturated or
unsaturated. An unsaturated Ci-C11 alkyl may contain one or more double or
triple bond
between two adjacent carbon atoms. A C1-Cll alkyl includes, but is not limited
to, the
following: methyl, ethyl, propyl, isopropyl, 1-propenyl, propynyl, 2-propenyl,
n-butyl,
isobutyl, 2-methyl-2-propenyl, 2-butynyl, 3-butynyl, tertiary butyl, sec-
butyl, 1-butenyl, 2-
butenyl, 3-butenyl, pentyl, 2-pentenyl, 3-pentenyl, 4-pentenyl,, 2-pentynyl, 3-
pentynyl, 4-
pentynyl, prenyl, neopentyl, hexyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-
hexenyl, 2-hexynyl, 3-
hexynyl, 4=hexynyl, 5-hexynyl, heptyl, heptenyl, heptynyl, octyl, octenyl,
octynyl, nanyl,
nanenyl, nanynyl, decyl, decenyl, decynyl, n-decyl, and undecyl. A C1-Cl l
alkyl includes
smaller subsets of alkyl radicals, such as a Cl-C6 alkyl, a C1-C5 alkyl, a Cl-
C4 alkyl, a C1-C3
alkyl, a C1-C2 alkyl as well as a C7-C11 alkyl, a C7-Clo alkyl, a C6-C8 alkyl,
a C8-Clo alkyl, and
a C8-C11 alkyl. In addition, each carbon of the C1-C11 alkyl may be optionally
substituted with
one, two or three X substituents.
The term "C3-Cio cycloalkyl" refers to a saturated or unsaturated C3-C10
cyclic chain
hydrocarbyl radical of from three to ten carbon atoms. A C3-Clo cycloalkyl may
be saturated
or unsaturated. An unsaturated C3-C10 cycloalkyl may contain one or more
double bonds
between two adjacent carbon atoms. A C3-Clo cycloalkyl includes, but is not
limited to, the
following: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexenyl,
cyclohexyl,
cycloheptyl, cyclooctyl, and the like, bicyclic ring strucutures, including,
but not limited to a
fused five- and -five membered cycloalkyl rings, a fused five- and -six
membered cycloalkyl
rings, a fused six- and -six menlbered cycloalkyl rings, and polycyclic ring
structures,
including, but is not limited to, adamantane. In addition, any single bond in
the cycloalkyl
may be a double or triple bond. In addition, each carbon of the C3-Clo
cycloalkyl may be
optionally substituted with one, two or three X substituents.
The term "-(CH2)õQp(CH2)õW" refers to a moiety where each n is independently
an
integer 0 to 6, p is independently an integer 0 or 1, Q is a oxygen, sulfur or
-NR3,
W is independently selected from the group consisting of hydrogen, C3-Clo
cycloalkyl, -(C3-
Clo cycloalkyl)-aromatic, and the following aromatic or heteroaromatic rings:
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
34
x
B
~ B co
x xo x r 01)x x
0
where B is -0-, -S-, -NR6-, where each carbon of the aromatic or
heteroaromatic ring may be
independently substituted by a nitrogen atom, and each carbon of the aromatic
ring may be
optionally substituted an X substituent. Each carbon of -(CH2)r, alkyl chain
is optionally
substituted with one to two X substituents. R3 is independently selected from
the group
consisting of hydrogen, and C1-C$ alkyl, where C1-C$ alkyl may be straight or
branched,
saturated or unsaturated.
When Rl is -(CH2)õQp(CH2)nW and Q is NR3, the moiety includes NR3W, -
CH2NR3W, -CH2NR3CH2W, -(CH2)2NR3W, -CH2NR3CH2CH2W, -(CH2)2NR3CH2W, -
(CH2)3NR3W, -CHZNR3(CH2)2CH2W, -(CH2)2NR3CH2CH2W, -(CH2)2NR3(CH2)2CH2W, -
CH2NR3(CH2)3CH2W, -(CH2)2NR3(CH2)2CH2W, -(CH2)3NR3CH2CH2W, -
(CH2)4NR3CHZW, -(CH2)5NR3W, -CH2NR3(CH2)4CH2W, -(CH2)2NR3CH2)3CH2W, -
(CH2)3NR3(CH2)2CHZW, -(CH2)4NR3CH2CH2W, -(CH2)5NR3CH2W, -(CH2)6NR3W, -
CH2NR3(CH2)5CH2W, -(CH2)2NR3(CH2)4CH2W, -(CH2)3NR3(CH2)3CH2W, -
(CHZ)4NR3(CH2)2CH2W, -(CHZ)5NR3CH2CH2W, and -(CH2)6NR3CH2W, where the terms n,
p, W and R3 are previously defined.
When Rl is -(CH2)nQp(CH2),,W and Q is a sulfur, the moiety includes -SW, -
CH2SW, -
CH2SCH2W, -(CH2)2SW, -CHZSCH2CH2W, -(CH2)2SCH2W, -(CHZ)3SW, -
CH2SH(CH2)2CH2W, -(CH2)2SCH2CH2W, -(CH2)2S(CH2)2CH2W, -CH2S(CH2)3CH2W, -
(CH2)2S(CH2)2CH2W, -(CH2)3SCH2CH2W, -(CH2)4SCH2W, -(CH2)5SW, -
-
CH2S(CH2)4CH2W, -(CH2)2S(CH2)3CH2W, -(CH2)3S(CH2)2CH2W, -(CH2)4SCH2CH2W,
(CH2)5SCH2W, -(CH2)6SW, -CH2S(CH2)5CH2W, -(CH2)2S(CH2)4CH2W, -
(CH2)3S(CH2)3CH2W, -(CH2)4S(CH2)2CH2W, -(CH2)5SCH2CH2W, and -(CH2)6SCH2W,
where the terms n, p and W are previously defined.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
When Rl is -(CH2)õQp(CH2)r,W and Q is an oxygen, the moiety includes -OW, -
CH2OW, -CH2OCH2W, -(CH2)20W, -CHaOCHaCH2W, -(CH2)2OCH2W, -(CH2)30W, -
CH2O(CHZ)ZCHZW, -(CH2)2OCH2CH2W, -(CH2)20(CH2)2CH2W, -CH2O(CHZ)3CHaW, -
(CH2)20(CH2)2CH2W, -(CH2)3OCHZCHZW, -(CH2)4OCH2W, -(CH2)50W, -
5 CHaO(CH2)4CH2W, -(CH2)ZO(CH2)3CH2W, -(CH2)30(CH2)2CH2W, -(CHZ)4OCH2CHaW, -
(CH2)5OCH2W, -(CH2)60W, -CH2O(CH2)$CH2W, -(CH2)20(CH2)4CH2W, -
(CH2)30(CH2)3CH2W, -(CH2)40(CH2)2CH2W, -(CH2)5OCH2CH2W, and -(CH2)6OCH2W,
where the terms n, p and W are previously defined.
The term "-(CHZ)õCHWa" refers to a moiety where n is independently an integer
0 to
10 6, and W is independently selected from the group consisting of hydrogen,
C3-C10 cycloalkyl,
-(C3-Clo cycloalkyl)-aromatic,, and the following aromatic or heteroaromatic
rings:
x
B
\ B co
X / Xo X B X
X
O
where B is -0-, -S-, -NR6-, where each carbon of the aromatic or
heteroaromatic ring may be
independently substituted by a nitrogen atom, and each carbon of the aromatic
ring may be
15 optionally substituted an X substituent. Each carbon of -(CH2)n alkyl chain
is optionally
substituted with one to two X substituents.
The term "phenyl" refers to an aromatic phenyl ring of six carbons. The phenyl
ring
may be unsubstituted or substituted. An "unsubstituted phenyl" refers to a -
C6H5 moiety. A
"substituted phenyl" means that one or more of carbon atoms of the phenyl ring
are substituted
20 with one to five substitutuents independently selected from the group
consisting of hydrogen,
halogen, methylenedioxy, -C1-C8 alkyl, -C3-Clo cycloalkyl, -CI-C$ alkoxy, -OH,
-CY3, -
OCY3, -CO2R3, -CN, -NO2, -COR3, -NR4R5, -SR3, -CONR4R5, and -NH-C(O)-R3, where
R3, R4 and R5 are independently selected from the group consisting of
hydrogen, and C1-C6
alkyl, and if R4 or R5, in which each carbon of C1-C6 alkyl is optionally
substituted with an X
25 substituent or R4 and R5 can be connected to give a heterocycle. The
substitutuents may be
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
36
meta, para or ortho to the attachnlent site. A substituted phenyl includes
subsets of substituted
phenyls, and includes
a phenyl substituted with one or more substituents selected from the group
consisting of -C1-C4 alkyl, -C3-C6 cycloalkyl, -C1-C4 alkoxy, -OH, -CY3, -
OCY3, -
C02R3, -CN, -NO2, -COR3, -NR4R5 and -SR3, where R3 is selected from the group
consisting of hydrogen, and Cf-C$ alkyl, and R4 and R5 are independently
selected
from the group consisting of hydrogen, and C1-C6 alkyl, and if R4 or R5, in
which
each carbon of C1-C6 alkyl is optionally substituted with an X substituent or
R4 and R5
can be connected to give a heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -Ci-C3 alkyl, -C3-C6 cycloalkyl, -Cl-C3 alkoxy, -OH, -CY3, -
OCY3, -
C02R3, -CN, -NOZ, -COR3, -NR4R5 and -SR3, where R3 is selected from the group
consisting of hydrogen, and Cl-C$ alkyl, and, R4 and R5 are independently
selected
from the group consisting of hydrogen, and C1-C6 alkyl, and if R4 or R5, in
which
each carbon of C1-C6 alkyl is optionally substituted with an X substituent or
R4 and R5
can be connected to give a heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -C1-C3 alkyl, -C3 cycloalkyl, -C1-C3 alkoxy, -OH, -CY3, -OCY3, -
CO2R3,
-CN, -NO2, -COR3, -NR4R5 and -SR3, where R3 is selected from the group
consisting of hydrogen, and C1-C8 alkyl, and, R4 and R5 are independently
selected
froin the group consisting of hydrogen, and Cl-C6 alkyl, and if R4 or R5, in
which
each carbon of C1-C6 alkyl is optionally substituted with an X substituent or
R4 and R5
can be connected to give a heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -C1-C4 alkyl, -C1-C4 alkoxy, -OH, -CY3, -OCY3, -C02R3, -CN, -
NO2, -
COR3, -NR4R5 and -SR3, where R3 is selected from the group consisting of
hydrogen, and C1-C8 alkyl, and, R4 and R5 are independently selected from the
group
consisting of hydrogen, and Cl-C6 alkyl, and if R4 or R5, in which each carbon
of C1-
C6 alkyl is optionally substituted with an X substituent or R4 and R5 can be
connected
to give a heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -C1-C3 alkyl, -C3-C6 cycloalkyl, -CI-C3 alkoxy, -OH, -CY3, -
OCY3, -CN,
-NO2, -NR4R5 and -SR3, where R3 is selected from the group consisting of
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
37
hydrogen, and Cl-C8 alkyl, and, R4 and R5 are independently selected from the
group
consisting of hydrogen, and C1-C6 alkyl, and if R4 or R5, in which each carbon
of Cl-
C6 alkyl is optionally substituted with an X substituent or R4 and R5 can be
connected
to give a heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -Cl-C3 alkyl, -Cl-C3 alkoxy, -OH, -CY3, -OCY3, -CN, -NO2, -NR4R5
and -SR3, wlzere R3 is selected from the group consisting of hydrogen, and C1-
C8
alkyl, and, R4 and R5 are independently selected from the group consisting of
hydrogen, and Ci-C6 alkyl, and if R4 or R5, in which each carbon of C1-C6
alkyl is
optionally substituted with an X substituent or R4 and R5 can be connected to
give a
heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -CY3, and -OCY3;
a phenyl substituted with one or more substituents selected from the group
consisting of -Cl-C3 alkyl, -C1-C3 alkoxy, -CN, and -SR3, where R3 is selected
from
the group consisting of hydrogen, and C1-C$ alkyl;
a phenyl substituted with one or more substituents selected from the group
consisting of -OH, -CY3, -OCY3, -CN, -NO2, -NR4R5 and -SR3, where R3 is
selected from the group consisting of hydrogen, and C1-C8 alkyl, and R4 and R5
are
independently selected from the group consisting of hydrogen, and C1-C4 alkyl,
and if
R4 or R5, in which each carbon of C1-C4 alkyl is optionally substituted with
an X
substituent or R4 and R5 can be connected to give a heterocycle;
a phenyl substituted with one or more substituents selected from the group
consisting of -C4-C6 alkyl, -C4-C6 alkoxy, -OH, -CY3, -OCY3, -CN, -NO2, -NR4R5
and -SR3, where R3 is selected from the group consisting of hydrogen, and C1-
C$
alkyl, and, R4 and R5 are independently selected from the group consisting of
hydrogen, and Cl-C6 alkyl, and if R4 or R5, in which each carbon of CI-C6
alkyl is
optionally substituted with an X substituent or R4 and R5 can be connected to
give a
heterocycle.
The term "heterocycle" refers to any C5-C12 closed-ring substituent wherein at
least
one or more carbon atoms of the ring is independently substituted with
nitrogen, and
optionally one or more carbon atoms of the ring may be substituted with
nitrogen, sulfur or
oxygen. In addition, any single bond of the heterocycle may be optionally
substituted with a
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
38
double bond. Heterocycle includes, but is not limited to the following:
piperidinyl,
pyrrolidinyl, morpholinyl, piperazinyl, pyrrolyl, imidazolidinyl,
pyrazolidinyl, pyrazolinyl,
thiomorpholinyl, and indolinyl.
The term "-C1-CS alkoxy" refers to a oxygen connected to a(C1-C8 allcyl),
which
includes straight or branched, saturated or unsaturated alkyl of one to eight
carbon atoms. A
saturated -Ct-Cg alkoxy includes, but is not limited to, a methoxy, ethoxy,
propoxy,
isopropoxy, butoxy, isobutoxy, pentoxy, hexoxy, heptoxy, and octoxy, and their
corresponding branched chains. An unsaturated -CI-Cg alkoxy includes straight
and branched
alkoxy moieties and includes, but is not limited to, a -OCHCH2, -OCCH, -
OCH2CHCH2, -
OCCCH2, -OCHCH2CH3, -OCH(CH3)CHCH2, -OC(CH3)2CHCH2, -OCHCHCH2CH3, -
OCH2CHCHCH3, -OCH2CH2CHCH2, -OC(CH3)CHCH3, -OCHC(CH3)CH3, -
OCH2C(CH3)CH2, -OCHCH(CH2)aCH3, -OCHCH(CH2)3CH3, -OCH2CHCH(CH2)2CH3, -
O(CH2)2CHCHCH2CH3, -OCHCH(CH2)4CH3, -OCHCH(CH2)5CH3, and the like. Preferred -
Ct-C8 alkoxy moieties include a straight, saturated -C1-C8 alkoxy. Preferred
straight,
unsaturated -C2-C8 alkoxy moieties include a -C2-C8 alkoxy with a single
double bond.
Preferred straight, unsaturated -C2-C8 alkoxy moieties include a-CZ-C$ alkoxy
with a single
triple bond.
The term "-SR3" refers to a thiol or thioalkyl moiety attached to a CI-C8
alkyl, which is
an alkyl radical of one to eight carbon atoms. When R3 is hydrogen, the "-SR3"
is a thiol, -
SH. When R3 is a Cl-C$ alkyl, the "-SR3" is a thioalkyl of one to eight carbon
atoms, where
the alkyl chain may be a straight or branched alkyl chain, or saturated or
unsaturated alkyl. A-
SCi-C$ alkyl includes saturated or unsaturated bonds, where one or more single
bond between
two adjacent carbon atoms is replaced with a double or triple bond. -SR3
includes -SH, -
SCH3, -SCH2CH3, -S(CHa)2CH3, -S(CH2)3CH3, -S(CH2)4CH3, -S(CH2)SCH3, -
SCH(CH3)2, -
SC(CH3)3, -SCH2CH(CH3)2, -SCH2C(CH3)3, -S(CH2)2CH(CH3)2, -S(CH2)2C(CH3)3, -
SCH(CH3)(CH2)3CH3, -SCH2CH(CH3)3(CH2)2 CH3, -S(CH2)2CH(CH3)3CH2CH3 and the
like,
and includes their unsaturated counterparts. An unsaturated -SR3 includes
straight or
branched, unsaturated thioalkyl moieties and includes, but is not limited to, -
SCHCH2, -
SCCH, -SCH2CHCH2, -SCCCH3, -SCHCH2CH3, -SCH(CH3)CHCH2, -SC(CH3)2CHCH2, -
SCHCHCH2CH3, -SCH2CHCHCH3, -SCH2CH2CHCH2, -SC(CH3)CHCH3, -SCHC(CH3)CH3,
-SCH2C(CH3)CH2, -SCHCH(CH2)2CH3, -SCHCH(CH2)3CH3, -SCH2CHCH(CH2)2CH3, -
S(CH2)2CHCHCH2CH3, -SCHCH(CH2)4CH3, -SCHCH(CHa)sCH31 and the like. Preferred -
C1-C8 thioalkyl moieties include straight, saturated -SC1-C8 alkyl. Preferred
straight,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
39
unsaturated -SCZ-C8 thioalkyl moieties include a-SCZ-C8 thioalkyl with a
single double
bond. Preferred straight, unsaturated -SC2-C8 thioalkyl moieties include a-SCz-
C8 thioalkyl
with a single triple bond.
The term "aromatic" refers to a C6-C13 aromatic ring(s) of six to thirteen
carbon atoms
which contain at least three double bonds. An aromatic ring may be a single or
polycyclic
ring structure, including, but not limited to benzene, indene, naphthalene and
fluorenone. In
addition, each carbon of the aromatic ring may be independently substituted
with one X
substituent.
The term "heteroaromatic" refers to a C5-Clo heteroaromatic rings of five to
ten carbon
atoms which contain at least two double bonds. Heteroaromatic includes five
and six
membered rings, five-and six-membered bicyclic rings, and six-and six-membered
bicyclic
rings. Heteroaromatic includes, but is not limited to, benzene, indene and
naphthalene rings
wherein at least one of the carbon atoms is replaced with a sulfur, oxygen or
nitrogen atom.
Heteroaromatics include, but are not limited to, pyridinyl, isoxazolyl,
benzimidazolyl,
thiazolyl, thienyl, furanyl, indolyl, 1,3-benzodioxolyl, imidazolyl,
pyrimidinyl, pyrazinyl,
triazinyl, oxazolyl, purinyl, quinolinyl, and isoquinolinyl, pyrrolyl,
pyrazolyl, isothiazolyl,
oxadiazolyl, triazolyl, thiadiazolyl, pyridazolyl, indolizinyl, indolyl,
isoindolyl, indazolyl,
benzthiazolyl, purinyl, quinazolinyl, quinoxalinyl, phthalazinyl, cinnolinyl,
benzothiopheneyl,
and benzofuranyl. In addition, each carbon of the heteroaromatic ring may be
independently
substituted with one X substituent.
The term "methylenedioxy" refers to a oxygen-methylene-oxygen moiety, -O-(CH2)-
O-. The methylenedioxy substituent is attached to two adjacent carbon atoms.
The term "-CY3" refers to a carbon with three substituents independently
selected from
the group consisting of hydrogen and halogen. The term "halogen" refers to a
halogen moiety
and includes fluoro, chloro, bromo, and iodo moieties. Thus, "-CY3" includes
fully and
partially halogenated carbon, and includes but is not limited to, -CF3, -CHF2,
-CH2F, -CI3, -
CHI2, -CH2I, -CBr3, -CHBr2, -CH2Br, -CC13, -CHCla, -CH2C1, -CF2C1, -CFC12 and -
CFC1H.
The term "-OCY3" refers to a methoxy moiety with three substituents
independently
selected from the group consisting of hydrogen and halogen. Thus, "-OCY3"
includes fully
and partially halogenated methoxy moieties, and includes but is not limited
to, -OCF3, -
OCHF2, -OCH2F, -OCI3, -OCHI2, -OCH2I, -OCBr3, -OCHBr2, -OCH2Br, -OCC13, -
OCHC12, -
OCH2C1, -OCFaCI, -OCFC12 and -OCFCIH.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
The term "-C02R3" refers to a carboxy moiety wliere R3 is selected from the
group
consisting of hydrogen and Cl-C8 alkyl. When R3 is hydrogen, the "-C02R3" is a
carboxyl
moiety. When R3 is a Ci-C$ alkyl, the "-C02R3" is an ester of one to eight
carbon atoms,
where the alkyl chain may be a straight or branched alkyl chain, or saturated
or unsaturated
5 alkyl. Thus, the term "-C02R3" includes -COOH, -COOCH3, -COOCH2CH3, -
COO(CH2)2CH3, -COO(CH2)3CH3, -COO(CH2)4CH3, -COO(CH2)5CH3, -COOCH(CH3)2, -
-
COOC(CH3)3, -COOCH2CH(CH3)2, -COOCH2C(CH3)3, -COO(CH2)2CH(CH3)2,
COO(CH2)2C(CH3)3, -COOCH(CH3)(CH2)3CH3, -COOCH2CH(CH3)2CH2CH3, -
COO(CH2)2CH(CH3)3 and the like, and their unsaturated counterparts.
10 The term "-COR3" refers to an aldellye or ketone moiety where R3 is
selected from the
group consisting of hydrogen and Cl-C8 alkyl. When R3 is hydrogen, the "-COR3"
is an
aldehyde -COH. When R3 is a Ci-Cg alkyl, the "-COR3" is a ketone containing
one to eight
carbon atoms, where the alkyl chain may be a straight or branched alkyl chain,
or saturated or
unsaturated alkyl. Thus, the term "-COR3" includes -COH, -COCH3, -COCH2CH3, -
15 CO(CH2)2CH3, -CO(CH2)3CH3, -CO(CH2)4CH3, -CO(CH2)5CH3, -COCH(CH3)2, -
COC(CH3)3, -COCH2CH(CH3)2, -COCH2C(CH3)3, -CO(CH2)2CH(CH3)2, -CO(CH2)2C(CH3)3,
-
COCH(CH3)(CH2)3CH3, -COCH2CH(CH3)2CH2CH3, -CO(CH2)2CH(CH3)3 and the like, and
includes their unsaturated counterparts.
The term "-NR4R5" refers to asi amino moiety where R4 and R5 are each
20 independently selected from the group consisting of hydrogen and C1-C6
alkyl. When R4 and
R5 are hydrogen, the -NR4R5 is a primary amino moiety, -NH2. When only one of
R4 and R5
are hydrogen, the -NR4R5 is a secondary amino moiety -NH(Cl-C6). When R4 and
R5 are Cl-
C6 alkyl, the -NR4R5 is a tertiary amino moiety -N(Cl-C6)2. The C1-C6 alkyl,
each
independently containing one to six carbon atoms, and where each alkyl chain
is
25 independently a straight or branched alkyl chain, saturated or unsaturated
alkyl chain. Thus,
the term -NR4R5 includes -NH2, -NHCH3, -NHCH2CH3, -NH(CH2)2CH3, -NH(CH2)3CH3, -
NH(CH2)4CH3, -NH(CH2)5CH3, -N(CH3)2, -N(CH2CH3)2, -N((CH2)2CH3)2, -
N((CH2)3CH3)2, -
N((CH2)4CH3)2, -N((CH2)5CH3)2, -N(CH2CH3)(CH3), -N((CH2)2CH3)(CH3), -
N((CHZ)4CH3)(CH3), -N((CH2)5CH3)(CH3), and the like, and includes their
branched and/or
30 unsaturated counterparts. The term "-NR4R5" includes moieties where R4 and
R5 are
connected to give a heterocycle.
The term "-CO-NR4R5" refers to an amide moiety where R4 and R5 are each
independently selected from the group consisting of hydrogen and C1-C6 alkyl.
When R4 and
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
41
R5 are hydrogen, the "-CO-NR4R5" is a primary amide moiety, -CONH2. When only
one of
R4 and R5 are hydrogen, the "-CO-NR4R5" is a secondary amide moiety"-CONH(C1-
C6).
When R4 and R5 are Cl-C6 alkyl, the "-CO-NR4R5" is a tertiary amide m.oiety"-
CON(C1-
C6)2. The C1-C6 alkyl, each independently containing one to six carbon atoms,
and where each
alkyl chain is independently a straight or branched alkyl chain, saturated or
unsaturated alkyl
chain. Thus, the term "-CO-NR4R5" includes -CONH2, -CONHCH3, -CONHCH2CH3, -
CONH(CH2)2CH3, -CONH(CH2)3CH3, -CONH(CH2)4CH3, -CONH(CH2)5CH3, -CON(CH3)2, -
CON(CH2CH3)2, -CON((CH2)2CH3)2, -CON((CH2)3CH3)2, -CON((CH2)4CH3)2, -
CON((CH2)5CH3)2, -CON(CH2CH3)(CH3), -CON((CH2)2CH3)(CH3), -
CON((CH2)4CH3)(CH3),
-CON((CH2)5CH3)(CH3), and the like, and includes their branched and/or
unsaturated
counterparts. The term "-CO-NR4R5" includes moieties where R4 and R5 are
connected to
give a heterocycle.
The term "-NH-C(O)-R3" refers to an amide moiety where R3 is selected from the
group consisting of hydrogen and Cl-C8 alkyl. When R3 is hydrogen, the "-NH-
C(O)-R3" is
an formamide, -NH-C(O)H. When R3 is a Cl-C8 alkyl, the "-NH-C(O)-R3" is an
alkyl of one
to eight carbon atoms, where the alkyl chain may be a straight or branched
alkyl chain, or
saturated or unsaturated alkyl. Thus, the term "-NH-C(O)-R3" includes -
NHC(O)H, -
NHC(O)CH3, -NHC(O)CH2CH3, -NHC(O)(CHa)ZCH3, -NHC(O)(CHa)3CH3, -
NHC(O)(CH2)4CH3, -NHC(O)(CH2)5CH3, -NHC(O)CH(CH3)2, -NHC(O)C(CH3)3, -
NHC(O)CH2CH(CH3)2, -NHC(O)CH2C(CH3)3, -NHC(O)(CH2)ZCH(CH3)Z, -
NHC(O)(CH2)2C(CH3)3, -NHC(O)CH(CH3)(CH2)3CH3, -NHC(O)CH2C(CH3)2(CH2)2CH3, -
NHC(O)(CH2)2C(CH3)2CH3 and the like, and includes their unsaturated
counterparts.
The term "-NH-C(O)-(C1-C6 alkyl)-aromatic" refers to an amide alkylaryl moiety
where a C1-C6 alkyl is attached to an aromatic ring. The C1-C6 is an alkyl
chain of one to six
carbon atoms, where the alkyl chain may be a straight or branched alkyl chain,
or saturated or
unsaturated alkyl. The term "aromatic" refers to a ring of C6-C13 carbon
atoms. Thus, the
term "-NH-C(O)-(Cl-C6)-aromatic" includes -NHC(O)CH2-aromatic, -NHC(O)(CH2)Z-
aromatic, -IVHC(O)(CH2)3-aromatic, -NHC(O)(CH2)4-aromatic, -NHC(O)(CHa)5-
aromatic, -
NHC(O)(CHZ)6-aromatic, -NHC(O)(CH)(CH3)-aromatic, -NHC(O)C(CH3)a-aromatic,-
NHC(O)CH2CH(CH3)-aromatic, -NHC(O)CH2C(CH3)2-aromatic, -NHC(O)(CH2)2CH(CH3), -
aromatic -NHC(O)(CH2)2C(CH3)2-aromatic and the like, and includes their
branched and
unsaturated counterparts.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
42
The term "-NH-C(O)-(C1-C6)-heteroaromatic" refers to an amide allcyl
heteroaryl
moiety where a C1-C6 alkyl is attached to an heteroaromatic ring. The C1-C6 is
an alkyl chain
of one to six carbon atoms, where the alkyl chain may be a straight or
branched alkyl chain, or
saturated or unsaturated alkyl. The term "heteroaromatic" refers to an
aromatic ring of C5-Cio
carbon atoms, where one or more carbon atoms is replaced with a nitrogen,
oxygen or sulfur.
Thus, the term "-NH-C(O)-(C1-C6)-heteroaromatic" includes -NHC(O)CH2-
heteroaromatic, -
NHC(O)(CHa)2-heteroaromatic, -NHC(O)(CH2)3-heteroaromatic, -NHC(O)(CH2)4-
heteroaromatic, -NHC(O)(CHa)5-heteroaromatic, -NHC(O)(CH2)6-heteroaromatic, -
NHC(O)(CH)(CH3)-heteroaromatic, -NHC(O)C(CH3)2- heteroaromatic,-
NHC(O)CH2CH(CH3)-heteroaromatic, -NHC(O)CH2C(CH3)2-heteroaromatic, -
NHC(O)(CH2)2CH(CH3)-heteroaromatic, -NHC(O)(CH2)ZC(CH3)'Z-heteroaromatic and
the
like, and includes their branched and unsaturated counterparts.
The term "-S(O)Z-(C1-C6 alkyl)" refers to a saturated or unsaturated, straight
or
branched chain hydrocarbyl radical of from one to six carbon atoms attached to
a sulfonyl
radical, -S(O)2-. A C1-C6 alkyl may be saturated or unsaturated. An
unsaturated C2-C6 alkyl
may contain one or more double or triple bond between two adjacent carbon
atoms, and
requires at least two carbon atoms in the alkyl chain. A Ci-C6 alkylsulfonyl
includes, but is
not limited to, the following: methylsulfonyl, ethylsulfonyl, propylsulfonyl,
isopropylsulfonyl,
1-propenylsulfonyl, propynylsulfonyl, 2-propenylsulfonyl, n-butylsulfonyl,
isobutylsulfonyl,
2-methylsulfonyl-2-propenylsulfonyl, 2-butynylsulfonyl, 3-butynylsulfonyl,
tertiary
butylsulfoinyl, sec-butylsulfonyl, 1-butenylsulfonyl, 2-butenylsulfonyl, and 3-
butenylsulfonyl,
pentylsulfonyl, 2-pentenylsulfonyl, 3-pentenylsulfonyl, 4-pentenylsulfonyl,, 2-
pentynylsulfonyl, 3-pentynylsulfonyl, 4-pentynylsulfonyl, prenylsulfonyl,
neopentylsulfonyl,
hexylsulfonyl, 2-hexenylsulfonyl, 3-hexenylsulfonyl, 4-hexenylsulfonyl, 5-
hexenylsulfonyl,
2-hexynylsulfonyl, 3-hexynylsulfonyl, 4-hexynylsulfonyl, 5-. A C1-C6 alkyl
includes smaller
subsets of alkyl radicals, such as a C1-C4 alkylsulfonyl, a Cl-C3
alkylsulfonyl, and a Ct-C2
alkylsulfonyl, as well as a C5-C6 alkylsulfonyl.
The term "-S(O)2-(C3-Cz0 cycloalkyl)" refers to a saturated or unsaturated,
branched or
straight C3-Clo cyclic chain hydrocarbylsulfonyl radical of from three to ten
carbon atoms. A
C3-Clo cycloalkylsulfonyl may be saturated or unsaturated. An unsaturated C3-
C10
cycloalkylsulfonyl may contain one or more double bonds between two adjacent
carbon
atoms. A C3-C10 cycloalkylsulfonyl includes, but is not limited to, the
following:
cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl,
cyclopentenylsulfonyl,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
43
cyclohexylsulfonyl, cyclohexenylsulfonyl, cycloheptylsulfonyl,
cyclooctylsulfonyl, and the
like, bicyclic ring strucutures, including, but not limited to a fused five-
and -five membered
cycloalkylsulfonyl ring, a fused five- and -six membered cycloalkylsulfonyl
ring, a fused six-
and -six membered cycloalkylsulfonyl ring, and polycyclicsulfonyl ring.
The term "-C(O)-(Co-C6 alkyl)-aromatic" refers to an aromatic ring attached to
a
carbonyl moiety via a Co-C6 alkyl. When the alkyl chain is Co, then the
aromatic ring is
directly attached to the carbonyl moiety. When the alkyl chain is C1_C6, then
the aromatic ring
is attached to the carbonyl moiety via a Cl-C6 alkyl; The C1-C6 alkyl is a
saturated or
unsaturated, straight or branched alkyl chain of one to six carbon atoms. An
unsaturated C2-C6
alkyl may contain one or more double or triple bond between two adjacent
carbon atoms, and
requires at least two carbon atoms in the alkyl chain. In addition, each
carbon of the aromatic
ring may be independently substituted with one X substituent.
The term "-S(O)2-(CO-C6 alkyl)-aromatic" refers to an aromatic ring attached
to a
sulfonyl moiety via a Co-C6 alkyl. When the alkyl chain is Co, then the
aromatic ring is
directly attached to the sulfonyl moiety. When the alkyl chain is CI_C6, then
the aromatic ring
is attached to the sulfonyl moiety via a C1-C6 alkyl. The C1-C6 alkyl is a
saturated or
unsaturated, straight or branched alkyl chain of one to six carbon atoms. An
unsaturated C2-C6
alkyl may contain one or more double or triple bond between two adjacent
carbon atoms, and
requires at least two carbon atoms in the alkyl chain. In addition, each
carbon of the aromatic
ring may be independently substituted with one X substituent.
The term "-(C3-Clo cycloalkyl)-aromatic" refers to an aromatic ring attached
to a C3-
Clo cycloalkyl. The C3-Clo cylcoalkyl is a saturated or unsaturated alkyl
chain of three to ten
carbon atoms. An unsaturated C3-Clo cylcoalkyl may contain one or more double
or triple
bonds between two adjacent carbon atoms. In addition, each carbon of the C3-
Clo cycloalkyl
may be independently substituted with one or two X substituents and each
carbon of the the
aromatic ring may be independently substituted with one X substituent.
An optical isomer, refers to any of the various stereo isomeric configurations
which
may exist for a given compound of Formula (I), and includes geometric isomers.
It is
understood that a substituent may be attached at a chiral center of a carbon
atom. Therefore,
the invention includes enantiomers, diastereomers or racemates of the
compound. If the
compound contains a double bond, the substituent may be E or Z configuration.
If the
compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may
have a cis- or
trans-configuration.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
44
A solvate refers to a compound, or an intermediate thereof, which contains a
fraction,
one or more molecules of a solvent. Solvate includes hemisolvate, monosolvate
and
multisolvate. Solvates may be formed with solvents including, but not limited
to,
pharmaceutically acceptable solvates such as ethanol and water.
A hydrate refers to a compound, or an intermediate thereof, which contains a
fraction,
one or more molecules of water. Hydrate includes hemihydrate, monohydrate and
multihydrate.
A pharmaceutically-acceptable salts refers to the reaction product of one or
more
molecules of any non-toxic, organic or inorganic pharmaceutically-acceptable
acids with a
compound of Formula (I). Illustrative inorganic acids which form
pharmaceutically-
acceptable salts include hydrochloric acid, hydrobromic acid, sulphuric acid
and phosphoric
acid and metal acids, such as sodium monohydrogen orthophosphate and potassium
hydrogen
sulfate. Illustrative organic acids which form suitable pharmaceutically-
acceptable salts
include mono-, di- and tricarboxylic acids. Illustrative organic acids are,
for example, acetic
acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid,
glutaric acid, fumaric
acid, malic acid acid, tartaric acid, citric acid, ascorbic acid, maleic acid,
hydroxymaleic acid,
benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salacylic
acid, 2-
phenoxybenzoic acid and sulfonic acids such as methane sulfonic acid,
trifluoromethane
sulfonic acid and 2-hydroxyethane sulfonic acid.
A patient at risk of neuronal apoptosis refers to a patient who, because of
the existence
of an identified risk factor associated with neuoronal apoptosis, such as
having had a stroke, a
genetic predisposition to such a condition, had or currently have neoplasms,
exposure of
carcinogenic agents, diet, age or has other risk factors associated with the
development of
neoplastic disease states. Preferred patients at risk of developing a
neoplastic disease state
include patients who are positive for oncogenic viruses, are in remission from
prior treatment
of neoplasm(s), use tobacco products or have previously been exposed to
carcinogens such as
asbestos, or are positive for various neoplastic genetic markers.
An effective amount of a coinpound of the formula is expected to vary from
about 1
microgram per kilogram of body weight per day ( g/kg/day) to about 500
mg/kg/day. A
preferred effective amount of a compound of the formula is from about 10
g/kg/day to about
50 mg/kg/day. A more preferred amount of a compound of the formula is from
about 20
g/kg/day to about 1 mg/kg/day.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
A compound of the formula may be administered in any form or mode that makes
the
compound bioavailable in effective amounts. Compounds of the formula may be
administered
by oral or parental routes. Compounds of the formula may be administered
orally,
subcutaneously, intramuscularly, intravenously, transdermally, intranasally,
rectally, ocularly
5 and the like. Oral administration is preferred. One skilled in the art of
preparing
pharmaceutical formulations may readily determine appropriate forms of a
compound of the
formula by determining particular characteristics of the compound, the disease
to be treated,
the stage of the disease, response of other patients and other relevant
circumstances.
A compound of the formula may be combined with carriers, excipients or other
10 compounds to prepare compositions of a compound of the formula. A
composition of the
formula comprise a compound of the formula in admixture or otherwise in
association with
one or more inert carriers. Compositions of the formula are useful, for
example, as convenient
means of making bulk shipments, or for storing, a compound of the formula. An
inert carrier
is a material which does not degrade or otherwise covalently react with a
compound of the
15 formula. An inert carrier may be a solid, semi-solid or liquid material.
Preferred carriers are
water, aqueous buffers, organic solvents and phannaceutically acceptable
carriers or
excipients. Preferred aqueous buffers provide a buffering range at which a
compound of the
formula does not degrade. Preferred buffering ranges are about pH 4 to about
pH 9. Preferred
organic solvents are acetonitrile, ethyl acetate, and hexane.
20 A pharmaceutical composition of a compound of the formula comprises a
compound
of the formula in admixture or otherwise in association with one or more
pharmaceutically
acceptable carrier or excipient. A pharmaceutically acceptable carrier or
excipient may be a
solid, semi-solid or liquid material that can serve as a vehicle or medium for
the compound of
the formula. Suitable pharmaceutically acceptable carriers or excipients are
well known to
25 those skilled in the art.
A phazmaceutical composition of a compound of the formula may be adapted for
the
route of administration. A preferred pharmaceutical composition of a compound
of the
formula is a tablet, troche, capsule, elixir, syrup, wafer, chewing gum,
suppository, solution or
suspension if the route of administration is oral, parental or topical.
30 A preferred oral pharmaceutical composition of a compound of the formula
comprises
a compound of the formula with an inert diluent or with an edible carrier.
Preferred forms of
oral pharmaceutical compositions of a compound of the formula are tablets,
troches, capsules,
elixirs, syrups, wafers, chewing gum, solutions or suspensions.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
46
Preferred pharmaceutical compositions of a compound of the formula contain
from
about 4% to about 80% of the compound. Preferred pharmaceutical compositions
contain an
amount of the compound of the formula from about 1 g to about 500 g; more
preferred
pharmaceutical composition contain an amount of the compound of the formula
from about 10
g to about 200 g.
A compound of the formula may be administered alone or in the form of a
pharmaceutical composition in coinbination with pharmaceutically acceptable
carriers or
excipients.
As used herein, the following terms have the indicated meanings: "g" refers to
grams;
"mg" refers to milligrams; "mmol" refers to millimoles; "M" refers to molar;
"h" or "hr"
refers to hours; ="min" refers to minutes; ="sec" refers to seconds; ="L"
refers to liters; ="mL"
refers to milliliters; "bp" refers to boiling point; "mp" refers to melting
point; " C" refers to
degrees Celsius; "mm Hg" refers to millimeters of mercury; "psi" refers to
pounds per square
inch; " L" refers to microliters; " g" refers to micrograms; " M" refers to
micromolar;
"TLC" refers to Thin Layer Chromatography; "Rf" refers to retention factor,
"Rt" refers to
retention time; "HPLC" refers to high performance liquid chromatography; "MS"
refers to
Mass Spectrum; "LC/MS" refers to Liquid Chromatography Mass Spectrometry;
"APCI"
refers to Atmospheric Pressure Chemical Ionization; "HTPMS" refers to high
through-put
mass spectrometry; "HTPMS RT" refers to high through-put mass spectrometry
retention
time; "ESI" refers to Electrospray Ionization; "CI" refers to Chemical
Ionization; "TOF-ES"
refers to Time of Flight Electrospray; "M+" refers to a positively charged
molecular ion;
"MH+" refers to a protonated molecular ion; "BOC anhydride" refers to di-tert-
butyl
dicarbonate; "BOC" refers to the t-butyloxycarbonyl moiety, "THF" refers to
tetrahydrofuran;
"CH2C12" or "DCM" refers to dichloromethane or methylene chloride; "DMSO"
refers to
dimethylsulfoxide; "TEA" refers to triethylainine; "SPE" refers to Solid Phase
Extraction;
"DEAD" refers to diethyl azodicarboxylate; "NMR" refers to Nuclear Magnetic
Resonance;
"TMS" refers to tetramethylsilane; "ppm" refers to parts per million; "Hz"
refers to hertz;
"MHz" refers to megahertz; "MeOH", methanol; "EtOH", ethanol; "N", Normal;
"HCl",
hydrogen chloride; "TFA", trifluoroacetic acid, "DIEA", diisopropylethylamine;
"RT PCR",
reverse transcription polymerase chain reaction; "HEPES", 4-(2-hydoxyethyl0-l -
piperazine
ethanesulfonic acid); "MgCla," Magnesium chloride; "EGTA", ethylene glycol-bis
(P-
aminoethyl ether) N,N,N',N'-tetraacetic acid; "EDTA";
ethylenediaminetetraacetic acid;
"DTT", dithiothreitol; "MOI", multiplicity of infectivity; "NaF", sodium
flouride; "BSA",
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
47
bovine serum albumin; "p.o.", oral(ly); "i.v.", intravenous(ly); "s.c.",
subcutaneous(ly).
Unless otherwise specified, all starting materials and reagents were available
from commercial
sources.
The compounds of Formula (I) may be prepared by utilizing procedures and
techniques well known and appreciated by one of ordinary skill in the art.
General synthetic
schemes for preparing these compounds are set forth in Scheme A, Scheme B and
Scheme C
wherein all substituents, unless otherwise indicated, are as previously
defined.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
48
Scheme A
CI
CI
6
N N~ step a \
Cf' 2'N N s R~ OH 2 N~
H CI N
1 3 R2
I \
step b
H2N N /
4
I / N I \
H~N
~ N step c
' ' " H N N ~
H2N N N \ 2 NH2 ll
6 CI/ \ N \
H R2
7 R2
step d
\ ~H
H,N H, N N
O i\ \ step e ~ N\ N
I \
O NN N O N NN N
I H x I H ry
t-Bu H R2 t-Bu R2
$ 9a R2 = cyclopentyl
9b R2 = isopropyl
9c R2 = cyclopent-2-enyl
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
49
In Scheme A, step a, 2,6-dichloropurine (1) is reacted with an appropriate
alcohol of
structure 2 to give the corresponding 9-substituted-2,6-dichloropurine
compound of structure
3 using techniques and procedures well known to one of ordinary skill in the
art.
For example, 2,6-dichloropurine (1) can be reacted with an appropriate alcohol
of
structure 2 such as cyclopentanol, isopropanol, or 2-cyclopenten-l-ol in the
presence of
triphenylphosphine and diethyl azodicarboxylate in a suitable anhydrous
aprotic solvent, such
as tetrahydrofuran. The reactants are typically stirred together at room
temperature for a
period of time ranging from 5 hours to 5 days. The resulting 9-substituted-2,6-
dichloropurine
of structure 3 may be recovered from the reaction zone by extractive methods
as are known in
the art. More typically, the resulting 9-substituted-2,6-dichloropurine of
structure 3 is
recovered by removal of solvent followed by charging directly onto a silica
gel column and
eluting with a suitable solvent, such as methylene chloride, or mixture of
solvents, such as a
mixture of methylene chloride and methanol.
In step b, the 6-chloro functionality of the 9-substituted-2,6-dichloropurine
of structure
3 is displaced by reaction with 4-amino-l-benzylpiperidine (4) to give the
corresponding 9-
substituted-6-[4-(l-benzyl)piperidinylaniino]-2-chloropurine of structure 5.
For example, the 9-substituted-2,6-dichloropurine of structure 3 can be
reacted with 4-
amino-l-benzylpiperidine (4) in a suitable anhydrous polar solvent such as
ethanol. The
reactants are typically stirred together at reflux temperature for a period of
time ranging from
minutes to 3 days. The resulting 9-substituted-6-[4-(1-
benzyl)piperidinylamino]-2-
chloropurine (5) is recovered from the reaction zone by extractive methods as
are known in
the art or, if the 9-substituted-6-[4-(1-benzyl)piperidinylamino]-2-
chloropurine of structure 5
precipitates out of solution, it may be recovered by filtration. More
typically, the resulting 6-
25 [4-(1-benzyl)piperidinyl-amino]-2-chloropurine (5) is recovered by removal
of solvent
followed by charging directly onto a silica gel column and eluting with a
suitable solvent,
such as methylene chloride, or mixture of solvents, such as a mixture of
methylene chloride
and methanol.
In step c, the 2-chloro functionality of the 9-substituted-6-[4-(1-
30 benzyl)piperidinylamino]-2-chloropurine of structure 5 is displaced by
reaction with trans-1,4-
cyclohexanediamine (6) to give a 9-substituted-2-[trans-(4-
aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinylamino]purine of structure 7.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
For example, an appropriate 9-substituted-6-[4-(1-benzyl)piperidinylamino]-2-
chloropurine of structure 5 can be reacted with a molar excess of trans-1,4-
cyclohexandiamine
(0. The reactants are typically placed in a pressure vessel, sealed, and
heated at a temperature
of from about 80 C to about 150 C for a period of time ranging from 30 minutes
to 3 days.
5 The resulting 9-substituted-2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinylamino]purine of structure 7 is recovered from the reaction
zone by
extractive methods as are known in the art and may be purified by
chromatography by
charging directly onto a silica gel column and eluting with a suitable
solvent, such as
methylene cllloride, or mixture of solvents, such as a mixture of methylene
chloride and
10 methanol. Concentration of the desired fractions provides the free base of
7 which may be
dissolved in an alcoholic solvent, typically methanol, and converted to a mono-
, di- or tri-acid
addition salt by methods well known to those skilled in the art.
In step d, the primary amino functionality of a 9-substituted-2-[trans-(4-
aminocyclohexyl)amino]-6-[4-(1-benzyl)piperidinylamino]purine of structure 7
is protected
15 by reacting a compound of structure 7 with di-tert-butyl dicarbonate.
For example, a 9-substituted-2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinylamino]purine of structure 7 is typically reacted with a
molar excess of di-
tert-butyl dicarbonate ("BOC anhydride") in the presence of an excess of a
suitable base such
as triethylamine at room temperature from about five hours to 24 hours. The
resulting trans-
20 {4-[6-(1-benzylpiperidin-4-ylamino)-9-substituted-9H-purin-2-
ylamino]cyclohexyl} carbamic
acid tert-butyl ester of structure 8 may be recovered from the reaction zone
by diluting with
water, and applying extractive methods as are known in the art. The crude
product 8 may be
purified by chromatography by charging directly onto a silica gel column and
eluting with a
suitable solvent, such as methylene chloride, or mixture of solvents, such as
a mixture of
25 methylene chloride and methanol.
In step e, the piperidine N-benzyl moiety is removed by catalytic or transfer
hydrogenolysis from a trans-{4-[6-(l-benzylpiperidin-4-ylamino)-9-substituted-
9H-purin-2-
ylamino]cyclohexyl}carbamic acid tert-butyl ester of structure 8 to give a
trans-{4-[6-
(piperidin-4-ylamino)-9-substituted-9H-purin-2-ylamino]cyclohexyl}carbamic
acid tert-butyl
30 ester of structure 9.
For example, a methanol suspension of a trans-{4-[6-(1-benzylpiperidin-4-
ylamino)-9-
substituted-9H-purin-2-ylamino]cyclohexyl}carbamic acid tert-butyl ester of
structure 8 and
palladium black is typically treated with a methanol solution of ammonium
formate and the
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
51
mixture is stirred and heated at reflux from 6 to 48 hours. The resulting
trans-{4-[6-
(piperidin-4-ylamino)-9-substituted-9H-purin-2-ylamino]cyclohexyl}carbamic
acid tert-butyl
ester of structure 9 is recovered from the reaction by filtration and
extractive methods as are
known in the art and may be purified by chromatographic methods as are known
in the art.
Starting materials for use in the general synthetic procedures outlined in
Scheme A are
readily available commercially.
In Scheme B, the secondary nitrogen atom in the piperidine ring of a trans-{4-
[6-
(piperidin-4-ylamino)-9-substituted-9H-purin-2-ylamino]cyclohexyl}carbamic
acid tert-butyl
ester of structure 9 may be acylated with various acylating reagents such as
carboxylic acid
halides; chloroformate esters; alkyl, aryl and aralkyl isocyanates or sulfonyl
chlorides; and N-
mono- or N, N-disubstituted sulfamoyl chlorides to provide amide, carbamate,
urea,
sulfonamide and sulfamide compounds of formula I, respectively.
For example, a methylene chloride solution of about equimolar amounts of a
trans-{4-
[6-(piperidin-4-ylamino)-9-substituted-9H-purin-2-ylamino]cyclohexyl}carbamic
acid tert-
butyl ester of structure 9, the desired acylating agent and triethylamine is
stirred from 2 to 24
hours at room temperature. Triethylainine may be omitted when an isocyanate is
the acylating
agent. When an N-mono- or N,N-disubstituted sulfonyl chloride is used a polar
aprotic
solvent such as tetrahydrofuran is preferred. The reaction is then treated
with an excess of
dilute hydrochloric acid solution resulting in hydrolysis of the BOC
protecting group and
precipitation of the desired acylated compound of formula I. The precipitate
is recovered by
decanting the supernatant, and applying extractive methods and chromatographic
purification
methods as are known in the art.
In Scheme C, steps g and h, N-monosubstituted and N,N-disubstituted urea
compounds I may also be prepared by protecting the primary amino group of
trans-4-[2-(4-
amino-cyclohexylamino)-9-substituted-9H-purin-6-ylamino]-piperidine-l-
carboxylic acid 4-
nitro-phenyl ester 10 (step g), reaction of the N-protected 4-nitro-phenyl
ester 11 with a
primary or a secondary amine, and removal of the N-protecting group to afford
N-
monosubstituted or N,N'-disubstituted urea compounds I (step h).
For example, a 2-[trans-(4-aminocyclohexyl)amino)-9-substituted-9H-purin-6-
ylamino]-piperidine-l-carboxylic acid 4-nitro-phenyl ester of structure 10 is
typically reacted
with a molar excess of di-tert-butyl dicarbonate ("BOC anhydride") in the
presence of an
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
52
excess of a suitable base such as triethylamine at room temperature from about
five hours to
24 hours. The resulting trans-4-[2-(4-tert-butoxycarbonylamino-
cyclohexylamino)-9-
substituted-9H-purin-6-ylamino]-piperidine-1-carboxylic acid 4-nitro ester of
structure 11
may be recovered from the reaction zone by diluting with water, and applying
extractive
methods as are known in the art. The crude N-BOC-protected ester 11 may be
purified by
chromatography by charging directly onto a silica gel column and eluting with
a suitable
solvent, such as methylene chloride, or mixture of solvents, such as a mixture
of methylene
chloride and methanol (step g).
In step h, a solution of the trans-4-[2-(4-tert-butoxycarbonylamino-
cyclohexylamino)-
9-substituted-9H-purin-6-ylamino]-piperidine-l-carboxylic acid 4-nitro ester
of structu.re 11
and a suitable solvent such as tetrahydrdofuran may be treated with a primary
or a secondary
amine in the presence of a base such as triethylamine and stirred at a
temperature of from
about room temperature to about 90 C for about two hours to about 24 hours.
The reaction is
Scheme B
(O)
'H 'X\
Ri
H, N N H, N N
O N N' step f i \
~ \
O!I''N N~N N H2N N~N N
t-Bu H \ R2 H ~
X=C,n=1 I
9 X=S,n=2
R2 = cyclopentyl, isopropyl or cyclopent-2-enyl
cooled to room temperature and stirred with with an excess of dilute
hydrochloric acid from
about one to about 24 hours resulting in hydrolysis of the BOC protecting
group. The solvent
is removed under reduced pressure and the crude N-monosubstituted or N,N-
disubstituted
urea compound I may be purified by chromatographic methods as are well known
in the art.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
53
Scheme C
AO
N~O H j
H H'N' v / H'N/
H,N N i N Step g IN~ N ~ I N" NOa OYN~,, N~ NO,
N N OtBu N
H R2 H R2
10a RZ = cyclopentyl 11a R2 = cyclopentyl
10b R2 = isopropyl 11 b RZ = isopropyl
10c R2 = cyclopent-2-enyl 11 c RZ = cyclopent-2-enyl
step h
0
H H,N
I
H ~ N~
N x
N N
i R, = N-mono- or N,N-disubstituted-amino
H
R2 Ra = cyclopentyl, isopropyl, cyclopenten-2-yi
I
Example 1
Chemical synthesis according to Schemes A, B and C.
The following examples present typical syntheses as described in Schemes A, B
and C.
These examples are understood to be illustrative only and are not intended to
limit the scope
of the present invention in any way.
Synthesis of Intermediate trans-{4-[9-cyclopentyl-6-(piperidin-4-ylamino)-9H-
purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (9a) According to Scheme A
Scheme A, sto a: 2,6-dichloro-9-cYclopent1-9H-purine (3a)
Dissolve 2,6-dichloropurine (1, 680 mg, 3.60 mmol), cyclopentanol (2a, 260 mg,
3.02
mmol), and triphenyl phosphine (950 mg, 3.60 mmol) in dry THF (20 mL) and cool
to 0 C.
Add diethyl azodicarboxylate (DEAD, 570 L, 3.60 mmol) dropwise over a period
of 15
minutes under a nitrogen atmosphere. Stir the resulting solution for 60 hours
at room
temperature. Evaporate the solvent in vacuo, charge directly onto a 500 g
silica gel column,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
54
and elute with DCM and concentrate the desired fractions to give 2,6-dichloro-
9-cyclopentyl-
9H-purine 3 a .
'H-NMR (DMSO-d6): S 8.82(s,1H), 4.95 (pentet, 1H), 2.3-1.6(m, 8H); MS (ESI)
257 (MH+);
Anal. Calculated for C10H10C12N4: %C 46.71; %H 3.92; %N 21.79; Found %C 46.70;
%H
3.90; %N 21.92.
:purine (Sa)
Scheme A, step b: 2-chloro-6 j4-(1=benzyl)piperidinylamino]-9-cyclopentyl-9H
Add to a solution of 2,6-dichloro-9-cyclopentyl-9H-purine (3a, 25g, 97mmol)
and 4-amino-l-
benzylpiperidine (4, 19g, 100mmo1) in ethanol (200 mL), diisopropylethylamine
(12.9g,
100mmol) and heat the reaction at reflux overnight. Concentrate the reaction,
dissolve the
residue in DCM, extract with water and brine, dry over sodium sulfate, filter
and concentrate
to dryness. Purify the material on a silica gel column (500g) eluting with
DCM:methanol
(4:1) and concentrate the desired fractions to give 40g of 2-chloro-6-[4-(1-
benzyl)piperidinylamino]-9-cyclopentyl-9H-purine 5a .
'H-MNR (CDC13): 6 7.75(s,1H), 7.3 (m, 5H), 5.77 (brs, 1H), 4.9(p, 1H),
4.2(brs, 1H), 3.56(s,
2H), 2.85(d, 2H), 2.25(m, 4H), 2.1(d, 2H), 1.85(m, 6H), 1.6(m, 2H); MS (APCI)
411 (MH+).
Scheme A, step c: 2-[trans-(4-aminocyclohexyl amino]-6-[4-(1-
benzyl)piperidinyl-amino]-9-
cyclopentyl-9H-purine (7a)
Heat a mixture of 2-chloro-6-[4-(1-benzyl)piperidinylamino]-9-cyclopentyl-9H-
purine (Sa,
10g, 24mmol) and trans-1,4-diaminocyclohexane (6, 40g, 6 wt. equivalents) at
140 C for 16
hours in a sealed reaction bomb. Cool the reaction to room temperature,
dissolve in DCM and
wash with water. Extract the water layer with DCM and combine the organic
layers. Extract
the organic layer with brine, dry over sodium sulfate, filter and concentrate
to dryness. Purify
the material on a 200g silica gel colunm eluting with DCM:methanol (4:1), and
concentrate
the desired fractions to give 2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinyl-
amino]-9-cyclopentyl-9H-purine (7a .
'H-NMR (CDC13): S 7.45(s, 1H), 7.3(m, 5H), 5.48(brs, 1H), 4.7(p, 1H), 4.6(d,
1H), 4.1(brs,
1H), 3.72(m, 1H), 3.52(s, 2H), 2.9(d, 2H), 2.7(m, 1H), 2.25-1.5(m, 20H),
1.21(m, 4H); MS
(APCI) 489 (MH+).
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
Convert 7a to the trihydrochloride by acidifying (pH=2) an ethanol solution of
7a with 6N
HCL and concentrate the solution to give 8.59g of 2-[trans-(4-
aminocyclohexyl)amino]-6-[4-
(1-benzyl)-piperidinyl-amino]-9-cyclopentyl-9H-purine trihydrochloride (7a
trihydrochloride). MS (CI) 489(MH); TLC (silica gel), DCM/methanol (4:1),
Rf=0.1.
5
Scheme A, step d: trans-{4-[6-(1-benzyl-piperidin-4 ylamino)-9-cyclopentyl-9H-
purin-2-
ylamino]-c clyl}-carbamic acid tert-butyl ester (8a)
Stir a solution of 2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinyl-
amino]-9-cyclopentyl-9H-purine trihydrochloride (7a trihydrochloride, 44g, 90
mmol), BOC
10 anhydride.(39.4g, 183 mmol), TEA (72.72g, 72 mmol), and DCM (400 mL)
overnight at room
temperature. Mix the reaction with water, remove the resultant white
participate by filtration
through CeliteOR, wash the filtrate with brine, separate the phases and dry
the organic phase
over sodium sulfate. Filter and concentrate the organic phase to dryness, and
purify the
residue on a 500g silica gel column using DCM:methanol (9:1) to give 40.2
grams of trans-{4-
15 [6-(1-benzyl-piperidin-4-ylamino)-9-cyclopentyl-9H-purin-2-ylamino]-
cyclohexyl}-carbamic
acid tert-butyl ester 8a as a white solid.
1H-NMR (CDC13): b 8.32 (s, 1H), 7.33(d, 4H), 7.25(m, 1H), 5.02(m, 1H), 4.85(m,
1H), 4.45
(1n, 1H), 4.25(m, 1H), 4.9(m, 1H), 3.6(m, 1H), 3.53(s, 2H), 3.42(m, 1H),
2.8(m, 2H), 2.2-1.4
(m, 18H), 1.45 (s, 9H), 1.23(m, 4H); MS (CI) 588 (M+, base peak).
Scheme A, step e: trans- 4-[9-cyclopent yl-6-(piperidin-4-ylamino -9H-purin-2-
ylamino]'
c cly ohexyl}-carbamic acid tert-but lester (9a)
Add to a solution of {4-[6-(1-benzyl-piperidin-4-ylamino)-9-cyclopentyl-9H-
purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (8a, 40.2g, 68mmol) in 400
mL of
methanol, a suspension of Pd black (2g) in a small amount of water. Then add a
solution of
ammonium formate (13.3g, 215mmol) in 100 mL of water, and heat at a gentle
reflux
overnight. TLC shows the presence of starting material (TLC, silica plates,
4:1
DCM:methanol; Rf: starting material 0.75, product 0.15). Add an additional 5g
of ammonium
forrnate and reflux 24 hours. Remove the catalyst by filtration through Celite
and
concentrate the filtrate. Dissolve the residue in DCM and extract with water.
Remove the
white precipitate by filtration through a pad of Celite , wash the filtrate
with brine, dry over
sodium sulfate and filter. Concentrate the filtrate and purify the residue on
silica gel (500g)
CA 02427338 2006-09-25
WO 02/42303 PCT/USO1/44835
56
using DCM:methanol (4:1) to give 33.4g of trans-{4-[9-cyclopentyl-6-(piperidin-
4-ylamino)-
9H-purin-2-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (9a as a white
solid.
'H-NMR (CDC13/D',0 exchange): 6 7.45 (s, 1H), 4.7(pentet, 1H), 4.65(d, IH),
3.76(brs, 1H),
3.45 (brs, 1H) 3.2 (d, 2H), 2.8 (t, 2H), 2.25-1.6 9(ni, 14H), 1.5 (m, 2H),
1.45 (s, 9H), 1.25 (m,
4H.C21
), 6 H42 N8 02 MW=498.6; MS (TOF-ES) 499.5 (M+ ).
Synthesis of Intermediate trans-{4-[9-Isopropyl-6-(piperidin-4-ylamino)-9H-
purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (9b) According to Scheme A
Scheme A, step a: 2,6-dichloro-9-isopropyl-9H-purine (3b)
Add DEAD (4.7g, 27.09mmol) slowly to a solution of 2,6-dichloropurine (1, 5g,
26.5mmol),
triphenylphosphine (11.75g, 44.5mmol) and isopropyl alcohol (2b lOrnl) in THF
(100m1),
and stir at room temperature for 24 hours. Concentrate the reaction mixture,
dissolve the
residue in DCM (20m1) and filter to remove the unwanted solids. Load the
filtrate onto a 90
gram silica gel column (Biotage), and elute with DCMlacetone (95:5).
Concentrate the
desired fractions to give 3.0 grams of 2,6-dichloro-9-isopropyl-9H-purine (,3b
.
1H-NMR (CDC13): S 8.2(s,1H), 4.95 (pentet, 1H), 1.63(d, 6H)
Scheme A, step b: 2-chloro-6-L4-(1-benzyl)piperidinylaminol9-isopropyl-9H-
purine (5b
Reflux a solution of 2,6-dichloro-9-isopropyl-9H-purine (3U, 3.0 g, 13mmol)
and 4-amino-N-
benzylpiperidine (4, 2.5g, 13mmol) in ethanol (100 mL) overnight. Concentrate
the reaction
TM
to dryness and purify the residue on a 90 gram silica gel column (Biotage)
eluting with
DCMlmethanol (95:5). Concentrate the desired fractions to give 3.1g of 2-
chloro-6-[4-(1-
benzyl)piperidinylamino]-9-isopropyl-9H-purine (5b).
I H-NMR (CDC13): 8 7.8(s,1H), 7.3(m, 5H), 4.92(pentet, 1H), 3.58(s,2H),
2.9(m,2H), 2.4-
1.9(m, 5H), 1.6(m,8H).
Scheme A, step c: 2-ftrans-(4-aminocyclohexyl)amino]-6-f4-(1-
benzyl)piperidinyl-amino]-9-
isopropyl-9H-purine 7b
Heat a mixture of 2-chloro-6-[4-(1-benzyl)piperidinylamino]-9-isopropyl-9H-
purine (3.0g,
7.linmol) and trans-l,4-diaminocyclohexane (6 18g) in a steel bomb at 140 C
for 60 hours.
Cool the reaction and dissolve the mixture in DCM/water (3:1). Separate the
layers, basify the
aqueous layer with saturated sodium carbonate solution, and extract with DCM
(2x 50m1).
Combine the organic layers, wash with brine, dry over sodium sulfate, filter
and concentrate to
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
57
dryness. Purify the residue on a 40 gram silica gel column (Biotage) eluting
with
DCM/methanol (4:1 with 0.5% ammonium hydroxide and concentrate the desired
fractions to
give 3.71 grams of 2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinyl-amino]-9-
isopropyl-9H-purine (7b).
TLC (silica gel): Rf=0.13, CH2C12/EtOH (4:1).
Scheme A, step d: trans-{4-[6-(1-benz y1-piperidin-4-ylamino)-9-isopropyl-9H-
purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (8b)
Add TEA (4.14g, 41.4mmol) to a solution of 2-[trans-(4-aminocyclohexyl)amino]-
6-[4-(1-
benzyl)piperidinyl-amino]-9-isopropyl-9H-purine (7b, 3.7g, 6.9mmol) and di-
tert-butyl
dicarbonate (3.0g, 13.9mmol) in 50 ml of DCM. Stir the reaction for 45 minutes
at room
temperature, and then wash with water. Filter through Celite to remove a
milky white
precipitate, wash the filtrate with brine, dry over sodium sulfate, filter and
concentrate to
dryness. Purify the residue on a 40 gram silica gel column (Biotage) using
DCM/methanol
(9:1) to give 2.7 grams of trans-{4-[6-(l-benzyl-piperidin-4-ylamino)-9-
isopropyl-9H-purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (8b).
1H-NMR (CDC13): S 7.5(s,1H), 7.4-7.2(m,5H), 5.45(brs, 1H), 4.62(m,2H),
4.44(brs,1H),
4.1(brs,1H), 3.85(brs,1H), 3.55(s,2H), 3.5(m,1H), 2.9(m,2H), 2.25-2.0(m,9H),
1.7-
1.4(m,17H), 1.3(M,3H).
Scheme A, step e: trans-{4-[9-isopropyl-6-(piperidin-4-ylamino -9H-purin-2-
ylamino]-
cyclohexyl}-carbamic acid tert-butyl ester (9b)
Add to a solution of trans-{4-[6-(1-benzyl-piperidin-4-ylamino)-9-isopropyl-9H-
purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (8b, lg, lmmol) and
methanol (40 ml), a
suspension of palladium black (0.25g) in a little water. Then add a solution
of ammonium
formate (0.4mg, 6.4mmol) and l Oml of water, and reflux overnight. Filter the
reaction
through Celite and concentrate the filtrate to dryness. Dissolve the residue
in methylene
chloride (50 ml), extracted with water, and filter through Celite to remove a
milky white
precipitate. Separate the organic layer, wash with brine, dry over sodium
sulfate, filter and
concentrate the filtrate to dryness. Purify the residue on a 40 gram silica
gel column (Biotage)
using DCM/methanol (4:1) to give 0.8 grams of trans-{4-[9-isopropyl-6-
(piperidin-4-
ylamino)-9H-purin-2-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester 9b .
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
58
H1-NMR (CDC13): S 7.5 (s,1H), 5.45 (brs, 1H), 4.64(m,2H), 4.45(m,1H), 4.2
(m,1H),
3.75 (m,1H), 3.5 (m,1H), 3.2 (m,1 H), 3.0 (m,1H), 2.8(t,1H), 2.5-2.0 (m,9H),
1.6 (m,2H),
1.53(d,6H), 1.45(s,9H), 1.25(m,3H).
Synthesis of Intermediate trans-{4-[9-Cyclopent-2-enyl-6-(piperidin-4-ylamino)-
9H-
purin-2-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (9c) According to
Scheme A
Scheme A, step a, 2,6-dichloro-9-cyclopent-2-enYl-9H-purine 3c :
Add to a stirred solution of 2-cyclopenten-l-ol (2c, 2.60 g, 30.9 mmol), 2,6-
dichloropurine (1, 7.00 g, 37.0 mmol) and triphenyl phosphine (9.70 g, 37.0
mmol) in dry
THF (120 ml) at OoC, diethyl azodicarboxylate (5.85 ml, 37.0 mmol) dropwise
over a period
of 15 min. under a nitrogen atmosphere. Stir the resulting solution for 60 hrs
at room
temperature. Concentrate the reaction mixture, charge the residue directly
onto a silica gel
column and elute with hexane:ethyl acetate (3:1) to give of 2,6-dichloro-9-
cyclopent-2-enyl-
9H-purine 3 c) (3.20 g, 41%.)
rH-NMR (CDC13): 5 8.05 (s,1H,purine H-8), 6.37 (m,1H,CH=C), 5.89 (m,1H,CH=C),
5.77
(m,1H), 2.49 - 2.78 (m,3H), 1.95 (m,1H).
Scheme A, step b: 2-chloro-6-[4-(1-benzyl)piperidinylamino]=9-cyclopent-2-enyl-
9H-purine
Sc
Add to a solution of 2,6-dichloro-9-cyclopent-2-enyl-9H-purine 3c, 1.0 mmol)
and 4-amino-
1-benzylpiperidine (4,1.0 mmol) in ethanol (200 mL), diisopropylethylamine
(1.0 mmol) and
heat the reaction at reflux overnight. Concentrate the reaction, dissolve the
residue in DCM,
extract with water and brine, dry over sodium sulfate, filter and concentrate
to dryness. Purify
the material on a silica gel column (50g) eluting with DCM:methanol (4:1) and
concentrate
the desired fractions to give 2-chloro-6-[4-(1-benzyl)piperidinylamino]-9-
cyclopent-2-enyl-
9H-purine Sc .
Scheme A, step c: 2-[trans-(4-aminocyclohexyl)aminol-6-[4-(1-
benzyl)piperidinyl-aminol-9-
cyclopent-2-enyl-9H-purine (7c)
Heat a mixture of 2-chloro-6-[4-(1-benzyl)piperidinylamino]-9-cyclopent-2-enyl-
9H-purine
Sc, 1.0 mmol) and trans-l,4-diaminocyclohexane (6, 6 wt. equivalents) at 140 C
for 16 hours
in a sealed reaction bomb. Cool the reaction to room temperature, dissolve in
DCM and wash
with water. Extract the water layer with DCM and combine the organic layers.
Extract the
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
59
organic layer with brine, dry over sodium sulfate, filter and concentrate to
dryness. Purify the
material on a 20g silica gel column eluting with DCM:methanol (4:1), and
concentrate the
desired fractions to give 2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinyl-
amino]-9-cyclopent-2-enyl-9H-purine 7c .
Scheme A, step d: trans-{4-[6-(1-benzyl-piperidin-4-ylamino)-9-cyclopent-2-
enyl-9H-purin-
2-ylamino]-cyclohexyll -carbamic acid tert-butyl ester (8c)
Stir a solution of 2-[trans-(4-aminocyclohexyl)amino]-6-[4-(1-
benzyl)piperidinyl-
amino]-9-cyclopent-2-enyl-9H-purine (7c-, 1.0 mmol), BOC anhydride (2.0 mmol),
TEA (1
mmol), and DCM (40 mL) overnight at room temperature. Mix the reaction with
water, filter
through Celite , wash the filtrate with brine, separate the phases and dry the
organic phase
over sodium sulfate. Filter and concentrate the organic phase to dryness, and
purify the
residue on a 500g silica gel column using DCM:methanol (9:1) to give trans-{4-
[6-(1-benzyl-
piperidin-4-ylamino)-9-cyclopent-2-enyl-9H-purin-2-ylamino]-cyclohexyl}-
carbamic acid
tert-butyl ester (& .
Scheme A, step e: trans-{4-[9-cyclopent-2-enyl-6-(piperidin-4-ylamino -9H -
purin-2-
ylamino]-cyclohexyll-carbamic acid tert-butyl ester (9c)
Add to a solution of trans-{4-[6-(1-benzyl-piperidin-4-ylamino)-9-cyclopent-2-
enyl-
9H-purin-2-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (8c,1.0 mmol)
in 40 mL of
methanol, a suspension of Pd black (0.5 wt%) in a small amount of water. Then
add a
solution of ammonium formate (2.2 mmol) in 10 mL of water, and heat at a
gentle reflux
overnight. Remove the catalyst by filtration through Celite and concentrate
the filtrate.
Dissolve the residue in DCM and extract with water. Remove the white
precipitate by
filtration through a pad of Celite , wash the filtrate with brine, dry over
sodium sulfate and
filter. Concentrate the filtrate and purify the residue on silica gel (50g)
using DCM:methanol
(4:1) to give trans-{4-[9-cyclopent-2-enyl-6-(piperidin-4-ylamino)-9H-purin-2-
ylamino]-
cyclohexyl}-carbamic acid tert-butyl ester (9c
General Method for Acylation of Intermediate 9-Cyclopentyl Analog 9a and
Hydrolysis
to Compound I According to Scheme B
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
Scheme B, step f
Stir a mixture of trans- {4-[9-cyclopentyl-6-(piperidin-4-ylamino)-9H-purin-2-
ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (9a, 0.2 mmol), an
acylating agent such
5 as a carboxylic acid halide; a chloroformate ester; alkyl, aryl or aralkyl
isocyanates; alkyl, aryl
or aralkyl sulfonyl chlorides or alkyl, aryl or aralkyl sulfamoyl chlorides
(0.2 mmol) and
triethylamine (0.2 mmol, omitted when isocyanates used) in methylene chloride
(2 ml)
overnight at room temperature. Add 1.0 ml of 4N HCl in dioxane and a
precipitate forms.
Allow to stand for 3 hours, decant the solvent and dissolve the solid in DCM
using a small
10 amount of methanol as co-solvent if necessary. Purify the product by
chromatography on a 2
g silica gel SPE cartridge pre-equilibrated with heptane. Elute the column in
three fractions;
first fraction 5 ml DCM; fractions 2 and 3 with 10-15 ml of DCM/methanol
(4:1).
Concentrate the desired fractions, dissolve the residue in ethanol and adjust
to pH 2.0 with
10% HCI. Concentrate to dryness to give 9-cyclopentyl compound I, and analyze
the product
15 by LC/MS as summarized in Table 1.
General Method for Acylation of Intermediate 9-Isopropyl Analog 9b or
Intermediate 9-
cyclopent-2-enyl Analog 9c, and Hydrolysis to Compound I According to Scheme B
Scheme B, step f:
20 Add to a solution of 6-(piperidinyl-4-amino)-2-(trans-4-tert-
butoxycarbonylamino-
cyclohexylamino)-9-isopropylpurine (9b, 100mg) or trans-{4-[9-cyclopent-2-enyl-
6-
(piperidin-4-ylamino)-9H-purin-2-ylamino]-cyclohexyl}-carbamic acid tert-butyl
ester, and
an acylating agent such as a carboxylic acid halide; a chloroformate ester;
alkyl, aryl or
aralkyl isocyanates; alkyl, aryl or aralkyl sulfonyl chlorides, or alkyl, aryl
or aralkyl sulfamoyl
25 chlorides (0.5 mmol) in DCM (2m1), 200 ~ 1 of TEA and stir overnight at
room temperature
(when the acylating agent is an isocyanate TEA is omitted). Add 1 ml of 4N HC1
in dioxane
and allow the reaction to sit for 3 hours at room temperature to effect
removal of the N-BOC
protecting group. The product precipitates and the solvent is decanted.
Dissolve the
precipitate in a small amount ofDCM/methanol (4:1) and load on a 5 gram silica
gel SPE
30 cartridge that is pre-equilibrated with heptane. Elute with 5 ml of DCM
into the f rst fraction,
followed by five 15 ml fractions using 4:1 DCM/methanol. Concentrate the
desired fractions,
dissolve the residue in ethanol and treat with 3 drops of 6 N aqueous HCl.
Further concentrate
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
61
to provide compound I as the HCI salt and analyze the product by LC/MS as
summarized in
Table 1.
General Method for Preparing BOC-Protected N-Monosubstituted and N,N-
Disubstituted Urea Compounds I and Hydrolysis to N-Monosubstituted and N,N-
Disubstituted
Urea Compounds I According to Schenle C
Scheme C, step g: trans-9-Substituted-4-[2-(4-tert-butoxycarbonylamino-
cyclohexylamino)-
9H-purin-6-Vlamino]piperidine-l-carboxYlic acid 4-nitro-phenyl ester l la l lb
and l lc~
Stir a solution of trans-4-[2-(4-amino-cyclohexylamino)-9-cyclopentyl-9H-
purin-6-ylamino]piperidine-l-carboxylic acid 4-nitro-phenyl ester l0a lmmol),
BOC
anhydride (2mmol), TEA (8mmol), and DCM (40 mL) overnight at room temperature.
Mix
the reaction with water, remove the resultant white participate by filtration
through Celite ,
wash the filtrate with brine, separate the phases and dry the organic phase
over sodium sulfate.
Filter and concentrate the organic phase to dryness, and purify the residue on
a 50g silica gel
column using DCM:methanol (9:1) to give trans-4-[2-(4-tert-butoxycarbonylamino-
cyclohexylamino)-9-cyclopentyl-9H-purin-6-ylamino]piperidine-l-carboxylic acid
4-nitro-
phenyl ester (11 a .
trans-4-[2-(4-tert-Butoxycarbonylamino-cyclohexylamino)-9-isopropyl-9H-purin-6-
ylamino]piperidine-l-carboxylic acid 4-nitro-phenyl ester l lb and trans-4-[2-
(4-tert-
butoxycarbonylamino-cyclohexylamino)-9-cyclopent-2-enyl-9H-purin-6-
ylamino]piperidine-
1-carboxylic acid 4-nitro-phenyl ester l lc may be prepared from trans-4-[2-(4-
amino-
cyclohexylamino)-9-isopropyl-9H-purin-6-ylamino]piperidine-l-carboxylic acid 4-
nitro-
phenyl ester lOb and trans-4-[2-(4-amino-cyclohexylamino)-9-cyclopent-2-enyl-
9H-purin-6-
ylamino]piperidine-l-carboxylic acid 4-nitro-phenyl ester (lOc under similar
conditions,
respectively.
Scheme C, step h:
To a solution of l la (0.1 mmol) in THF (40mL) was added a primary or
secondary amine
(0. lmmol) in the presence of TEA (0.2 mmol). Stir the reaction at about room
temperature to
about 90 C for 2 to 24 hours. Cool the reaction and add 4N HCl in dioxane
(1mL). Stir the
mixture for about 3 hours and remove the solvent under reduced pressure.
Purify the residue
by chromatography on a 2 g silica gel SPE cartridge pre-equilibrated with
heptane. Elute the
column in three fractions; first fraction 5 ml DCM; fractions 2 and 3 with 10-
15 ml of
DCM/methanol (4:1). Collect and concentrate the fractions containing compound
I where R2
CA 02427338 2006-09-25
WO 02/42303 PCT1US01/14835
62
is cyclopentyl. N-Monosubstituted and N,N-disubstituted urea compounds I where
R2 is
isopropyl or cyclopent-2-enyl niay be prepared in a similar manner from l lb
or l lc,
respectively.
Preparation of N-Mono-substituted Sulfamoyl Chlorides
The preparation of N-methyl sulfamoyl chloride was performed as described by
G. Weiss and
G. Schulze [Liebigs Ann. Chem. 729, 40-51 (1969)] , A
suspension of anhydrous inetliyla.mine hydrochloride (1 mole) and acetonitrile
is treated with
sulfuryl chloride (1 mole) and SbC15 (0.5g), and then heated under reflux with
vigorous
stirring (HCl gas evolves from the reaction). After 4 hours sulfuryl chloride
(1 mole) is
added. After 24 hours the mixture is evaporated and the residue is distilled
under high
vacuum (70 C, 0.04 mmHg) to afford N-methyl sulfamoyl chloride (125g). Other N-
monosubstituted sulfanioyl chlorides may be prepared by this procedure
including N-ethyl-,
N-propyl, N-isopropyl, N-isobutyl, N-butyl, and N-cyclohexyl-sulfamoyl
chlorides.
Preparation of N, N-Disubstituted Sulfamoyl Chlorides
N,N-Disubstituted sulfamoyl chlorides were prepared as described by Binkley
and Degering
[J. Am. Chem. Soc., 61, 3250-3251 (1939)]. For example,
diethylamine (0.33 mole) was added very slowly to sulfuryl chloride (0.33
mole) with
vigorous stirring and ice water chilling. The mixture was warmed and heated
under reflux for
24 hours. The cooled mixture was extracted with anhydrous ethyl ether, and the
extract was
concentrated and the residue distilled under reduced pressure to afford N,N-
diethyl sulfamoyl
ehloride, b.p. 69 (10 mmHg). N,N-Dimethyl-sulfamoyl chloride was purchased
commercially.
Preparation of Compound I Sulfonic Acid Amides
Scheme B, step f:
Treat a stirred, cooled (0 C) solution of N-methyl sulfanloyl chloride (0.2
mmol) and
anhydrous tetrahydrofuran (275 mL) with a solution of trans-{4-[9-cyclopentyl-
6-(piperidin-4-
ylamino)-9fi-purin-2-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester (9a,
0.2 mmol)
triethylamine (9a 0.2 nunol) and tetrahydrofuran (4 mL) overnight at room
temperature.
Warm to 55 C, cool to room temperature and add 1.0 ml of 4N HCI in dioxane.
Allow to
stand for 3 hours, concentrate and dissolve the residue in DCM using a small
amount of
methanol as co-solvent if necessary. Purify the product by chromatography on a
2 g silica gel
SPE cartridge pre-equilibrated with heptane. Elute the column in three
fractions; first fraction
CA 02427338 2006-09-25
WO112/423113 PCT/US01/44835
63
nrl DCM; fractions 2 and 3 with 10-15 ml of DCM/nlethanol (4:1). Concentrate
the desired
fractions, dissolve the residue in ethanol and adjust to pH 2.0 with 10% HC1.
Concentrate to
dr}mess to give 4-[2-(4-amino-cyclohexylamino)-9-cyclopentyl-9H-purin-6-
ylamino]-
piperidine-1-sulfonic acid methyla.mide. Using N,N-dimethyl sulfamoyl chloride
under
5 similar conditions provides the corresponding trans-4-[2-(4-amino-
cyclohexylamino)-9-
cyclopentyl-9H-purin-6-ylamino]-piperidine-l-sulfonic acid dimethylamide. The
corresponding 9-isopropyl and 9-cyclopent-2-enyl compound I sulfonic acid
amides are
prepared in a similar manner from 9b and 9e.
Preparation of 2-Cyclopenten-l-ol
Heat a mixture of cyclopentene (l Og, 147mmo1), N-broniosuccinimide (13g,
178inmol) and benzoyl peroxide (0.5g, cat.) in carbon tetrachloride (25m1) at
reflux for 1
hour. Cool the reaction and concentrate under vacuum to give a dark oil. Stir
the oil in
sodium bicarbonate (saturated, 50m1) overnight and then extract the mixture
with DCM
(2x l 00ml). Combine the organic phases, dry over magnesium sulfate and
concentrate to
yield 5 grams of a reddish residue. Vacuum distill the crude residue to give 2-
cyclopenten-l-
ol (bp 71 C, 46mmHg, 2.5 g, 41 %).
'H-NMR (CDC13): 6 6.02(m,1H), 5.85(m,1H), 4.8(m,1H), 2.55(m,1H), 2.4(m,2H),
1 .75 (m,1 H).
Preparation of Salts of Compounds I
Salts of compounds I may be prepared by methods well lanown to those skilled
in the
art. For example, one dissolves the purified compound I in a minimum volume of
absolute
EtOH, and adds 1 to 3 equivalents of the desired inorganic or organic acid to
provide to
provide the mono-, di-, or tri-salt of compound I, such as the mono-, di-, or
tri-hydrochloride.
One isolates the solid salt by filtration, or by removal of the EtOH in vacuo
or by a stream of
nitrogen under gentle heating. The isolated salt may be recrystallized and
dried by methods
well known to those skilled in the art. Selection of pharmaceutically
acceptable salts may be
based on but not limited to the salts discussed by Gould [International
Journal of
Pharmaceutics, 33, 201-217 (1986)] or Berge et al. [J. Pharm. Sci., 66, 1-19
(1977)].
Pharmaceutically acceptable salts include but are not
limited to salts of hydrochloric acid, hydrobromic acid, phosphoric acid,
sulfuric acid, nitric
acid, acetic acid, fumaric acid, maleic acid, gluconic acid, citric acid, or
methanesulfonic acid.
Other acids such a s oxalic acid and picric acid may be used to aid in
purification of
CA 02427338 2006-09-25
WO 02/42303 PCT/US01/44835
li-l
compounds I and those salts may be subsequently converted to a
phanilaceutically acceptable
salt of compound I by methods well known to those skilled in the art.
High Performance Liquid Chromatography (HPLC) - Atmospheric Pressure Chemical
[onisation Mass Spectrometry (APCIIMS) Analysis of Examples
Conditions for product analysis are readily ascertainable by one skilled in
the art. The
following conditions represent typical analytic parameters. HPLC columns or
cartridges were
obtained from YMC Inc., 3233 Bumt Mill Drive, Wilmington, NC 28403, and Waters
Corporation, 34 Maple Street, Milford, MA 01757. The conditions for the
product analysis
are surnmarized as follows, and the particular set of conditions used is
indicated by reference
in the table of examples to one of the following HPLC-APCI/MS conditions.
HPLC-APCI/MS Condition A:
A) 95/5/0.1 % Water/Acetonitrile/Acetic acid
B) 5/9510.1 % Water/Acetonitrile/Acetic acid
The above sample was analyzed using a HPI 100 binary HPLC system and a
Micromass
TM
LCT mass spectrometer equipped with an electrospray ionization source. The
column was
TM
a YMC ODS-AQ (2 mm x 50 mni) cartridge. The initial HPLC conditions consisted
of
100% (A) flowing at 1 mLJminute. After 0.1 minute a linear gradient was
perforn-ied so
that at 2 minutes the HPLC conditions were 100% (B). These conditions were
then held
until 3.5 minutes at which time the systenl switched back to initial
conditions and
equilibrated for the next analysis.
HPLC-APCUMS Condition B:
A) 95/5/0.1 % Water/Acetonitrile/Formic acid
B) 5/95/0.1 % Water/Aceton.itrile/Formic acid
The above sanlple was analyzed using a HP1100 binary HPLC system and a
Micromass
LCT mass spectrometer equipped with an electrospray ionization source. The
column was
a YMC ODS-AQ (2 mm x 50 mm) cartridge. The initial HI'LC conditions consisted
of
100% (A) flowing at I mL/minute. After 0.1 minute a linear gradient was
performed so
that at 2 minutes the HPLC conditions were 100% (B). These conditions were
then held
unti13.5 minutes at which time the system switched back to initial conditions
and
equilibrated for the next analysis.
HPLC-APCI/MS Condition C:
A) 95/5/0.1 % Water/Aeetonitrile/Aeetic acid
CA 02427338 2006-09-25
V1'O 02/42303 PCT/USO1/4-483a
B) 5/95/0.1 'No Water/Acetonitrile/Acetic acid
rht TM
The above sa.mr)le was analyzed using a Waters 600 HPLC system and a Finnigan
SSQ-
TM
710 or 'TSQ-700 mass spectroineter equipped with an atmospheric pressure
chemical
ionization source. The colunin was a YMC ODS-AQ (4 nun x 50 mm) cartridge. The
5 initial HPLC conditions consisted of 100% (A) flowing at 1 mL/minute. After
0.1 minute
a linear bradient was perfoinled so that at 2 minutes the HHPLC conditions
were 100% (B).
'I hese conditions were then held until 6 minutes at which time the system
switched back to
initial conditions and equilibrated for the next analysis.
HPLC-APCI/MS Condition D:
10 A) 95/5/0.1 % Water/Acetonitrile/Formic acid
B) 5/95/0.1 % Water/Acetonitrile/Formic acid
The above sample was analyzed using a Waters 600 HPLC systenl and a Finnigan
SSQ-
710 or TSQ-700 mass spectrometer equipped with an atmospheric pressure
chemical
ionization source. The column was a YMC ODS-A (4 nun x 50 mm) cartridge. The
15 initial HPLC conditions consisted of 100% (A) flowing at 2 mL/minute. After
0.1 minute
a linear gradient was performed so that at 2 minutes the HPLC conditions were
100% (B).
These conditions were then held until 3.4 minutes at which time the system
switched back
to initial conditions and equilibrated for the next analysis.
HPLC-APCUMS Condition E:
20 A) 95/5/0.1 % Water/Acetonitrile/Formic acid
B) 5/95/0.1 % Water/Acetonitrile/Formic acid
The above sample was analyzed using a Waters 600 HPLC system and a Finnigan
SSQ-
710 or TSQ-700 mass spectrometer equipped with an atmospheric pressure
chemical
ionization source. The column was a YMC ODS-AQ (4 mni x 50 mm) cartridge. The
25 initial HPLC conditions consisted of 100% (A) flowing at 2 mL/minute. After
0.1 minute
a linear gradient was performed so that at 2 minutes the HPLC conditions were
100% (B).
These conditions were then held until 5 minutes at which time the system
switched back to
initial conditions and equilibrated for the next analysis.
HPLC-APCI/MS Condition F:
30 A) 95/5/0.1 % Water/Acetonitrile/Acetic acid
B) 5/95/0.1 % Water/Acetonitrile/Acetic acid
The above sample was analyzed using a Waters 600 HPLC system and a Finnigan
SSQ-710 or
TSQ-700 mass spectrometer equipped with an atmospheric pressure chemical
ionization
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
66
source. The colunm was a YMC ODS-A (4 mm x 50 mm) cartridge. The initial HPLC
conditions consisted of 100% (A) flowing at 2 mL/minute. After 0.1 minute a
linear gradient
was performed so that at 2 minutes the HPLC conditions were 100% (B). These
conditions
were then held unti13.4 minutes at which time the system switched back to
initial conditions
and equilibrated for the next analysis.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
67
LL
an C? ~ \
O -
d~U v
O
cn
ax~~~N
Z ax
L7
-~-~ a co ~
N
~o \
0
E' w z ~// 2 z
w [-~ 2 z~ 2
a zilli
0- z
LL
v
N 0
U
~
o p
P+ O ,.,,
Oy=~~~~
~ ~ O c~ .=~+ ~
p~
w z
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
68
LL OO
o \ / \ z/ \z
Y
U U U
n n n u
O O O O
U U U U
~ Oi vcqi
N N N
i-=~
Vl l~
O tr !1 V1
r-
kn
U U U U
U U U U
N N N N
U U OO
z/\Z
- - ~/ -
0 0 0 0
U U U U
o o~'~ , o ~ o t?= ~~ o s?a'~ b
ol~C czs~d~ =d ~ ~th~" ~m p b
u ~ ~ = + ig p u cd c~ 0 - ipG O u c~ ~a Qi 0 o O
i
d' ~, l+' O ~"i =-}~i=~ ,~ d' ~, ~.+' O ~"i ~"i ,.~ ~.t' ~, ~.+' O ,r=+' S~
S.7 .~+"
p pt~ ~ p U U N~ p
~ p 0 O p 0 O O ~
~ =--~ =--i ~ '~ F~ =--~ ~" ,~ i ~ ~ =--~ i =~ ~-~ =--~ ~ ~--~
>
ci 3y U~o a'o d U 0 U U~p
N m V v1
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
69
M
O-U
- M -
U O-U U
U n U u
0 ii 0
O v O
~.
U V
~n ~n o 0
N N N N
M M
M O
V7
U U U U
U U U U
N N N N
U =
0-0 ~ M -
0-0 0 0 O 0
U U U U
~ b ~
~ =~x ~.o ~-d~ =~x a.o ~,zy.., =~x ao ~b~ =~x s~. b
o ~ Rt cCt r'" ~, = o
--i F+ N ,--i r o N ,--i
~r a r~o ~r ~r .~'o Ir o
SC~s .' ~.
0 ID M e-. 0 a) N.-. pt~ i N p ~ i a) N '~1 p p
O ~ ~ ~+' O O ai ~ ,~~" 'D
r~
ci~>,p.-~d c O~i c~i~o p.ro .~t- o ci~>,~
rn
~ T-
CA 02427338 2003-04-29
WO 02/42303 PCT/USO1/44835
U-
O U m ~ ~
p LL, ~ ~
- U
~i U u
0 P, O O
U ~= U
00 m 00 ~
a ~n o
c14
rn ~ 00 00
o
kn
~
v w w d
N ,
N N
"'o ""0
~ co
O 0
co% 0 LL
-
J. -~ ~ ~
O
0 0 0
U U C?
t? ~
0
i ~
, 9 :~ N OCy N~ N N d' Fr" N d' o Q+ U O~
v =~ xj f~ ' t1..~~ TJ c~ 'L7
N 7 P. o N
' ' , ~ ~.~== ~ U '=-i ~ ~ ~=y ~ U i ' y y v 0 ~ o ~ ~
O N N O
0 N .~ ~ O ~ ~, ~ = r~. ~~+ C U .~ O ~'~+ ~ ~ .~ O 0 . ~+
~ p p~ ~ '~ f~~" o o ~cC+ ~'i =~=~ ~ ~ ~ ~ ~ ~ N ~ ~i U U ~ ~
>+ ~ ~+
bd 0 ~~n 5,~~3 b U Q ~o ~ c>'i~ ~
o ~ cq m
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
71
U U U U ~~''
p p-U O
p ~ ~ p O
V
O ~
8_ ~
V C
j
00
o, M
0 o
0
M m
kP7 in
~
m M
04
=
V m
2 j U
U U
O O~U O O
p 0-0
_ _
p
O 0 '-' U
U U U
U '
.~ ~ ' =~ ~ ~ p~ ' o~ '~ iC ~ ~ ~ y
~ '2~ O~ ~ ~ ~ S~ '1 RP,'~ ~' i ~p P+'~ .~~'~, O O Q+=~"i i O
o O
RS
ln cC
= >, o ~o ~ d= >,1~'' o ~ ~ ~r >,~' o~~==' ~r k ~ >,1~'' o ~ ~ ~ ~ ~ ~
NO ~ ='-! ~ O O~-+ ~ ~p .~ ~ ~ "~'' ~~ 0 .i~'~' ~+ ~ =-~i
~" G +'~ tcf > v~~ ~,
O cc! 4
O O,~ "~ N
Cd Cd
b~ tj
ti Q 0 c~ \,o a, CL ki i v 0
00
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
72
~co
O
clq 00 N
N N C'1 .
~
00
kn in kn tn
~
Uce)
M y
O = !1
N ~ V Vd' U
= Op -~ N ~
U .s =
o V U U
0 0
0 ~ r, ~,__,~ ,...= , -~
cd .~ '~, =~' .~+ ~ '~ ~ =Q" ~
p
~'
cd="~
Q~
p 0
~ i~C L~"= p si" 7 ~r ?~C ~~. +' ri" ~ i~C p~ p-~r y~'v P, f" ~r S~< q!~ ~ O
.--, O ~ ~ "~i .-~ .~ O .~ ~ ~-' v ,--~ =-~ O .~'i G~. ~ ~i ~ "'" p ,~' ~1. 'i
~' O ~1 S~ ~ .~7
cn O O w '~ ++
c"
t3~ U U~>,
O
N
N
~, N
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
73
C\l
U ZU N
O
/ \ - - >
U U U
u n
~ 0 0
U U U V U
m o 0 0 ~
~--~ 00 00 00 M
~ ~
N
co z z z
o
/ ~ - -
0 0 0 0 0
U U U U U
O~ ~'C~. IS p O~ s~ 'd ~y 01 d
O Q,=~ N ~ p p~,+=~ Q., ~ O P,=~~~ ,~ , O R=(~,+=N ,~ ~ O Q,=~,N
~ ~ =~+ ~, ~ ~ ~ .A.
,NJ ~ ~ Q, =~ ~ ~ ,N_, c" cci cd
d >,~ o p
'-=~-' DC F' ~ ~ ~ "+-' >C F," !~ p '=~-' iC .3"'. ~+" p '-~' DC Fl -S'1 ~ p V
DC L~ Sy a~ ~U
~ V V ~i'T r%-. ,~" ~ ~ ~ ~ p ~ ~ r~Ui '-=~-.i N ~ ~ ~ .r . N ~ ~ ~-~i '~ ~
N N N N N 00
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
74
M TS
co U / \V '0
~
O U\\ p 0
I U~
U u Q,
o 0 8 8 8
U V (3 ~5 0
0 0 00 o kf)
' ~--~ 00 m
N kf) V1
U U C~ U U
N N N N N
= U
CIY
~" = U ~o
0 o 0 o
~ U
0 O O O 0
U U U U U
~ ~ a~ ~ ~--~ ~ '--~ ~ ~ ~--=~ .~
a; =~ o~ o o~ ~ o~ ~ ~ p~ ~ ~ ~ a~
~ O~=~ O O ~ M ~ i O
U v
~ =0x p, i 'o~ =0 * p ~ . v
N pi t.], O '''=' ~,"+ Oi >, N N ~ ~Q.~ O .~ ~+ N pi p, =~ ~ ~ ~y O~ 'Q. ,_!,
~U
ai ~ p+ N O N Cd O R3 =--i ~~ U O u ~ ~'G ~ O u at .-y ~ r'~, O
V k 0 ~Ei o -C~ ci >,~4' 0 4 >,~' o a~i L~
i ~ U y =~ p i ~ N N U ~ p p N =ai M ~ O ~ ~ ~ 0 =~
M O f7 !~. O~ '"==i O,.[.," S]. D=~ O O N 8 ,--' O O
O O O M
cC 'b
~i U U ",_, =.r ~ U ,~ ~+ N ,, '~'" ,~,~" U U õ..., N ~" ~-+ U U ~'-N ~ U U ~
'"~' N
1~ Q c~'i c~i ~O >, Cd b~ "o o
N M Crl m
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
2
O O U
1S' <
U U
o o
~ v
~ U U (~
.--~ .--i '--i .--i
tn tn tn
U U U U
N N N N
M / \
I
O rO
U
= O
C
O O O 0
U U U U
~ O P,'~ u ~p p,'~ O ~ O~'~ ~, ~ p~;='a~i >~+ a~
,~.a x v
o; a '
o
~O iC d p UO O~J~
O O cd M cl P.
~~ ~1 O O c~ M~~ O O cd
-'s
ci ci~>,p.b tj ci C-)~>,a>-o
d N ~p l~
M M M M
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
76
o ~V
U U
U - -
0
o p S2
V V U
.-(lq-
U U U U U
N N N N N
_
U U
_ =
0
0 0 0 0 0
U U U U U
,
'O _ ~
~ O~ kO 0Ob N=~i p x!]. ~ v O,-~i P, ~' 'b p x P. , p "t O~ O O
,
N R~~ O ~~ cci ci P, O u 0 ~"i P, P+ +~ cci O
~
d 4 r-i .~
o
>, S
~, p SG ~-+ O ~.-~ O V '~" =--~ O N .-+ O ~+
O Oz N 0 O~.-l ~y O O cC N~7 ~ a3 N'b O cl N'~
cbd
~~n >, p. 1~ o o~o >, ~ d ~ U~o p, a~ =d d U p~o >, o J-1 o o~o ~, p. v
~
00
M d V
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
77
M
U)
U V
o 8- 0_
U ~ U U
~-+ N N
.--i '-i .--~ ~--i
d Q~ m h V') V)
U U U U
N N N N
lL
U =
U UU
M
U)
U
O O O O
U U U U
,
, O'N-, o~'N õ~~L' o .-~~+
rn
a; p,~"i. .r
O ~, cd ~ ,~ = O O ~o N
o ~
o 51 4
V61 ~
-~5 Q" 0 ~
O 0
~J~
=~ d o o~o 51 cn
~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
78
m
LL
= M co
U U M =
" M
U
U U
~ U 0
U _
U r" i U
p o' 0 O
_ O v
v U
U v v U
p~ N O ~
.-~ ~il =-~ M l~
kn Ii' kn
d d d d d
N N N N N
LL
ce)
m
~ 0-=
o
0 0 0 0 0
U U U U U
~
o~
,~ NRA Y.y N i S~ N d' ,- . o
M'~ U ' N O N N U N d' N=-"~
~ .~ ~j =~+ O ~ r+~ ,~. O O 'tf ~ =~ i A'~ 'C d' '~i 0~1 '~'' ~' O .b ~ =~i ~
~ , P+ N ~y
c~ cd O 43 O~-i -+ cC .-i
'-r -i i--~
>,~''o~ ~ k ~ 45 ~~r >,~''o A
N
~ =zy
t~+
v~ , r O O cd N~ v~ . O O~ cy p~ i~ , A~y O O~C N~~ m,~ O O~
Cd
.b d o o l0 ~, .-w .t~ d U v~o >, >, .k1 d. o o w>, .~
d v~
~ T-:t o T;;~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
79
= 2
- m U U
U PF
U ~ U
O ~ U 0 O
U O U ~.
U U
O M M tn
'-i .--i .--i .--i .--i
r- M
~ O 00
Lr1 d=
U U U U
N N N N N
= M
M U U
=~ ~
O O 0
O O
U U U U U
~ ~ ~
p~~'~ N d= p~ N fp~" N~ p~~ O N'~t p~~~, N~t p~ p~ N
P+N'd TJ ~~",p.DC b u ~r~i TJ
" O
o
O d ~
~ N N '.L~ O ~ ~ p p ~+ p i ~ y y p i ~ y y ~, O p ~ i N N ~+ Gy Ot~
~ .~." i]. '~', 'ni " ,~ r=' .0~. .~ L]. = O H O O O ~ ~ v~ . ~ O O ~ ~ ~ q ~
v~ , p O O 3 ~+'O
kt Q c~i c~'i ~o ~, ~d 1~ p p~o >, 'C fi c~ c> ~>, ti b c~ c~ ~0 5, ~ v~s d c~
v~ 5, v
N M d N ~D
~ ~ ~
tn
In
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
co
U 2 =
m
U 2
=
co
= l U U U~ -
U \J ~~==--
Q, o
0 O_ O
0 O D U U
vn a,
N O o ~n O
(lq
N o MO N
V l d ch ~n
x x x x x
N N N N N
CY)
U co cn
2 co I
U V =
m = U / ~
U U
O O O O O
U
U U U
U
, , , ,
,
, r= , , ~ ~ , ~ , , ~
, A ,
b ~ O ~'d ~ ~ 'd
c~ o O O-Y :21 .D =~
0 A.
x~.
- ~ ~' = ~. .~ 0 cct ~' .O O u cci ~, ~ NJ cct ' o
D --~ r--~ P+
>, .'~' o -~ >, ~'' .~ ~= >, ~'' o ~
4~ irl
~
~Q,~r~r ~~b
.~ ~ ao
O O N? 'CS y O O ' 1~ O O c~ N'C .' O O~ 'b O o (V
}~{ ~ ~~,2 c~C I
o 0 ~I. O
~
d o o b o~>, o~t Q a o~o ~, ~ b
00
rn o ,-,
lo
tn kIl v-~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
81
2
toy
u ~
v U 0
O 0
U V
U U
00 O N h m
.-i
00
Lri
d d d d d
N N N N
_
U ~ S o
0
? ~
0 0 0 0 0
U U U U
~
v c~ ~b ~
c~ U~ N d' ~ U~ N et ~ U A~. N~t ~ U ~ a) N Qi =' N~
4 _44 L1 ~ ~ ~ L" = p+ O 'C '_' ~ ~ ~ Lf ~ ~ ~ = Q. ~
i cc!
O ~ c~ ~ " ~ ~ cC ~ Qi'~ Q' p u cC ,~ t~ O O ~-~.=+ ,~ ,~ ~~
>1
O. XP O
O y
v y ro7
~r
,-p o DC ~" Fl U p c~ -r h+s" a~ c~ ~ v ?C t~. g~
a~ o a~ p o~ o~ a~ ~~ r~ o~~ a~ a~
~
o ,.q p s?= o s~ a i cd o ~ ~ ~ a '
O~.--~ ~ ~ O O c~ O 0
I~d o c>~o >.-d bd u o~ 0 ci~>,a~ib
~ cn kn
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
82
m
~ ~z P-z LL -P V U p
U U V V
0 O 0 0 0 11
'U U U U ~"
U
00 N
c~
O
i
00 00
O ~ kn kn
d d d ~ d
m
z V
LL
,~ ~ ,~ =~ ='=
p O O
O O "
U U U U U
91 v o 1
t~,'G >, ~ o ~n o , ~
~ O , , i ~y ~ N i ~ ~h , N '~ !' = Q+ c~C
~ . ~ ~i ~, M ~ . ~ r~j P+ v,' '~,~ = ~ r~i Q. O 7, ~ '~ =~a. , Q. ~ ~ ' y
~+ ~ ~ S~+ f. ~
u lC .--i i. rt ~ u Cci O
~" i ?C !~ ~'+ O'~ ''~C y.~" o~i , N N.~ N O~ ~ i y 4) =~~ ~~ ti i 4) N=~
~.M..i.-~i
rn .~ O O 3 .-y ,~+ rn .'~,~" ~ ~ ~ ~+ .~' ~ = o "aiõ ' ~' ~ F: ~ O O ~ ,~+,~
v~ .,.~".~ O Cd
~ V V ~ r~ N ~ ~.= U U ,~ ~ .~' r~ f'~-' ~ ~ ~ .-'~'i .~ ~= "7U' ,-~'i .~
ci ~, b u 6 Jb G~ ts o c~ ~>, u b d o o~ ~, t~
~ 00
~ o
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
83
2 m U -
U_ U
O O O O
v O ._, ~-
U V U U V
ti ~y ~ .ry '-r
00 VMl
in in in
U m U -
O ~ U U
U U ,
, ~ ~ , =~ ~= ' ' .~ ' ~
-
00 ~'' N.~
~y o ...J x a.5,~~: =~x p, ~ x s~ ~s~ =~~ p.?.
u '~l ,"i , ~ 1 '~ L1 ~ O~ ='" ~" ~ N , ~+ o ,~ N ~ ~ O
Cd+ Q'' O~ u Ri .~ ~ Ng u ~.-~ o~ u os ti'~ r'-i Q N
0
~ ~ y N=~ C~l _~ ~ ~ N N.~ (+l s~ , ~ U) N=0 4_
O2
v~ -i"'+ O O N ._', ~ .~ o ~ O cci . ~+ ~ ~ ~ O O ~'cGi r'.~ =~ ~ O ~O O~ .~
,y~,~ cia O ~ .~ ,s~i'
q R~ ~ tJ Q c~i c~i ~>, ~ 0 "o >, k~
~ ~ ~ ~ ~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
84
U
O
U _ U - U - ~ O
O 0 0 O
V U U V U
o kn r c~l
o~
kn
v~i v~~ v~i 0
W E
..~ ...
d ~C Q a w
1 ~ ~ x x
N N
_ / \ m
U U U
O
- , O
0 0 0 0 0
U U U U U
~ =U ~ ~ ~~ =d O ~ ~ ~ 'U o ~ ~ ~ J ~ b ~1 '"
O~+ =s-~+ "~ O O~=F~" O O ~ O P+ =-~,+ O O i O 'tdJ- O,p=~ =~==~ ;'d m
cC ~' Qi =' "D ~ u cC ~~i "'b ~ u cC ~" = Q" O O N~ Q' U~' F.
r-~ , N ti r~ ,
v ~,~o ~ ~tr ~'o~ ~, U~~
~ N N d ' U~ X r L+" , , DC S~ ~, i r DC ~, ~
N t~ O .a> N=
~ O ,s.," f1. i =-+ 0 ,s;
S~. ~= ' i '-' ~ O ,~ p,i ~y ~ .~ ,-~ O ,s.= O = ~i = O y..~ ~
O ~ .~ ~ v~ . o ~O ~ =~ ~r, m . O
~y ~ ~ =-~'i ,-~ ~ ~' '~' >' cd .-'~''i '+~. ='~ ~ ji ~ U O ~
.~i Q' c~ o~o >, .kt ~ ~~>, J~ c> ~ ~o >, b Q~ c> =~>, >, a~ 7~ c~ c> ~o .~ p
~ 00
00 00
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
2
U U
O p
O 0 O =
9 U i U
p
O & 8-
C~
O~
M l~ d C)
00
h W) h kn
w r.~ w w w
x x x x x
N N N N N
Z
CY)
2 ~ U V
0 p p
~..
_ 0
0 MU
p 0
O O O O O
U U U U U
O C~ =~ , F.,= o~ '~'i ~ i O ~ =~ '~' , F? O O~ =y,'"',} 'S''~" O ~ =~ f=,.J="
'-, O ~+ i
'd ~ O ~, + ~ 'tl ~ ~ p Q. ~ 'Nõ ~ O p+ = ~ 'd O P. = C~" "~ ~
~~d' ~x=~ o v ~~,~, '"d cd C5
Cd c~ l~,+ .U- O ! ~ ,~' =.U- 'oi.y ,==i O v at .-'r Q" ,V-i ~I O v '~ =.Ur ~-
' O v 3 ' ~i" .~i N ~ Hp
5~,g O
'~~ o4 o~y' a~ a~ o~C o' a~ o
fl o >, s~ p. ~ .fl o .~ O 0 ~,.s~ o O f ~ Cj y~ ~n O O c~ s~- N H O~
>' U o '.~. ~, "/U, >' U ' .~ :~" c~C >, ~, ~, U N , '~,' N "V/, >, ?~ U ,~
:.L~. ~ ', '/V, ~, U .~--~i o >, :,~.
o c>
o~
N M ~n "o
00 00 00 00
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
86
M
Spo1
LL ON / \ U
0 / O O
O 8_ O O
.~ ~- O " .~
U U U U U
in kr) C14
CDN
M VMn ~ M 1
kt) tn vi d'
w w w w w
U U U U U
N N N N N
pp0O___
0 i 0
~
O 0 0 0 0
U U U U U
~ ~
~ ~ U~~== i i U ~ i U i U ~ U
d
n.=~ b o s~.'~ ~d
' U"'~ Y N U==" Gj
.5 vJ
U U N y iiU
:= N O , c~il
O
~, ,~ ~ a~~~~ x0x a~~~x~a a k ~
~xgox
~0 a. o ~~ a 10,11 o d a~ a~ 0 o d a~ a~ o 0
~ o o ~ ~
o o o o p o o o o ~ ~ '~
~
o ~, ft
~
~ 'd ~! U U ~D '-+ .~ U U ~O ~ =.~i 'd
~ d\ Q\
F.- 00 oo
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
87
N M
co M =
0
o 0
8 o 0 0
U U V U ._
rn cn cn kn
rn 00 m
rn ~ rl- 00 00
d= ~r v~ ~r ~r
w w w w w
U U U U U
N N N N N
M 0
U z =
V / \ U
-
i
~
0 O / 0
~
0 0 0 0 0
U U U U U
~
,~ v .o =~ , ~ '~ a~ =F
p' ~ ,0
o a'~ -d o ? v b o o?='~ ~d ~ o v o o a,'G
~='~
U ++ U -f''i U Q)
a,~~~=~x,p.cd x.acod~~
,=U. ,~ ~ ~ =.U-i ~ O 4 c~ ~ =U 0 4 ~ ~ ~ =~ t~ O
== a-- ~ r
N r-~' >, ~ O >+ N >, ~ O ~, +U=' ~
u N N O~ '' G~ o~ u iC S 1 o S~ U u?C ~" o~ u i< F~ O y pU
=O r a~ aJ = N p N a) a) N=
d= ~-+ ,.O "G .S_~ ~1. ~" ,D 'Cy =~~= ,O .? d"
O O ~ ~ O O O at t~ p ~ fn O O 3 s~ ~ O
~~>+U ~ cy >vi RR~'U R
U U~ r; a~ ki U o
o ~ a~ b U U~o ~~ b tj U U~ ~ a~ tt U c~ ~~ p=C
rn ~ rn rn ON
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
88
i5lo o-i~o
O = O z 0 ~
~ U 0 0 10 O
11 u
o 0 0 V ~5 U (~ C5
~ m 00 ~
00
N In N
w w w w w
U U U U U
N N N N N
m
U 2 2
U U-O O-U
O O / 0 0
EP1__
i /
0 0 0 0 0
U U U U U
p~
~, p p. 'd y,~ O P. 'C~S O O P. ~ 'd N O~+-~ 'd O P+=~ 'd ~+
~b~ ~x,Q= s~ ~
~ pi S~ U N ~+"
u
Y ~ Ai U N~" d ~~ U p~~~ ~ s d
, cd .~ i '. O v , t~ =-.+ . ~ .-~ i ..-~ U -i O v .-y ~ =-+ i r-.-r . O cC
r---i :-~ r~ .-~.~ ~ i--~ =--~ ~ =--~ ~ :--~ N
~ 7~ ~, N O
cn DG F~ iC k U u ~C ?C u DC ?C p U u ~C A aC aa U u pC q ~ 1
O U O N N' O~ N N= 0.. O N N p+~ O N N' p O U p
P. p o 1ili
U U~~ a~ ~d t~ U U~ r+ a~ U U ~o r+ ~~ k~ U U w a~ R7 ~ U U~o -'C .p ~
O p' o 0
~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
89
c+m
\ U U = U
0 0 0 _
U V U cli
O 0 0 O
O ,. U V
U V U
rf) O rf)
.~ cn v~ rn ~
00 M 'n
~ O vi v
i
W [--~
.,....
w w Q1 w w
U U U U U
N N N N N
--(_
~ f) U= U LL
0 O
0 ~
O 0
O O 0
U
O
~
P. P
d+ du p O ~~ o~ P= ~ s_~ C,
U U U U U ~
~=.-~ cd i ~..r cC ~"i ' U ~+ 01 QQ~~ O\ S~ .-r cC
x '~=ti ~ O ~,~ '~-ti ~".ti =~" c~ p
v ~i Vi
o >, 4,204 cV ~
u?< ~" i~" ~k y U u iC f~" iC ~ U u k r- = >C y~ 7~ U' DC ~ .~ N
N N O O N N' o o N py O~~ N U O N i i O
d a 4 Z -d
,~
o o ~ ~' o ~, ' o o z o o
~, >, o = ~"
c~ v b o G~c -d 1:1 o o .010
a ~ cv v.b U o~ a a, "b
0 0 0 0 0
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
z =
U U
o
O -
0 0 _ ~ l Z
0 0 0 0 =
U U U U
(=>
~ ~ ~ 00
W) tn tn
w w w w
U U U U
N N N N
U U U
r~ r t I Z
O
M
2
N N N N
O_ O
0 0
1 1
1 1 1
~ ~ ~ ~ p ~1= ~Ir c*i ~;' dl=
~~~ dr F; C O ~ 1 1~ O ~ 1 1~ O 4
v ~ ~'N ~~/-. ~ '~O ='~~1 '~ .-~i 1 '~7 =.~- ~--~ ..~.+ p1 '~ =~ '-~' N 'C7
'"r ~ Sy ~ ~" 1-i Ql ~ ~ =~~ at "cl Q~yl O, Z ~ ~ A Q, 4 k
u cC .!1 ~' ,~7 N O "b O O 0
R v > ~
Z s~ a. o ~ ~ ai Z ~ a 1 g b Z a -.5~'
~.~ o 0,0 - i~~ o o~~'~ 45
~ ~~''~ ~ U aa,~ ~=~'' ~ ~'' ~~ ~ '~~
I~t d o v~ ~'v o o h o 0 o fl a p, -~d k3 >'i bEn, >, ~g =d
~
0 0 0 ~
~ ~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
91
M M
U ~ =
m
o
zS
o / \ = z=(
Y U)
c\l
0 O ON 0
U U (~ U
00 In M N
v'~ ~o d: ~G
N r-i r-e ti
w w
x x x x
N N N N
cl)
U L- U ~'p
O, U O~
Z2
o / \ z z=(
N N N N
O O_ O_ O
1 1
r~ =O Q ti 1 ~ ~ Q~ ~ v~~~ ~ O 'J 1 U)
0 -1~'1 = i-I {/ LJ c~
_'.cd
I&Yi
-~ 5- 4 O~ ~ 'o
715 U' DC ~1 p' t" N U t' DC S~ ~~' N U 1 iS ~ 'o N v
N Z C Z p a~ a~ O r O Z a~ a~ 1 ~"d 1 O
d~ ~ ''~~~~. oo~1., Nop o
p 0 t~.
>, >, 1 0 ~ >, >, a~ =
F~ d a c~ ~o r= cct -d c~ o u. Q, d c~i ~~~~ b!~ ~ o n..o p. u. b
,--1 N M d
.-+ .--~ .-=1 ~
,-r .--1 .-==~ .-1
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
92
_
O=.( U
Z2 O / \ U
~
N
cn 0 U)
O 0 O
U U
00 N
w w w w
CJ U U U
N N N N
ce)
O==<U
z
/
N N N N
O_ 0 O_ 0
1 1 1
0?
4 ~ =~ ~ r~ I 1 ~ 1 j ='~~' ~ ~ ~ 1
1 , cy
a ~~.A c! U~~zN C\=~' ~" b~C~Z >r~cCb
c~ ~ 1~ '~' yO Q', i~.-'r ~ =~".~ O cV .~ ~i"~' ~ O ~.: '~" ~''~ O
~'r ~, J~' o "'' N .L7 ~ ~, .'~=+' y ~' .~+ 4 ~"/, .'~...' o '-~' a. ,~ ~=
~'"/, ~.+'
iC Sa L7 ~~' Tf U ' ?C ~I c~d r~ t1 ~' ~C A ~'
Zo~p.1 z~a~~' ~..~C~o~p~o~Oyz
~ =i"+ o o ~ .-~''~r y 'C# o o ~ o '~, ~i '~ v~ F~ o o Rf ~ -v o o ~
a~ =~
o (D
,~ o c) c~ ~ ,. ~ , cd ,=~ ' ~ ~ ~, r~' vl~i ~ ..5~-' ~, ~, S'" y . ~.
~ "0 00
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
93
N
0 Z
' / i ~
U _ U~ U - -
O co U 0 0
p
U U U
cn
tn 00 O \ 00
V~ ~/'> l0 l0 V)
w w w w w
U U U U U
N N N N N
N
0 '
~
N N N N N
0 0 0 0 0
1 1 1 1
1 1
d~+ N d~ d
42 i
c 0 ==' c~ r~i pi."' ==~ \p
C~ 'C1 'D 1 p 1 'DU ,~ ~ f V N
Ii .y
Cd
QQQ~~~ rj' r===Y ~--~ C~ ~--I r=1 .~ 1 .'d
a~ ~,=, p 1 ?Z a~ a
~~ ,Z v ' I'Z lo >,= ~; Z o
r~ ,~a 1'Cy p 1 r~ ,-1 S~" 1 R7 p 1 r. ,~a . 4=i '6 O 1.=-. .a--1 L." 'U O O
~. s=. r=. ~y =,-1
v ~, F "+ ~i ~O .~ ~, 1~ p vi' ~O '~ ~, .=( "+ '~.~' ~i' ~O ,~ ~, i. '+ p ~D
,~ '; ~+ ~+' ,~ " ~ .~i
c,'~ pe o b d ~'
~o5 ~G o~ N ~'~ ~~oo~ r ~oU
~ ~, ~, = a' ~ ~ ~ ~, ~, ~' ~, = = ~' ~ ~, ~ ~ =?' ~ "/' ' ~
o U ~ U p 'C .p ~+ ~+ T1 =~ C~ o>' L. ~4 ~"L7
o p P. >
~
Q\ O N N
.--+ ~ .-N-1 '-r r=+
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
94
= 0 O
U = _ 0 Z
UYU \ c~
~ cn
N
O O U) O 0
04 0 U V U
~ o
r-i .--i ('q .--i .--i
V1 O 00 00 Vl V) 1t) kn lrl
w w w w
U U U U
N N N N N
= 0 0
U = 0 Z
cn
N N N N N
0 0 0 1 1 1 1
1 t ~~ N M~ O ~/=,
p
O
40-'
~ '~ =~ I O ~ '~ v ~ ~ '~ e p 1 ~+ N e =~ , N
Z od~Z ~4 ZN>,~v
\'o "! b ~ '~' ' ~ ~ ~~~~
s~. ~ Z~ .~ a~ aa'd Z4 p~b o
~ o o ) A , o
o c's Cd ~+ >, = =~ ~ ~ Q"
ss. b k~ 0 u C)~.. Cd ~ C.) ;I p. u. Tt 2Y ~ ~~ p.
N N N 00
'.-, =--~ .--+ .--~ .--1
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
=m co
U LL
U U
= V U ~
U N /U
z
- - \uN
u) 0
~ ~ON 0 O U
U U U U
o
c~ o~i o "'
tn vn tn ~o In
w w w w w
U U U U U
N N N N N
M co
U V U "' = ti
U U U
z O
N N N N N
O O O_ O O
1 1 1 t 1
1 1 1
1
1 .rl d' ~ 1 ~ ~ N ~y
p 1,~..1 ~=r~' Q~i =~ 0 1 '~ O ~j ' w~+ 1 N p 1 , N
~ ~ 1 F"r d~ r~~' b = ' ~ O~ x T3 ~ t+~ 'b ~ ~ p ~ ~ 't) 1 1 ~ ~
o .-r-Ir N ~ 'CS
,d = "
p .~ N O 1 i~ 4~ ~' ~+ N 0 40a ='i' p i s'=~ lp!~> +.
s' ,.
~1' d' .~ '-' V' v ~=-~ .d' '~ ~~ ~,y .r d. 4 1
,l 1 ~1 ~ . ~ '/ ~l ,~.a" =.-i ~
'q' N Qj N~ O 1 N~ p~ N~ O N N F~." 7~~ O N O
~ ~ 'd P, =~ Z ~ ~ ~ 'd a .~ z b u .~ Z ~ u ~r ~ '~ a~ Z a s . 1+ a b a~
cn o'~
a, p = ~" >, 'O ~ >, ~" ~ . P~ ~ ~ :~ '' .2 >, 'O ~"~J a >, U~ . ~" ~ ~ >, >,
~ = .~
-~ U v S~. c~ N"tj 4b P, U N"d c) U~.D S~, f~. 't7 ti 0 U N!~.
O% O .--~ N M
N M M M M
''-~ =--~ ti =--1 "=-1
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
96
U = 'o m
~ 0
~ 0 p,U
uN
O O O O
C) U U
v~ o ~n M
M M l~ C1
N 00 41
kn h
w w w w
N N N N
'IQ "0 "0 "0
U O V 2
0 0 L / \ 0 0,
m
N N N N
O O 0
I 1 1
~y 1
ct ' =~ .~~ N M
F ". .-~ t ~ x 1 ~ ~ =~ O ,~ ~ ~ ~ r~i ~ =--~ tr-i ~
u~ ~~ d O N u ~~
i=i
C', 42 -
,o~.. 4 ~'o ~ ~ d' .o~ vi'o~~
Z , o ~ 0 Z Q> p. 4 a. - Ji b n ia. p, ~v b~ o ~6 ,~ ~u b ~ c~'i .fl ~
~
M
~--1
T!--
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
97
(u
U U = 0
V Uz
C
o ~
0 p
U V
~ 00 cn 00
00
N
o rn - cn
"0
w w w w
U U U U
N N N N
= M
N U =
U U M Z U Z~~ 0 U
N N N
O O 0
O
1 1 1
1 I
O ~''( 1'~ ~ O 1 ~=1=~ ~ O'~ =~ O ~ 1
~y 'I ~ ~ ,~ ~ F4 .~ ~.y ~ s1 Qy ~L===i' ~ ~
1 1 Ol U 1 1~ 01 U 1 1.=-i 01 i U'~ 1 O 1.~ c~
c j N
d
,=~.~ Z o > '
, ,~ Z
~ 4=+ 1 'C O 1 ~ ,...i 1 'D 1 ~ 4-=~ ~---~ N O 1 ~ .r ~ N =.r O
,O ~ 7, 3 y ~i '
N U U 1 iC q ~~ o
t~'1
5!
zoo ~~ '~Zoo~~ Zo~ 0
t 45
.- -~ u~=~ ~r. a~ o ov o 4 o
= Q' ~ >, ~ = Q' >, 'O ~, = ~ cd ~ . ~ ~
k~ U 'C n~. t]. =C k~ U U tU p. t1 d b U U.D !~, U N~ U U>,'d s," >+'d 'L1
00 O1 O J
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
98
2 Z
O'U z / \ Z \ / \
- _
- Z
11
~ 0 ~ O
0
U U
vMi kn-~ 00
00
a~ v o vMi 00
00 c~ -r- n
W E~
... ...
w w w pa w
U U U U U
N N N N N
0
0-
/\ c-
z
z - zo ~ o o ~
,
~rn =0 ~
a~
0 1 a) '0 ~ , 0
~~ ~~eC b c~~ b ~ 'C
oo ?' rd p ~ x=~ tN7 o 0
r~= ~_p, b o z
:Ej 4 ~fl~u
~! " N v ~ PC i~ ~t F~ N U'+C t" .
o~ O~ U', ,~C ~, r~~ U DC F7 F iC ~ U
a~ a> k O N a~ a~ , O N -, , ~ a~ O a) a) p ai 0
ooo~ ''~z a~
0 o '~~ o
4r
U U ~ p'~ >,~,~'=~~~ ~>,~ a.R >,>,>'
~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
99
LL = U U = O-U
~pp
- Z Z II u U U 11 11
11
0 0
0 O
~
00 M
.===i .--i ~--i .--i .--i
00
00 Vl [--
kn V'1 tn tn
w A w w w
x x x x x
N N N N N
tL V V =
2
~ C)
- ~ - o
Z Z = z
z
o 0 0 0
L) v L) c~ U
0 4
o t~.'~
d=~x.a.~,~vd=~~,~,~ v~=~~ p,~ ~,a~;b~=~x.~~~'d~'~x.?~~ o~..~
4 1~1 4 c~ O ::2~ .r~ ~;~
~y .7, O
p ai N o o ~ a p ~~ p u ai a
~ ~ p ,~ o u~ a~i p O~
~', ~"'=. !3, ~ fl 4 sa !3. d' a cl p i 4 .-O O ~ t1. 0
.~'~= O O
= O O ~ ~..~ ~ O O .-~ ~ y O O at ~ ~,,= ~ O O
c' o D'
v o ci v I'D 0 b o o ~O r,
R t~. -b 0 U ~O ~-=+ c~ ~t7 ~t v U\D
o - d ~n
~
100 TRI
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
100
M U /
LL O-U O
O '
-
1zi z z z
~ II II II
0 0 11
0 0
v00j N
M d ~ ~}' ~n
N W) kn
w w w w w
U U U U U
N N N N N
LL = U
0 0 / \ / 0
t
z z- _/ \ _- z=
~ I , ,
0 0 0 0 0
U U
U
U U
, , ,
, ' , ' 'C , ~ ~ , =v ' , Q)
' , G." ~ , N , ~"+ p , ~ , ~ F". ~~'i] , , , =~~+ p , 'ti
p~ .4 c~ ~ p\ '~ ~ =p y Q~ ~ ~ ~ '~y ;b ~'0
p P. C" cc > O S3 i'd . b 4 O R~~ ~" d L
.r esS , .y .-i N , , , ..., ~--~
~" = p. ~ ~ b ~ ' ~ r~ A. ~ +-V ~
~ ~I O 1 - ~ b ~ ~3-~
4:+" k > U u S~C >
' N N=~ p P. p , N N=~ p k O , , y N=~ +~-~ p N=~ p,k' y7 ' N N'~ p ti'C7
O
m -y.~ = ~ a ~ p
O a .o p ~ '~ o o ~ ~
O ai s-~ s-~ rn .~ .~ .s~ fn = r+ ~.~ ~ ~~7 ' ~O O.c~ ci-'C Fi 'C
V >, s7 ~ V V >, c~ a> s~ ~ ~ V V >' V ~ ~
>V V ~,
~f \O . ~=, ~i-,' T1 c) V ~O ,~ '=~ ~ ~= , ~ a) ~ ~
~, ~C ~Y U V ~O >, ,.o =d V V ~ ~ ~., "C1 .~ Q V V ~o .-~ p. t
tn
kn kn
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
101
u."'
U = U~~ V M M~~
z
Z z z z
O O D U U
~ 0 0
M V'1 '--' M ~--~
p r, cy ~--'
r-i ~--i .--i ~--i .--i
00 00 00 d d
"It tn W) in kn
w d 4 d
L~ U U U U
N N N N N cl)
LL
U = U
cl)
_
_ - Um
Z = 2 2
Z j
0 0 0 0 0
U U U U U
,
0
~ O C.,
O P. =i: 'd U O P. 'O ~ N '~ =N , N ~ '~ '~ .-~'~ N ~ '~ =N ~ N
x,6~ ~
t~ .-ti t~' ..U-i ~ O v =-~r ~i ' =.Ur ~..' ~ O ~ cd .-~ t~'~ U ~ ~ U CCS O
N ~, O ~, ~ ~I~ N ~, l+' O ~, ~+" ~ ~ N ~/ O ~, S~~ cC :21 N
u Sc DC >, U u 5< F. pC , U u SC
S. iC , U u iC TJ i< U u SC L~ ~?C ~ U
N N=~ p~ O N N=~ o ~~ o N N=~ o 0 o' N N= o~, O N N p~+
o~, aoa
p o ~ ~
o E;l
~ 4 g >, >, 5, Q. ;-~ T V u.
b o U~o ~.~ "v b o 0~4 .b p, b U o~.o ~- v b U U~ y r, 2y
00
rn o
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
102
= N U LL
_
~ \ p / \ %) LL
- - / - -
z z z z z
u u
O O 0 p O
r .--i -~
00 00
00 vNi in
kn v1
x x x x x
N N N N N
!b = = U L_
o / \ U / \ ,~
- - ~ - -
= z z z z
z
0 0 0 0
U U ~ U U
~p P, c~t
0~ oL
.p. =0 x .Q.~
~,=d
b '0 2 d
a o ,' p. r .~. o; r~ U ~
v =--i t .~ S~ O ~..i ~ =--~ ~ =~ i,i O , O .ii O
N O O ~, 'p (y ~/, ~' O ~, ~,
iC U u PC L~ PC ~ U
4
O ,~ U" ~. ~ OO 0 4, ,-~ P. 9 ~ O d' ~U+' Q= ~ ~ ~ v' 'D
O O c~ O O O~~ y O d 0
~, U o .~ ~+ ? N '~" cC ~, ~, ~' U ~ ~J ~, >, "/t' U ~ .~ >, ~ ~, U +r~
U U ~D ~ ,a 0 U U U I'O .~ cd ~'' U U ~O r, U 'C U U "D
J ~ ~
.--~ ~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
103
U m ~
0
Z Z
z V V Z
ii p p
O 0
O
kn 00 N ' .- -
=--~ =--i ~--i . ~--i '-=i
00 00 kr) kr) W) V)
U U U U U
N N N N N
U m Z
O
2 =
Z i i z =
I
O O 0
O O
U U U U C)
a~
, ' c~ ~= :b , ai a~ ' a~ a~ a~ ai a~
~ ~:d ~~ i b v ~ ~'~' ~y ~..i ~ i "Cy ~=-i i
p A.'~ U~ O~~ b ccf O~+ ~" 'd 11 O~~+ 'd c~ O~ L+ C N
"G '~ ~ .t? N ~ b f .0 ~.Q=' ~ ~~ C ~ ~ =~+ ~ ~'U
Ci .-~ ..V-~ ta O ~ ,-cCti '~ '~' =.V-1 S"-~i O u cd
-. -t~ a~ r - - r- -.
~+ ~ N /, 1~' O ~, q N r~, N >+ O ~, u iC L7 ?C c~ u>C F." 47 >C p c~ u?C F~
pC t~ u 0 G3 iC O c~ d'~ u pC pC G],. pc~
~
~ N N p O t,"
d ' O O O~ O~ N N p~+ O d N N O~ N N S: t~ O O I~. ~ O ~~1 t3. s~ P. o o
3~. ~ ~
o pi ~ ~~
1
>, ~, 5' u .~ ~ ~ >, >, U o R R ?, y U U >, U o ,"
o c~i ~~~ b~1 c~i c~'i ~=-; a~i '~d 00
i
'--~ H ~--I ~--~ ~--=I
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
104
M M
/ \ U U O-U
C o/\
0 0
U z U z
U
O U 0
0 0
o r . p N
~ o 0
U U U U
N N N N
/ \ cz, ~ o-~
/ \ /
o 0 o _- -
z \
z z
z
t I I I
0 0 0 0
U U U U
4
ON N 94
.v. ~ ~ S"1-r = ~ p p~ ~ aY 'p ,~ ~ ~' . ~ ~ O U ,~ p--ri ~+ U ~N =~ O
U uXA[."iC U u h 3~ DC p ~ ~
Z+ p .~ ~1, ~, iU ~ p O ,i.~" ~," ~ ~ o O ~ p d' p~." P, 0 O O ~ ~ cC O 8 v~ O
O N ~ 0
ti o >U, s D, . lb c~i c'~i a~i JE C>), 'D p.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
105
U C~
U U ~~ M U
U LU
-
LL
z Z
0
11
O 0 O
M N N 00
O O N
\10
U U U U
N N N N
L U U
L'
U
I 0 o 0 0
U U U U
o oN'~ ~rn- od~ cv ooN oo~ 44
~ p.'~
- .vd ~~.~~ ~.~~
P.
v ~ ~ =~ O ~ O ,cU .-y =.Vi ~ O v ~ ~ ~ ~ O ~ ~ ~+ V = ;b i~=~
.-r r~ N ~' O
cy >, O O j ~ A L~' p
N xO R i~ p u N N k0 V~ 0 i~ O~i N N O 0~ O u N N kp M O~
st Q, d Q., ..n O o>, 'r o o c~ ' o o>, '~ o O .o O o>,
~ o ~ N '~ o ~ ~ ~ O -' ,G
t ~ ~>, c~ m a~ >' c> c> >, c~ O c~ ~>=, c~ ~ O O c~ D, ~ ~ O
0 ~ ~o .-+ ~ p. o~ c~ c> ~-= ~~i P. b ki c~i c~'i ~~ c> ~ tl, v~ c> c~ ~-= ~~
p. ~
00
~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
106
cl)
U
L' " O
z
z
v u z
O 0 V U
O O
M V 00 M N
.-1 N .-~ ~--i .-=-i
.-.i r-i r=i .-=i *-i
N l~ 00 M ~
U U U U
N N N N N
U U
L LL
2 ~ -
z
I Z
/
0 0 0 0 0
U U U U U
ci~ ooNr ~~
cC b
~
~ o a'~ b
5, ~
v P. ,-V. O v ,~ P" ..=V=~ ~i O ,~ at r'=~ '~'' ,.V. ~=' ~d =.=V. ~ O
~ >, >, .E' O N ->'
1
u pC ~" F." iC 0 U u iC G7 iC + U >C L, !~
o 'o o iG tL U u iG L."
O O
0 0 o o' N N O 0 0 d N s~
~ N O' O'
q ~ a ~ ,.o n >.'o 'r o o - ~,-o
o o c~ ~ o o ~a
kj o o~-= b~i b o o~o .~ ac ~ t~ o a~o ~ v~ b o ~o ,~~ k~ o o~- s3. v
O N M
00 00 00 ~
~
.--i ~--~ .--i .--~ ~--'
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
107
cn-U O D U
O-Q O
Z
z
U U U
O O O
00 N N Q1 00
~ N O G
,~ .-=i ~--i '--i ,--i
Vl v) kn Vl h
d d d d d
N N N N N
U = 0 = 2
0P~0 o
= Z i = -
% ~ I
i
,
0 0 0 0 0
U U U U U
ocn o~=~ ~i oo~'~ c~
ti 'd '-' Q, '~ b =M
p,'~
'~ v~,
~b '~=d d ~x ~~.~=dd u,~ ~-a
~ o ~
4 c~ " =.V-i y o d: C~ ~" = 4: cC! o d: ~ ~= . U ~, ' 0 :U
=-r ~ =--~ , r-, .--~ CFy , --~ r, .= , ~ r--i .= Fi ~ ,--r r-~ 2 0
u i~C ~~ k N~U u~ 0 5,
s" ~ u k Q F1 ~ U
r ~~ O~ O ~~ O~+ O ~ N N o P+ o
O ~ .-O ~, N ~, .~ S~. ~, ,.O t~ d= .~I t3. .D .~ '.~-~ d' "~7 ~' ~" "" ~' '~
O O at - - ~ =d O O ~y '~ O
~~ ~ N ~ > ? ki ~ o \o c~ o ~o c~ 0 ~~ fl~ o o u 0~o ca -d
kn 00
rn
00 00 00
~ ~ ~ r ~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
108
z
M
U = m U U
U U 0 - z U
z n z
z z
V U
U 0 0 U 0
p O
N -+ O N
~ 00 ~
V'1 kn vl N
d d d d
U U U U U
N N N N N
M
m
U z U~ m V U
cl)
2
0 /~ _/\
o
z ~ _- -
z
z I
~
0 0 0 0
U U U U U
po~ ~Nr A 4 ~ ~o~'~ a~i o;'~ ~=~ ~d ~~'~ ~riv '
~ ~ i , ~ v i b~ , b ~+ ~ v=~
Pa'~ 'd c~ O O~+ ~'d N p Q+'~ cd ~ O p~+'a~"i d ai
d =~ t~i .Q. ~ T~" ~ =~ ~=y =u~, 12 ~'G d =~ 1-~i .a. v " =~,~ t~1 =Q+..-~-i
~i" d =~ F~i s~, .~ vU
b ~ ~ :=~ N O v c~' cd~" 4
O ~, O cd
u aC 0~C >, '~ u~C q ~C t~, U u>C ~ H U u k 0 4 u X ~ U
y NH U.U =C ' N N p~~ p
N N p' N N O ' O ' N Nt], p~ O N i O.
'~' -~ A~ ..O O aJ ..~'a' ~" aC
~ 4 "
.-O .~ S], ~,
O O c~ ~+ s.. .ty O O c~ ~+ k m O O~ t-~ 'a-=~ ~~ O O cC ~ N y.~ O
~+" U U ~ Q" = U U ~ p ~ ~ U U f ' U U ~ ~ Q O U U ~ '~
~'S U ~'/s U U ~ .~-. ~ U
~~- ci ~~ 0 b k~1 ci ci t~3 c~i ~~>, o ami
O N M
c~ C71,
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
109
~--U I \ Um V U
O O O V ~
o O O~
- n m - ~
U Z ' ~
= z
O 0
~
.--i .--i ~-i F-=i ~--i
O 00 O
C\j C)0 0*1
U U U U U
N N N N N
= m =
0 rU
O 0 0 U O
~ \ 0
~ \ z U - O
_ ' I = _ _ _
~ \ I I
O O O O O
U U U U U
A c~ '7
N p P.'~.. c's ~ =~, p S~='~'i 'd i ~., p~+' =~"=i "d O S~,' .~". 'C ~ p G~.'
=~"=i cc! ~+
N U ~ N ~ U'd N N U >C N
oi 4 ~ P' o ~ ~ ~'~"
rn 's~ 0 4
c~i ~ ~ O 'd p ~ .-ti '~' =.U-i U ~ O ~ ~ = cd O c~ ~ ~ . o
~ r--~ F~ i r~ =--' i~ ~--~ ==-= i ~.--i .-~ ~~r'
cd
ai O~ ai 0 o b.. Uo ~ U o
=T. .O N .' ~O~,., sy6 N O O P. O ,~
S]O. O
M Fp.' O O it3 sr = ~N O ~ = .=tiO
v~ . r+ ~ .~ p ~ =-==~ .-+ ~ =~~. ~ v~ .~ ~=c~= y~ ~ a3 ~ ~ ~ ' !~ ~ =~~. N
~
U~, c~ U U U>, U d U
b d U ci' ->, o b b at >' U~' >' ~ .-
o~O .-=~ p. C o o~O ,-~ ... t~. b 1~ U U~o D, .a ~t7
'~ rn o~i 00
o ii
~ ~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
110
LL LL
co
LL
L' U ~ 0-0
Z Z u-
U U U U
11
O O 0 0
N =- ~ N
O O O
U U U U
N N N
L.L L1-
U
~ M
V V
Z Z LL
I
0 0 0 0
U U U U
o~=~~v o~ A c~ oc~ d'
o?=' b ~ o?='a~i b o A,'~ 'd '0 o?,'
=d
.==~ ~ ~ ' '.=~' O ~i ~ ~ ~i ~ .~ '-a ~ =.= ~7 ~" o
N ,Sy7 N ~+ ~' Oi~ ~ N ~ =~' O r1, ~ ~j
'~ N N=~ ,~p V' O~ Vo 4 N N= a p~D O,.~'~ Osy u N N.~ ~O N~,~ p 4
N N=~ kp M~~ O~..~
O O S}-+-'~ ~==i0 ~ ~ =~ J, O O aiL'+ s-~p '~,,,'~' =II ci~ ,~O ~õ~O ~ ~ ~
5~.~ ~ 0 O =~~=~ ~ ~ ~ q ~
c.1
0 Q
O ~ N N
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
111
= M
~ ~
LL - U
z 11
U z U U
v O U O 0
~
0
l-- N cn
00 N
\ vNi d 00 M i v ~
U U U U U
N N N N N
,_-o 'l-0 '.10 .I_o ".-0
M
Z M
~
U U LL = () P
_ 2
Z 2 z z
~ ~ z I i
0 0 0 0 0
U U U U U
o' a o O1 =~ o'
b b o
.0 '
o vcmd
ai y'.
z.~.~ m cud C,.~.~~
~
O u~ .-+ G 4~ Q
~
'!~'
o
P
a x Q Lse 0 r. k a o
4 o 0 0 0 d c" d fl
' ~ 0 O at ~ ~ O O at ~ O y O ~~~ cn O ~ s-~ ~., y O O c~ F+
> ~ .~-t ~, ~ ?' >, ~ ~, ~ >,
c.~ ~ ~ ,-' p b -G c~ ~o 21 b u u u u \o b o \.o lC
00
0 0 0 0 0
N
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
112
U V U
O
U U U
0
O O
N N
00 V~1 0
~ v
U U U
N N N
M
--C M
2
U
U U U
O
2 -
Z = 2
Z Z
I
.-. .~ ,-.
O 0
O
U U U
t
dj
~ d U 0" c~i
-.~, O~ ~,
UI<i O v ~ g v,~
oa~ a'u'o >,.~a >,' ~ ~
~o -iC
d o r~, 4 a
>, 0~ a 00 0
~
>,?'~ R>,~'~ Es!
o o~o -. 'C Z7 o o~D -~C7 J~ c~ .~ >, o a R. z7
T N
CA 02427338 2006-09-25
WO 02/42303 PCT/USUI/1483a
113
Example 2
Cyclin-dependent kinase Assays
The IC50 values for cdkl/cyclin B, cdk2/cyclin E, and cdk4/cyclin D1
inhibition are
determined using the following methods:
The cdkl sequence (accession number Y00272) is amplified by PCR and cloned
into
TM
the BamEII and SaII sites of pFASTBACI (Life Technologies). The sense
oligonucleotide
primer, SEQ ID. NO. 1 5'-
GTCAGGATCCTATTCGAAACGATGGCGCTCCGAGTCACCA-3', contains a BamHI
and Asull restriction enzyme sites for clorung and the translational
initiation codon, ATG (the
cd1c1 sequence is underlined). The antisense oligonucleotide primer, SEQ ID.
NO. 2 5'-
TGACGTCGACGA.ATTCACTACATCTTCTTAATCTGATTGTC-3', contains SaII and
EcoRI restriction enzyme sites for cloning as well as the stop codon, TGA (the
cdkl sequence
is underlined).
The cyclin B 1 sequence (accession number M25753) is amplified by PCR and
cloned
into the BamHl and SaII sites of pFASTBACI (Life Technologies). The sense
oligonucleotide
primer, SEQ ID. NO. 3 5'-
GTCAGGATCCTATTCGAAACGATGGCGCTCCGAGTCACCA-3', contains a BamiHl
and AsuII restriction enzyme sites for cioning and the translational
initiation codon, ATG (the
Cyclin B1 sequence is underlined). The antisense oligonucleotide primer, SEQ
ID. NO. 4 5'-
TGACGTCGACGAATTCATTACACCTTTGCCACAGCCTT-3', contains SaII and EcoRI
restriction enzyme sites for cloning as well as the stop codon, TAA (the
cyclin BI sequence is
underlined).
The cdk2 sequence (accession number X62071) is amplified by PCR and cloned
into
the SpeI and XhoI sites of pFASTBACl (Life Technologies). Tlie sense
oligonucleotide
primer, SEQ ID. NO. 5 5'-ACTAGTTGGCGCTTCATGGAGAAC-3', contains a Spel
restriction enzyme site for cloning and the translational initiation codon,
ATG (the cdk2
sequence is underlined). The antisense oligonucleotide primer, SEQ ID. NO. 6
5'-
CTCGAGGGAGGAGAGGGTGAGATTAG-3', contains Xhol restriction enzyme site for
cloning (the cdk2 sequence is underlined). This primer would anneal in the 3'
untranslated
sequence.
The cyclin E sequence (accession number M73812) is amplif ed by PCR and cloned
into the XbaI and XhoI sites of pFASTBACl (Life Technologies). The sense
oligonucleotide
CA 02427338 2006-09-25
WO 02/-123113 PCT/USO1/44835
114
primer, SEQ ID. NO. 7 5'-
GTCATCTAGATTCGAAACGATGAAGGAGGACGGCGGCGC -3', contains a XbaT and
AsuII restriction enzyme sites for cloning and the translational iiutiation
codon, ATG (the
Cyclin E sequence is underlined). The antisense oligonucleotide primer, SEQ
ID. NO. 8 5'-
TGACCTCGAGGAATTCATCACGCCATTTCCGGC-3', contains Xhol and EcoRI
restriction enzyme sites for cloning as well as the stop codon, TGA (the
cyclin E sequence is
underlined).
The cdk4 sequence (accession number U37022) is amplified by PCR and cloned
into
the BamHI and EcoRl sites of pFASTBACI (Life Technologies).. The sense
oligonucleotide
primer, SEQ ID. NO. 9 5'-GCCGGATCCATGGCTACCTCTCGATATGAA-3', contains a
BaniHI restriction enzyme site for cloning and the translational initiation
codon, ATG (the
cdk4 sequence is underlined). The antisense oligonucleotide primer, SEQ ID.
NO. 10 5'-
GCCGAATTCACGATGCATAGTCAGGTACATCGTACTCCGGGTTACCTTCGTCCT -3',
contains and EcoRl restriction enzyme sites for cloning as well as the
henlagglutinin (HA)
sequence and the stop codon, TGA (the cdk4 sequence is underlined an d the HA
sequence is
italics).
The cyclin D1 sequence (accession number M64349) is amplified by PCR and
cloned
into the BarnHl and EcoRl sites ofpFASTBAC1 (Life Technologies). The sense
oligonucleotide primer, SEQ ID. NO. 11 5'-
CGCGGATCCATGGAACACCAGCTCCTGTGC-3', contains a BamHI restriction enzyme
site for cloning, the translational initiation codon (the Cyclin D 1 sequence
is underlined). The
antisense oligonucleotide primer, SEQ ID. NO. 12 5'-
GCCGAATTCAGTGATGGTGATGGTGATGGATGTCCACGTCCCGCACGT-3', contains
an EcoRl restriction enzynie site for cloning as well as the His6 tag and a
stop codon, TGA
(the cyclin D1 sequence is underlined and the His6 tag is italics).
The cDNA for each of the cyclin-dependent kinases (CDK) and the corresponding
cyclins are
cloned into the baculovirus expression vector, pFASTBAC 1(Life Technologies).
The
sequences of each of the constructs are confinned by automated fluorescent DNA
sequencing
TM
according to the manufacture's protocol (Perkin Elmer/Applied Biosystems Inc).
The full
sequence of each of the clones is presented in SEQ ID. NO. 13-18.
The insect cell (Sf9) expression is optimized for each of the CDK/cyclin pairs
according to the manufacturer's protocols (Life Technologies). For cdk4-
HA/cyelin D 1-His6
an infection of 0.1 multiplicity of infection (MOI) for 48 hours gives the
best expression
CA 02427338 2006-09-25
WO 02/42303 PCT/USO1/44$35
IIS
Icvc{s of the complex as well as activity. For cdk2/cyclin E, the best
expression is observed
with an infection of 1.0 MOI for 72 hours, while for cdkl/cyclin B, the best
expression is
obscrved with 2.0 MOI for 48 hours.
The Sf9 cells are grown at 27 C in 500 ml of SF900 II SFM medium (Life
'Technolo ;ies) until the cells reached a density of -2 x 106 cells/nll. The
viruses are added to
the cells and the culture is incubated at 27 C for the desired time. The cells
are harvested by
centrifugation at 3000 rpm for 10 minutes. The cells are snap frozen on dry
ice and stored at -
80 C_
Cell extracts are made following a standard procedure. The cell pellet is
resuspended
in lysis buffer (50 niM HEPES, pH 8.0, 10 mM MgC12, 1 mM DTT, 2.5 niM EGTA, 1
mM
EDTA, 10 mM [i-glycerophosphate, l mM sodium vanadate, 1 mM sodium fluoride, I
x
TM
Protease inhibitor cocktail). The cells are lysed using the microfluidizer
(Microfluidics) for
minutes. Cell debris is removed by centrifugation at 100,000 x g. The cell
extracts are
aliquoted in 1 ml aliquots, frozen on dry ice, and stored at -80 C.
15 The kinase reactions are performed following a standard procedure. The
enzyme and
inhibitor are diluted in kinase buffer (50 rnM HEPES, pH 8.0, 10 mM MgC12, 2.5
mM EGTA,
10 mM (3-glycerophosphate, I mM sodium vanadate, 1 inM sodium fluoride, and I
nilV1 DTT)
and pre-incubated for 30 minutes. The cdk2 and cdk4 enzyme activities are
assayed using 500
ng of the GST-pRb substrate (see description below) in the presence of 10 M
cold ATP and
20 1 Ci of [y-33P] ATP for 30 minutes at room temperature. The cdkl enzyme
activity is
assayed using Histone H1 (Sigma) in the presence of 10 M ATP for 30 min at
room
temperature. The reactions are terminated by the addition of 50 L of 10 mM
cold ATP to
stop the reactions. The reactions are transferred to a pre-soaked 96-well
multi-screen plate
containing 30 L of 100% TCA per well. After incubation for one hour at room
temperature,
the plates are washed twice with 200 l of 20% TCA, followed by 200 l of 10%
TCA and
finally with 200 l of 5% TCA. After drying the plates at room temperature,
the filter plates
are placed in adapter plates (Packard) and 40 I of Microscint-O (Packard) is
added to each
TM =TM
well. Top Seal A film is used to cover the plates before counting in a Top
Count Scintillation
Counter.
Glutathione S-transferase - retinoblastoma fusion protein (GST-Rb) (Kaelin, W.
G.,
Jr., et al.., Cell 64: 521-532, 1991) is obtained from Dr. William Kaelin. GST-
Rb is prepared
by transformation of E. coli with the plasmid pGEX-Rb (379-928). The
transformed bacteria
CA 02427338 2006-09-25
WO 02/42303 PCT/US01/44835
116
zu=e grown overnight to saturation, then diluted in YT broth and incubated at
37 C for 2 h. The
protein is induced by incubation with 0.1 inM isopropylthioglycoside for 3 h.
Following
scdimentation by centrifugation, the cells are lysed by sonication in STE
buffer (0.1 n-i1VI
NaCI, 10 mM Tris, pH 8.0, 1 mM EDTA) containing 10 % sarkosyl. Particulate
matter is
removed by centrifugation and the lysate is incubated with glutathione-
Sepharose at 4 C. The
beads are washed with kinase buffer and then quantitated of Coomassie blue-
stained proteins
separated by SDS-PAGE using a protein standard of known concentration.
Determination of IC50 Values:
The % remained activity of the uidicated Cdk/cyclin kinase complex in the
presence of
inhibitor is calculated by the ratio of cpm in the presence of inhibitor to
cpnl in the absence of
inhibitor (%Activity = vi/vo x 100%). The IC50 values are defined as the
concentration of
inhibitor that results in a 50 % inhibition of the indicated cdk/cyclin enzyme
activity. Table 2
shows inhibition of activity for select compounds using this assay method.
The ICS values for the CDK inhibitor flavopiridol are presented for
comparison.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
117
Table 2
INHIBITION OF CYCLIN B/CDK 1, CYCLIN E/CDK 2, AND
CYCLIN D1/CDK 4 ENZYME ACTIVITIES
rZ~
Ra
H", W0
N ~ N
~ \>
HN~N N
~2
NH2
Compound Z Ra R2 CDKI CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
64 98 555
1 -C(O)- ~aF
2 -C(O)- 48 92 427
CF3
3 -C(O)- Nz~ CF3 55 48 1122
4 -C(O)- N~ ~ 197 339 641 N
5 -C(O)- j
,0 O
6 -C(O)- ci 160 201 87
7 399 487 96
O
i
CH3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
118
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
8 -C(O)- 74 137 711
O
CH3
9 -C(O)-
10 -C(O)- s 49 57 761
0\/
11 -C(O)- 46 78 620
'CH
3
O
12 -C(O)- F 88 5 614
CF3
/
13 -C(O)- Br 197 364 373
14 -C(O)- CI 164 514 17
CI /
-C(O)- CI 61 291 732
CI
16 -C(O)- OIN CH3 43 83 372
1I
H3C"O CH3
17 -C(O)- CH 89 189 467
3
H3C.0
18 -C(O)- 506 336 1490
TIIL(CH2)3CH /
0
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
119
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
19 -C(O)- )aO 62 567 883
(CH26CH
161 352 682
20 -C(O)- )at-Bu
21 -C(O)- )a(CH 89 121 476
Z )3GH3
22 -C(O)- 182 571 383
(CFi2)4CFi3
23 -C(O)- ~ 300 596 629
(CH2)5CH3
24 -C(O)- a(CHACH3
25 -C(O)- 56 79 629
CN
26 -C(O)- N02 31 78 564
27 -C(O)-
NO2
28 -C(O)- 20 52 140
29 -C(O)- 0 27 56 632
CH3
30 -C(O)- { H3 25 77 683
CH3
31 -C(O)- 105 5 2041
CI
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
120
Compound Z Ra R2 CDKl CDK2 CDK4
No. IC50, IC50, IC50,
nM nm nl\4
32 -C(O)- 24 53 189
/CH3
H3 C'O
33 -C(O)- 58 30 427
34 -C(O)- 0 ,CH3 31 58 997
H3C
35 -C(O)- ~"~~CH3 48 55 766
V/ '
36 -C(O)- 45 79 697
37 15 32 1697
38 -C(O)- 0-CH3 27 66 703
39 -C(O)- 66 51 664
40 -C(O)- 36 61 238
~
41 -C(O)- 59 93 404
CH3
42 -C(O)- 21 51 103
CH3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
121
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, ICs0, IC50,
nM nM nM
43 -C(O)- 51 77 293
44 -C(O)- CF3 129 76 1495
76 154 485
45 -C(O)- j!~PH3
CH3
46 -C(O)- -:Z~ 153 55 709
47 -C(O)- ~CH3 36 14 361
H 0
H
48 -C(O)- 48 61 503
49 -C(O)- 121 49 88
50 -C(O)- , 43 44 206
~ ~
O.H
51 -C(O)- CH3 109 65 99
__,+
CH3
CH3
52 -C(O)- 40 59 350
53 -C(O)- ,,CH3 40 80 934
54 -C(O)- ~CH 45 49 315
55 -C(O)- 99 56 621
56 -C(O)- ~~CH3 43 53 909
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
122
Compound Z Ra R2 CDKl CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
57 -C(O)- /~/~CH 193 480 1305
I' 3
CH3
58 -C(O)- '--/CH3 52 68 357
59 -C(O)- "'*Y CH3 93 52 721
CH3
60 -C(O)- CH3 83 37 91
v CH3
61 -C(O)- 40 38 750
62 -C(O)- 25 66 167
63 -C(O)- 23 66 441
64 -C(O)- 65 62 593
65 -C(O)- 72 50 764
=
CH3
66 -C(O)- 234 325 1721
O
67 -C(O)- 824 441 3155
ION
68 -C(O)- 136 84 1442
iN
69 -C(O)- F 48 84 852
CF3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
123
Compound Z Ra R2 CDKl CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
70 -C(O)- CH3 277 430 4506
71 -C(O)- Br 53 91 698
72 Cl 51 89 864
73 -C(O)- CH3 100 73 410
74 -C(O)- 62 239 560
Br
75 -C(O)- 71 58 801
CI
76 -C(O)- Nz~ 57 179 787
77 -C(O)- 100 71 606
CH3
78 -C(O)- ci 101 155 523
79 -C(O)- ci 44 73 483
CI
80 -C(O)- 244 39 8100
CH3
81 -C(O)- -O 16 39 67
Br
82 -C(O)- -O 31 45 131
CiH3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
124
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, ICso, IC50,
nM nM nM
83 -C(O)- -O 19 44 185
CH
0
84 -C(O)- -O 19 9
69
cH
85 -C(O)- -O N~ 26 8 65
86 -C(O).= CH3
CH3
CH3
87 -C(O)- -O 15 42 27
~ /
F
88 -C(O)- -O 35 7 204
/
CI
20 42 65
89 -C(O)- -O ~CLN02
90 -C(O)-
~
91 -C(O)- CH3
-O1,~CH3
92 -C(O)- IN O'*~-CH 45 18 2102
3
93 -C(O)- O~CH 46 5 856
3
94 -C(O)- O 27 69 827
,
N02
95 -C(O)- 75 23 526
96 -C(O)- "IO~_,CH3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
125
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
97 -C(O)- O CH
3
CH3
98 -C(O)- O CH
3
99 -C(O)- -O ~ 6 33 9 1515
~ ,
O2N
100 -C(O)- o60 50 >1000
0
101 -C(O)- ~H3 31 80 >1000
0 O 0 02N):)~ O
CH3
102 -C(O)- 31 42 926
103 -C(O)- 0 CH3
-"~CH3
3
104 -C(O)- OCH3 ~ 750 731 8000
(~.H3 CH3
105 -S(O)2- 7 8 69
106 -S(O)2- 118 8 15
F
107 -S(O)2- 250 35 10
O
108 -S(O)Z- I~ 7 10 170
~
CI
109 -S(O)2- 18 45 12
~aCN
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
126
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, ICs0, IC50,
nm nm nm
110 -S(O)2- CH3 27 9 158
H3C N
111 -S(0)2- 0 17 9 51
O'CH3
112 -S(O)2- l4zz~ CF3 32 48 224
113 -S(0)2- CH3 18 7 39
O
HCH3
15 80
144 -S(O)2- ~aBr
115 -S(O)2- 5 5 14
N CH3
H
116 -S(O)Z- 18 32 382
117 -S(0)2- OH 290 31 558
CI
CI
118 -S(O)2- 22 38 38
119 -S(0)2- 25 31 65
120 -S(O)2-
NOZ
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
127
Compound Z Ra R2 CDKl CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
121 -S(O)Z- CI 120 50 83
( '
/
CI
122 -S(0)2- 10 38 590
123 -S(0)2- 62 54 49
124 -S(0)2- 14~ 10 26 77
~ ,
CH3
125 -S(0)2- CH3 180 38 62
CH3
126 -S(O)2- 20 6 55
oH
0
127 -S(O)z- N02 14 17 48
128 -S(O)Z- ~ I 9 7 5
129 -S(0)2- 60 9 60
CH3
130 -S(O)2- ~ 8 53 159
~
CH3
CH3
131 -S(0)2- ---\,CH3 100 17 70
132 -S(0)2- NO2 74 35 590
CF3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
128
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
133 -S(0)2- 200 55 85
CF3
134 -S(O)2- 200 35 84
ol CF3
135 -S(O)a- O 80 4 62
I OH
136 -S(O)2- Br 50 317 10
137 -S(O)2- ~H3 26 7 144
CH3
cc:__________
138 -S(O)z- Nz~ cI 40 60 69
CI
139 -S(O)2- -~~ 23 6 64
CH3
140 -S(O)2- IIZ~ NO2 36 41 75
CI
141 -S(O)Z- N 27 61 66
.CH3
CH3
142 -S(O)2- Nzz <5 9 47
1O
CH3
143 -S(O)2- NO
2 7.5 28 154
144 -S(O)Z- N 2 2 75
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
129
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
145 -S(O)2- 21 70 8800
CHa CHa
CN
146 -C(O)- NH N~ 18 42 200
147 -C(O)- NH ~ 38 46 258
/
F
148 -C(O)- NH-'~-CH3 197 61 699
149 -C(O)- NH 30 51 91
CF3
150 -C(O)- NH I~
26 55 91
CI
151 -C(O)- O-CH3 60 32 391
NH 6 O
CH3
152 -C(O)- NH F 17 42 753
/
153 -C(O)- NH a20 30 444
O
CH3
154 -C(O)- NH 11 30 285
O\~,CH
O
155 -C(O)- NH O.CH 20 43 482
/
~ 3
156 -C(O)- 75 79 1618
~ /
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
130
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
157 -C(O)- NHy CH3 310 32 2038
CH3
158 -C(O)- CF3 82 87 825
NH ~
i /
159 -C(O)- NH ~ CF3 4 16 702
i~
160 -C(O)- CH3 85 94 357
NH i ~
/
161 -C(O)- CH3 56 78 601
NH i ~
/
162 -C(O)- NH S~ 15 72 603
Br
163 -C(O)- p-CH3 37 57 855
NH 6
164 -C(O)- NHu-~"CH2 151 86 739
165 -C(O)- NH ~ CI 11 21 711
i /
166 -C(O)- F 6
NH 6F
167 -C(O)- CI 4 54 63 6
NH 6CI
168 -C(O)- Br 29 52 111
NH 6 6
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
131
Compouiid Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
169 -C(O)- CI 28 45 130
NH 6
170 -C(O)- NH Br 3 51 156
~ ,
171 -C(O)- OCH 51 89 963
3
NH 6
172 -C(O)- 0 23 62 829
NH
173 -C(O)- O 18 30 424
N H~O
CH3
174 -C(O)- O-CF3 48 89 795
NH ~
, /
175 -C(O)- NH 12 114 682
1)'0
CF3
176 -C(O)- NH ~ CF3 7 378 898
~ ,
CF3
177 -C(O)- CI 7 60 432
NH 0
CF3
178 -C(O)- CF3 49 100 879
NH
CI
179 -C(O)- NH CF3 8 261 497
CI
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
132
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
180 -C(O)- F 12 44 431
NH
F
181 -C(O)- NH 67 548 1303
182 -C(O)- NH CI 32 174 305
/
CI
183 -C(O)- NH 17 64 338
~ /
CH3
184 -C(O)- NH-N--\,CH 77 85 377
3
185 -C(O)- NH 72 79 280
CH3
186 -C(O)- NHa11 56 465
S
i
CH3
187 -C(O)- 280 61 831
NH
188 -C(O)- N H ( 14 31 170
~
CH3
189 -C(O)- 0 20 28 66
HN CH3
~ /
190 -C(O)- NH 23 40 357
CH3
CH3
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
133
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
DM DM nM
191 -C(O)- NH 1-1: 23 36 297
OI
H3C
192 -C(O)- CH3 1000 237 400
NH+CH3
CH3
193 -C(O)- 0 O.CH 26 8 507
3
NH
194 -C(O)- HN (: CN 40 15 88
195 -C(O)- 0 50 28 6
HN ~ O
~ /
CH3
196 -C(O)- Oi 350 2 6
NH 6
H3C
197 -C(O)- N H 200 8 381
198 -C(O)- NH O-CH3 40 20 7
O-CH3
l
O--CH3
199 -C(O)- 0 70 20 670
NH CH3
200 -C(O)- F 10 23 597
NH
1
CF3
201 -C(O)- CF3 170 41 986
NH ~
~ /
F
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
134
Compound Z Ra R2 CDK1 CDK2 CDK4
No. IC50, IC50, IC50,
nM nM nM
202 -C(O)- CF3 137 48 673
NH ~
F
203 -C(O)- NH -' 61 10 51 733
CF3
204 -C(O)- NH-~~ 200 51 39
CH3 6
205 -C(O)- HN-2,O 6 290 232 3249
206 -C(O)- NH--\,CH3 210 7 85
207 -C(O)- F 50 46 44
NH 6
208 -C(O)- CH3 180 8 73
NH ~
209 -C(O)- NHq13 34 50
CI
CI
210 -C(O)- NH CH3 20 28 74
I
211 -C(O)- N H ~ 197 612 7000
CH3 -CH3
)aOCF3
Flavopiridol 13.0 85 50.8
(4.1, (17.8, (23.5,
n=6) n=5) n=5)
CA 02427338 2006-09-25
W(.) 112/423413 PCT/US01!-44835
13S
Example 3
Ir: Vitro Tumor h-ihibition
In Pitr-o Proliferation Assay:
The proliferation of tumor cells can be measured using a tetrazolium salt-
based assay
known as the MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) assay.
The proliferation test is performed essentially as described by Carmichael et
al., Cancer Res.
47: 936-942, 1987. For the assay, the cell lines are plated onto 96 well
plates at 1000 to 2500
cells/well (depending on the properties of the individual cell lines), left to
attach and recover
overnight. (Leukemia cell lines grow in suspension and do not attach to the
tissue culture
plastic, however, the time frame for drug addition after seeding plates is the
same.)
Compounds are added as DMSO stocks (10 mM) to cover a concentration range of
0.023 to
50 M. After 3 days, the cells are incubated with MTT dye (3-[4,5-
Dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide, Sigma # M5655, 10 mg/ml in Hank's Buffered
Saline) to
estimate the amount of live cells remaining vs. concentration for the test
compounds.
Specifically, MTT solution is added to a final concentration of xx mM and the
plates
incubated at 37 C for 2 to 4 hr. The MTT and culture medium is then removed
from the
cultures and 200 l of DMSO is added to solubilize the dye from the cell
layer. The
TM
absorbance at 570 nm is determined for each culture using a Spectramax plate
reader
(Molecular Devices).
Another method for measuring proliferation of tuinor cells in vitro is a
sulforhodamine B assay as described in Skehan, P., et al., J. Natl. Cancer
Inst. 82: 1107-1112,
1990. Tumor cells are harvested with trypsin-EDTA, cells that excluded trypan
blue are
counted, then added to 96-well plates and incubated overnight at 37 C.
Compounds are
added to the wells following dilution in culture medium. Three days later, the
mediuni is
removed and replenished with medium containing fresh drug and incubated an
additional 4
days. The cells are then fixed with 0.1 ml 10 % TCA for 60 min at 4 C. The
plates were
rinsed five times with tap water, air-dried and stained for 30 min with 0.4 %
sulforhodamine
B in 1% acetic acid and air-dried. Bound dye is solubilized with 0.1 ml 10 mM
Tris (pH
10.5) for 5 inin and the absorbance measured at 490 nm using a plate reader
(as in the MTT
assay above).
IC50s were determined from the raw data from either the MTT or SRB-assays. The
IC50 equals the amount of drug that causes a 50 % decrease in absorbance
values relative to
those nieasures from cell cultures that received no test compounds.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
136
Cell Lines:
MCF7 is a human breast adenocarcinoma, hormone-dependent (HTB 22);
MDA-MB-231 is a human breast adenocarcinoma, hormone-independent (HTB 26);
MDA-MB-435 is a human breast carcinoma, hormone-independent (HTB 129);
HT-29 is a human colon adenocarcinoma, moderately well-differentiated grade II
(HTB 38); HCT-15 is a human colon adenocarcinoma (CCL 225);
A549 is a human non-small cell lung carcinoma (CCL 185);
NCI-H460 is a human non-small cell lung carcinoma (HTB-177);
HL-60 is a human acute promyelocytic leukemia (CCL-240);
Jurkat is a human acute T cell leukemia (TIB-152);
Molt-4 is a humau acute lymphoblastic leukemia (CRL-1582);
PC-3 is a human prostate adenocarcinoma, hormone-independent (CRL 1435); and
DU 145 is a human prostate carcinoma, hormone-independent (HTB 81).
All of the cell lines were obtained from American Type Tissue Collection, with
the
ATCC accession number in parentheticals. MCF-7 and and MDA-MB-231 cells were
grown
in improved minimum essential medium (Biofluids) without phenol red,
supplemented with 5
% fetal bovine serum, 0.01 mg/ml gentamicin and 3 mM L-glutamine. All of the
other cell
lines were grown in RPMI 1640 medium (Life Technologies) supplemented with 5 %
fetal
bovine serum, 0.01 mg/ml gentamicin and 3 mM L-glutamine
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
137
ti a Cj
..i
U n
E, o
~'1 O O
U U
1~ 00
N a' o 0
~
O~ z~ z~ av
C-+ Z Z M 4-
= Z N
Zlilz O
LL
N 0
U
b
0
~z ~
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
138
Y. N
,4 L)
..~
N N r+ 00
xa~
~
N N N
N O O O O Q
p p o
o V V V
U
00 M N N N N N~" N
~o 1
P-ia N pp
O O O O O O O
N M N N N M N
M~~
K
N N M M tn ol
o ~
N N
O O O OO O O
U LL
O~O U =
O-U
zZ ~0\
O-U
N O 0 0 O O O O O
N M tn "O 00 01
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
139
.-.
' o o N
.-. ~
N
M 00
~a~o 0 0
N o
~ O N N
o U U V o 0
U
N N 14
4-~~ ~h N k oo I~ v~ rn d -
V7 O~ l~ 01
o otn N N O l~
N N
'd 00 v~i 00 00 O ~ i ~ vNi
rA U~ I:t N N N 00
C~ O O
cM
cl)
U M =
U
0 U U %~ _
0 O'U
LL
.-. .-. .-. .-. .-. ,-. .-.
N O 0
O O O O O
U U U U U U U
~ z o ~ N cn d ~n ~o
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
140
ti a U
s-.
a U
bi)
d\o,' o
'..
N
O p y
U U C
N M N~
d oo, N
0~1 0~1 d~
p- U th N
..~
4-
~ y o N ~ v00i N dM,' o 00
N N N
_ = M
U U CO
_ _
= N N ~ V ~ V
c\j
O/U U U m = = 2
U (~ U
O O
~
U
_
O O O O
O O
N 0
U L) U U U U U
00 ~ N N N N
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
141
ti a U
a U
bf)
xa~ o 0
N p C~ d
U V C o 0
U ~ rn cq r- N ~ 00
p~ 0 U c*i N ~ cq o N O
Cd~ 00 00 cn
N N
U cn -- o M O O
cl)
U z N N cl)
O
Z Z o
U
o p U O
.2
.-. .-, .-. .-. ~-. .-. .-. ,
O O O O O O O
U U U U U U U
Z N N N N N N
O
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
142
~
tiaU
a U
on ~
xaU
r--i
~..~
~,
O
U V
U ~v~i o o~o c 00 m M
Yi
N oO.
0 U d o 0 0 0 0 ~
~~~o 00 0, ~o 00
~ O o d N M M N N
Utn O o ~ O O -
M
U
O O O V O
O ~ O
2
O O O 0 0 0
O
N U U U U U U U
~ ~ ~ ~ ~ ~ ~
~" Z M M M M M M M
O
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
143
tiac.~
1-~ 00 l~
0 o M v~ N ~
r~,' a U O o O O
N
N 0 O
0 U U o o V o
e-.
~o rn rn n rn
00
vo ,O N o N ~t r+
p~ O O O O O O O
M
~~ o Va N ~ N cM
U O O o - O O O o
M
U U 2
~ 1\ U 0 I~ ~~ V UV j~
,-. _IITII_
. .-. r. .-. .-. ,-N O O O O O O
C) U U U U U
~
0
z M ~ ~ ~
~
a
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
144
x o
a U
a U
x ''a U
..~
o
N
O 0 0 _.
o
U U ~
O.J, 00 = O 01 00 01 l~
00 01 tt')... W) I'O 00 v) V)
, a U'~ O O r-1.i O O O O O
a~..~
M
6 a~o
~
N
Li
cl)
LL
M \ _ ~ M
v'O-
0
12, 11
.
0 O O O O O O O O
U U U U U U U U CU
0 ~ O l~ 00 C1 0 N M d' v'1
F tn tn kn in tn
FO
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
145
x
tiaU
U
o~
~-+ M
41 M d' ~O V~ 00
U!;; ci o
a~Uo =-+ o 0 0 0 0
.-+ ~O N O~ '- M
\O 01
U O O r+ O O O
ce)
M =
V U T
m = U U
U U U /
.-. .-. .-. .-. r-. r. s-. .-. .-.
N O O O O O O O O O
U U U U U U C) U U
00
~ tn
~= z
~
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
146
xav
x '-a U
v~ ~
N O -
~
U U G
M Y~ 01 M V~ M
U v~ a N 01 00 M ~O O
p, o U n; -a o d o 0
r'n
v o o \0 00 o
~~U cn ~ o o 0
M t L _
0 z V p o
~ ~ ~ ~ ~ ~ ~
N O O O O O O O 0
U U U U U U U U
~Z ~ ~ r- 00
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
147
~aU
,-.
x'~ U
v~ ~
O p o
UUC
~
~ v) O d 01 M I~ O
U~ o m N l-~ N
põ1 o U r ~ - -~ - ~ o n
A''
tn+'
cn ~~ r' c- 00 l~ cn \o tn
Q) cM M vi N
u
V m U V U U ~~
- - - - - - O
r. ~. r. :. r . ~ . r, .'.
O O
N O O O O 0 0
U C) U U U C) U U
c) 00
P, Z 00
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
148
a-.
o d~ ~ N o
~avo 0 0 0.~ o
o 0 0 0 0' N
0 o so' o
a U
L oo Ca' ~D
d- ~ o 0 0 0 0 0 ~r a' o
~,,~Uo 0 0 0 0 0 .c'+~ o
t..
~n ~
o p~ M tiD l~ M M 41 CD' d
~ O o O O O O o N *-+ O
UU U O O O O O O O, O
~
~ N N N N N ci N
~ fl 11 11 .-: ~ il
C, ~.' cq C-l "D S-" U'n - r+ N - d oo I) ' vi
a~ U p p p p p p p p p p p M O.'~_..~'? p p
P-4 O O o O O o 0
N N N N N N N
M~~ II il II II
C%4 0
o ci o ~ p ~ 00 0 0 0 0 0 0 0
= M
" - -
O J~ O ~ O O O
1 U U U U U
0z 00
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
149
~ O N 10 00 00
-4 1-4
ti a U o 0 0
0 0
r, ~
N
~
o ~ o 0 0 0
x a V o 0 0 0 0 0
~ O N N N
x,aUo o 0 0
v~ ~
O p~o O N 00 p Q
U U U o o 0 0
~
N N N
M~ ~\U 00 M IS-~'" "~ Ifr" V~ ~
Urn o O v~ M N N - N M ~D
(~ ~ O o O O O ~ o ~ O D O -
0 0 0
N N N
N
C'n M
00 \O M ~n
~as o O M M M N~ N M
~~~ O o O O O o 0 0 0 0 0 -
0 0 0
N
0 M = z m =
Z U = \ V U
r~ - cm)-{
0 0 % i i 0 e =
0
U
/ 0
N O O 0 0 0 0 O O 0
U U U U U U U U U
~
-4
~Z ~ rn ~ rn rn
0*1 cl%
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
150
a O O O 00 ~~
r-i
~ N
p O 6
xa~ ~ v ~
o
to r- N N N
d' o
U o 0 0 0 0
~n ~
_ Cf)
oU(.) o 0 0 0 0
U ~
~ N N N N
N O I I3. N I lt . l~ t I~~ d' O I I'~," NOC)
o 0o N . N N N un oo d
pU 0 U O O~ O ~ O O o O ~ O~ O I~
p"~ O O O OO
N N
m~~ N N N6
c~ N + N ~
~ ~ N
U O O 0 O ~ O O cq N O o O N
O O O O O
_M
= 2
U
M ~
U-O 0-0
0 0 2 U-
0 ~ ('Z ' ~ o
0 z
0
~ o
~ ~ , , ,o ,
~ ~ ~ ~ ~
N O O 0 O O 0 O 0
U U U U U U U r~ vP
b
00 cl~ o 0 0 0 0 0 0
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
151
+'-4~ ~ e~~C?N ONN ,--~
a U o o~ o~ o
00 00
xaL) 00
C o 0
bn
'D~ o N N N N 00
O
~,,..a U o 0 0 0 0 0
Lr)
N' p 00 00 00 N O o
U~jUo 0 0 0 o V
a~ N N N N N M
a U o p 00 p p p N o r~+
p"0 o OO OO O OO O
~ N N N N N M
CY)~~ II II II II II
C, 00 ~'. tn
\6
OO o O O O
cl)
M
ce)
U V V U u-
fp U Oa~
z=
- - U ~ ~
M
1 1 1 1 1 1 1
14
~7 O O 0 O 0 O 0
c~ G~ c~ r~ v3
~
0 cq m
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
152
~-.
x~
a~ ~
~..i
N
N
o O
xac~
N O
O O o ~
O 0
UUC
~ N N
00 O I~I." V1 M o0 N N Ir.l.~'
U v~ o ~
a U O tn cn =--~ M O O O o
N
M 00 o
06 O O O ~
ce)
Z
o O::~U O
Z
z 0 ~
N N N N N N
N O O O 0 0 0 0
.~ " " .~ '. .~ ...
rs1 r~ v?. rs1 v~ 0?
~
v'~ 00
0
Z 0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
153
~ N
a U o
N
x a U o
tn
o
0 0 o
U U ~ o
N
r--+
U a~ oNo tn N v) N cq
a~ U O O C? ~ O --~ O
a,~ o
Ln N
d' Cd 00 M
N o
U O O O o O ~ O
' V V
= O O
U U oz
r. r. : : : :
O O O
N O O O 0
o? ri? ri?
O - N M d' v) CO j l~
~ N N N N N N N
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
154
tiaU
c:)
4 Cj V
...
,0
v~ ~
o 0
o Cj ~ o
U ~
00 ~ o v~ ~D N d ~ O1 [~
a O U O O N - O ~ 00
(~ .~ O
II
U O O O O O 0 01 O
czs 2. d ~t 000 00 cl)
U U V "o _ ~ um
zN
N N N N N, N iV
N O O O 0 0 O 0
... .~ .~ ..~ .~ .~
r-? r? C? I?
00 (ON C14 CC) 'IT
0 N N o M M M M
0
c~
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
155
a U
..i
xa~
o
xa~
N O
O p o
U U u
U "1 oa v) m
P,
krl
00
y M vi DO
~~UM o 0 0 ci o
= T M N
O U
/ \ < / \ / \
' - \
O U'O O-U :ffi V Z
~
N O O 1 O O 0 kn 00
M M
M M M
~'. =--=--.--~ --.----O
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
156
r-.
N cNn tn N
U o 0 0 0
~..i
clq
aU o o O o
NY ~ M
U 0 0
kn
N O~ N O
O O O
o U U v v
u
N M M N m
_ il
Ln II
Cn y r'
M M N
pi 0 U O O O ~ ~O 0 0 ~ V~: O
O O O ~; O
N ci M cn
d' cd oo ~ t0 N (n M I0 IA Ir
U O O O C-1 O
O ~ O ~ O
~~..s
cq LL
0-U 0 ~
Z /\
_ z-
z z Z =
z
N N N ry
tv O O O O O O O O
..., ~. .~ .... .~ .~ .., .~
r-? I? U U U U
06 ~ dM It 00
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
157
NoM
tia V o 00 ~
'~'i a U o o
N
N k
0
0 0
0
0 U U o 0
~ c~n N N M m m
~
U ~ o N >~ O oMO ~ N >~ ~ >~ M
P U p p OO
~'' C o 0 0 0 0 0
M N N M M M
M~~ I
.. ~t cd ~- f- O a r' M 00
O O O o O o O O O O ciO O O Z
U M
M
'-' 0 O-U " O-U o O
~ ~ O
- 12 0
2 = %
Z Z z 2 Z z
Z
.-. .-. .-. ~-. .-. ~-. ~-.
N O O O O O O O
U U U U U U U
z n vi vi vi
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
158
N
ti a U O O O
~O O O O
a U
"p o 00 .-~
ry
U o 0 0
N p O
p o
U U U co 0 0
~
00 M 01 l0 -.N. ~--~ 01
U~ o M M M ~O 01 N C1
~
0 M
O O -- O GO: O d
~..~
C'n ~ y vi N N m O ~ O
ci o -~ o o in
~
M LL
~ _ cl)
~
~
Z z Z Z z z z
Z
, ,
O O O O O O O
N
U U U U U U , C~
, , , , , ,
Z ~ 00 p
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
159
N N
a U o 0 0 0 0
C
~~~o 0 0 0 - o
a U V o 0 o V o
N 00 tn N
a U o c o 0 0 0
N p~~ N N O O ~ p
oUtj o 0 0 0 o
M ac'i o M- O 00 tn N N
pU,.~ U O O O O O o' O
00 M 00 Vn -+ 41 V)
y o o N ~ -- N
pq L) O O O O O O O
LL U oo =
LL
_ _ = Z Z 2 =
Z z
z z z
r. .-. -. .-. .~ r. r-.
N O O 0 O 0 0 0
U C~ U U U U U
b
9
0 tn 00 rn o' ,~
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
160
00
N
U o 0 0
a~~ = '
N
~,~ U o 0 0
0 0 o o ~ o
o U U o 0 0
U tz~
U M tn
tl o O o0 N N a ~ -
o U.- ~ ri o 0 0 0 0
C
vi
En ~ ~ =~ cv =~ c~ ~r
M
,-~PQU c-i o 0 0 0 0
= M LL
V O-U U LL7 U
O 0 ~O V U ~ \ V
O - - _ -
z ~ Z = = z 2
z z z
~. ~. ~ Al .=. r. .~
N O O O O O 0 0
C) U U U U U U
C14 00
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
161
x~ o o N m ~ rn
b ~ o 0 0 0 0
~ o O o o
o o *N-i N ~ N
~,.~ U o 0 0 0 0
tn
oUtj o 0 o V o
U ~-+
o c~ O N ~ =--l~ d;
py C) ~ O O O O O O O
C'n
d o ~r tn
y o cy -- N -- [~ N
U O O O O O O O
u
~N V ~ V ~ V ~ i V ~ V ~ Y
_M
cl)
c0
U
U U U U U
L- ~ "z
- _ -
= z z =
z z z z =
z
N O O O O O O O
U U U U U ~) U
~
Z r- 00 00 00 00 00 00
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
162
M N M
~a~o 0 0 0
N 0
V V V Vo
r-r
bo
o N N M d
~ '~ O O O O
xa~
0 0 0 0 N
0
oU~jo 0 0 0
U v
M~ ~ ~ o M N N
pU, o U o 0 0 .-~ o 0
,-.
'/7
C'n
~i Cd o O N d 00 O O N
U O O O - O O
= 0
2 U U = _ O-\
U op0oop z z = Z z
N O O 0 O O O
U U U U U U
b
0z 00 ~ 00 00
00
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
163
x ~ N
tiav ~
C,~~
xa~
tn
o~ ~o 00
0 0
U U U
u
m 00 rn 00 rn rn
oo 00 M ~n o
pU O~ ~,.._; O O O O =-+ M
~..~
~-.
cd M Otn 0tn0
~~U ~ o 0 0 0 o cv
= M M
U U
~~ V U
M O
TCI) O O O 0
= o
z ~ z M ~
z
2
z
= z z =
= Z
O O O 0 O O U 0
N U U U U U U
u u u
~
o rn oM, rn rn rn rn 00
z
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
164
xiy N
a U O O O O
a v v v v
to 00 01 M d'
d- +~- --=--i M v~
O O O O
x'~ U
o ~ o o
O ~ o O O O
Cj
U "O
N N
~ o
a, U O O '-O O N -
a
M
czs o N O V~ N N ~n 00
U o O ~ o o ci ~
M
U- u. LL 2
M M U
LL, ~ I~ ~~ ~
- -
z z LL Z z
z 2
Z
, .-l ~ .-. .--. . r. .-. .-.
N O O O O O O O
U U U U U U U
ON N N N N N
O
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
165
00
O c~ Q1
o 0 0
N
O O OrN+
oV
~ N O O N
r-~
~ M
O N
cq o O O O
U U U O o 0 0
N
cn oo ry o I
p,a c~i o o O o Oo
'..
kn
U) 00 01 01 N N
y o~p =-i d i \G O O~
ci o O o 0 00
cn ~
" U = U ~
C)
LL I ~ ~ 0
o
~ ~
_
z z z z = = w
z z
N O O O O 0 O
U U U C) U U
00 ON N ON N N N
0
U
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
166
In Vivo Assays
Example 4
Metllod for In Vivo Treatment of HL-60 Human Leukemia and
PC-3 Human Prostate Tumors in Nude Mice
Antitumor efficacy is assessed using two subcutaneous human tumor xenograft
models. The
studies are performed using conventional assay techniques. Briefly, HL-60
(leukemia, 5 x105
cells) and PC-3 (prostate, 5 x 106 cells) tumor cells are injected
subcuateously into nude mice
(Crl-CD 1 -Br-nu, Charles River Laboratory, Wilmington, MA). Dosing with
compounds began
when tumors reached 50 to 100 mm3. The dose route/schedule for the test
compounds is
ip/qld (5x/wk). The test doses are set based on the maximum tolerated dose
(MTD). The
MTD is defined as the level of compound that did not cause more than 20%
decrease in body
weight or result in death following five daily doses (ip) in non-tumored CD1
mice. The test
doses for the efficacy studies are set at 1/3rd the MTD (low dose) and the MTD
(high dose).
The results are shown in Tables 4 and 5 (HL-60, leukemia) (PC-3, prostate
cancer). The
length of the treatment phase is dependent on the tumor growth rate for the
two models. This
treatment phase is typically about 3 weeks for the HL-60 model and about 5
weeks for the PC-
3 model. Flavopiridol (3.5 mg/kg/day) is used as a reference compound for
these studies.
Dosing with flavopiridol is for the same time frame as for the experimental
compounds in
both xenograft models. Tumor volume (twice weekly) and body weights (once
weekly) are
monitored throughout the course of the treatment phase of the experiment.
Tumor sizes are
measured by external caliper measurements of protruding tumor. Volumes are
calculated
using the following formula: volume =1/a (a x b2), where b is the smaller of
two perpendicular
diameters.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
167
The results are provided below in Tables 4 and 5, below.
Table 4 Effect of Chemical Group A on Growth of Human Tumor Xenografts
Compound Dose - PC-3 PC-3 HL60 HL60
No mg/kg Mean Vol. P-value vs. Mean Vol. P-value vs.
SD Control SD Control
NA 2698 1815 NA 6275 1990 NA
87 1 3271 2262 0.585 3718 2715 0.051
87 3 1396 958 0.105 7096 3079 0.538
88 1 1601 1348 0.193 4415 2740 0.145
88 3 2278 2110 0.676 2624 2108 0.003
89 1 2572 1052 0.867 2444 2291 0.003
89 3 866 384 0.025 4278 2801 0.125
149 1 1084 929 0.048 4010 2371 0.058
149 3 2089 1382 0.464 2505 2104 0.002
154 3 1385 873 0.095 2641 3024 0.033
154 10 1707 721 0.184 2950 1929 0.004
106 1 1860 741 0.256 4271 3851 0.219
106 3 1482 906 0.120 7368 2592 0.361
109 3 1807 1388 0.290 2597 2240 0.006
109 10 979 734 0.034 3466 3730 0.088
i l l 3 1083 704 0.043 3798 2431 0.043
111 10 2114 1320 0.475 2387 1282 0.001
112 0.3 1302 869 0.078 5413 2845 0.495
112 1 1155 872 0.055 4170 3111 0.156
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
168
Table 5 Effect of Chemical Group A on Growth of Human Tumor Xenografts
Compound Dose - PC-3 PC-3 HL60 HL60
No mg/kg Mean Vol. SD P-value vs. Mean Vol. SD P-value vs.
Control Control
NA 1308 852 NA 8341 5355 NA
81 1 1258 523 0.890 5802 2996 0.295
81 3 1007 1120 0.556 5104 4014 0.217
82 1 810 600 0.200 5164 5516 0.279
82 3 967 407 0.330 2841 1845 0.035
83 3 899 593 0.286 5906 2948 0.867
83 10 1426 1131 0.817 4057 2599 0.200
84 1 770 567 0.162 4790 6912 0.284
84 3 1386 752 0.850 4886 3467 0.175
85 1 912 755 0.342 3590 2674 0.064
85 3 1208 1247 0.855 5215 4068 0.258
3 1 671 672 0.120 6370 4655 0.465
3 3 785 473 0.158 6092 4278 0.392
12 3 1063 693 0.538 4948 2803 0.172
12 10 1107 606 0.595 2624 2108 0.107
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
169
Example 5
Red Blood Cell Binding
Compounds, including one positive control, are assessed for red blood cell
(RBC)
uptake, using a modified procedure based on the protocol reported in Sun,
J.X.S., et al. High-
performance liquid chromatographic analysis, plasma protein binding and red
blood cell
partitioning of phenprobamate. Biopharmaceutics and Drug Disposition, 8 (1987)
341-351.
Briefly, RBC uptake is evaluated by comparison of the levels in spiked plasma
(n=3)
and plasma isolated from spiked whole blood (n=3). Compounds are incubated
with human
and mouse whole blood, respectively, for 30 minutes at 37 C using a nominal
concentration of
500 ng/inl. Following centrifugation, the plasma is removed and submitted for
analysis. Each
compound is also spiked into blank plasma at a nominal concentration of 500
ng/ml, and
submitted for analysis. Levels in the two plasma samples (Cp' and Cp in the
equation below)
and the blood hematocrit are used to determine the red blood cell to plasma
ratio (Crbc/Cp).
(1) Crbc Cp' (1- H)
Cp Cp=H H
In equation 1, Cp' is the level of drug in the spiked "blank" plasma, Cp is
the level of drug in
the plasma of spiked whole blood, and H is the hematocrit. The hematocrit
values are
determined as 0.4 for human whole blood and 0.41 for mouse whole blood. The
samples are
analyzed with ESI LC/MS, using positive ion detection with an internal
standard. The results
are summarized below and in tables 6-16, following.
The red blood cell to plasma ratio is determined for each compound using
equation 1.
Tables 6 and 7 summarize the respective mean Crbc/Cp values and standard
deviations for
mouse and human whole blood, respectively, in descending order based on the
red blood cell
to plasma ratio, where"*" denotes Positive Control, and "ND" denotes Not
Determined.
MDL 108552 is included as a positive control for red blood cell uptake.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
170
Table 6. Red Blood Cell to Plasma Ratio for compounds in mouse whole blood
Compound No. Mean Red Blood Standard
Cell to Plasma Ratio Deviation
83 112.2 19.2
154 17.8 3.1
85 6.1 0.4
89 4.7 0.7
81 4.5 0.6
88 3.5 0.4
84 3.5 0.3
87 3.4 0.5
149 3.4 0.4
81 3.3 0.1
106 3.0 0.3
112 2.4 0.3
109 2.4 0.3
111 2.2 0.6
3 2.1 0.2
12 1.9 0.6
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
171
Table 7. Red Blood Cell to Plasma Ratio for compounds in human whole blood
Compound No. Mean Red Blood Cell Standard
to Plasma Ratio Deviation
87 8.4 1.6
85 7.1 1.1
3 7.0 0.5
82 5.8 0.4
81 5.3 1.3
109 5.0 1.0
89 4.2 0.6
154 4.1 0.7
83 4.1 0.7
106 3.9 0.8
112 3.7 1.0
12 3.6 1.1
149 2.8 0.7
88 2.6 0.8
84 2.0 0.6
111 1.2 0.6
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
172
Example 6
Bioavailability Experiment in Mice Given Single Intravenous Cassette Doses
of CDK Inhibitor Compounds
Male mice are given single intravenous cassette doses of CDK inhibitor
compounds.
Each cassette contained 4-5 test compounds and a CDK reference standard, MDL
107167.
Groups of mice (n=3/timepoint) are euthanized at specified intervals from 0-24
h after dosing
and concentrations of the administered compounds in plasma are quantitated by
an assay
based on LC/MS. The key results are:
Cassette #la
Compound 83
Compound 12
Compound 85
Compound 109
Compound 111
Reference Compound MDL 107167DA-004
HN
~
iJ
~ H2N ~,. H N N N
MDL 107167DA
Cassette #2a
Compound 3
Compound 81
a DA = dihydrochloride salt; and TA = trihydrochloride salt
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
173
Compound 84
Compound 154
Compound 819
Reference Compound MDL 107167DA-004
Cassette #3a
Compound 87
Compound 149
Compound 112
Compound 88
Reference Compound MDL 107167DA-004
Cassette #4a
Compound 818
Compound 82
Compound 89
Compound 106
Reference Compound MDL 107167DA-004
Doses are adjusted for the weight of the individual dihydrochloride and
trihydrochloride salts.
The compounds are stored desiccated within a closed cabinet at room
temperature before use.
Dose levels are prepared on the morning of each study.
A single intravenous cassette dose (18 or 15 mg/kg free base) is administered.
For each
compound, this is equivalent to a dose of approx. 3 mg/kg free base. The
compounds are
dissolved in 5% Dextrose in Water (D5W) at a nominal concentration of 0.3
mg/ml of each
compound (1.8 or 1.5 mg/ml total). The dose is administered at a volume of 10
ml/kg (total
volume of approximately 0.25 ml/animal).
Animals:
Male mice (Hsd:ICR (CD-1 SD ), Harlan), each weighing approximately 20 - 30 g
at the
start of the study. The mice are fasted overnight (approx. 16 h) before
dosing. Food (Certified
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
174
Rodent Diet #5002, PMI Feeds, Inc.) is returned approx. two hours after dose
administration.
Water is available ad libitum throughout the study.
Dose Administration and Sample Collection:
A single cassette dose of 5-6 compounds is administered by bolus injection
into the tail vein
over a 10 - 15-second period. Groups of mice (n=3/timepoint) are anesthetized
with
isoflurane at 0.083, 0.25, 0.5, 1, 3, 6, 8, and 24 h after dosing to draw the
blood sample.
Whole blood (approximately 0.6 ml/sample) is obtained by cardiac puncture and
transferred to.
3 ml glass tubes containing 45 U sodium heparin.
The doses are administered in the morning.
Sainple Processing: Plasma: Whole blood is centrifuged at approximately 3,200
rpm for
min at approximately 5 C and the plasma (approx. 0.3 ml/sample) is transferred
to chilled
plastic vials and stored at approx. -70 C until bioanalysis.
Sample Analysis: Concentrations of each test article in plasma are quantitated
by a
non-validated method based on LC/MS using the following protocol.
Detailed Bioanalytical Methods Summary
Samples are removed from the freezer, allowed to thaw at room temperature, and
vortexed to
insure complete homogenization prior to sample manipulation. Samples are then
prepared
according to the following scheme:
1. transfer 48 L of plasma (blank mouse sample) into a 12 x 75 mm test tube.
2. add 12 L of working standard to the blank plasma for standard curve
preparation.
3. Add 60 l of plasma sample to appropriately labled 12 x 75 mm test tubes.
4. add 60 L of 2% glacial acetic acid in acetonitrile containing internal
standard(a similar
solution containing no internal standard is used for predose time points and
the zero
level standard).
5. vortex for 3 minutes and let sit for 15 minutes.
6. centrifuge for 15 minutes at approximately 4500 rpm.
7. transfer the supematant to injection vials, cap, and re-centrifuge for 5
minutes.
8. Inject 25 L on LC/MS.
Chromatographic Conditions:
CA 02427338 2006-09-25
WO 112/42303 PCT/US01/4483-5
'I'M
Column: 2 x 50mm, 3 , C8 Luna iiianufactured by Phenomenex.
Temperattire: heat to 40 C
Mobile Pliase: gradient
Mobile phase A: 95% DI water and 5% acetonitrile.
Mobile phase B: 95% acetonitrile and 5% DI water.
Buffer and pH are adjusted by adding 250 L of glacial acetic acid
and 100 gL of concentrated ammonium hydroxide to both A and B
mobile phase.
Flow rate: 0.2 ml/min
Injection volume: 25 gL
Retention time: approximately 4.0 minutes
Switching valve: Zero to 3.5 minutes is diverted to iste;
3.5 to 4.5 minutes switch to MS
Mass Spectrometry - Finnigan TSQ-700/SIM
Ioriization mode Positive Electrospray
Manifold pressure 2 x 10"6 ton
ESI spray voltage 4.5 kV
ESI spray current -10 uA
Capillary temp 225 C
Electron multiplier 1600 V
Data Analysis: Concentrations of Compounds in plasma of individual animals are
determined
by bioanalytics. Where appropriate, concentration values in the text and in
the
pharmacokinetic sununary tables, provided below, have been rounded to the
nearest whole
number. The lower limit of quantitation was approximately 1 na/ml plasma for
the test
compounds. Statistical analyses are limited to simple expressions of variation
(mean and
standard deviation). The plasma AUC (area-under-curve) is detemlined by the
linear
trapezoidal rule. Absolute bioavailability (F%) is calculated from the ratio
of the dose-
normalized AUC(0-oo) achieved after intravenous administration. All PK
parameters are
CA 02427338 2006-09-25
W'O 02/32303 PC"I'/US01/4-1835
176
TM
cictcnnincd by noncompartmcntal methods using WinNonlin version 3.0 (Pharsight
Corp).
1'lasina vs. time profiles are prepared by Signla Plot (SPSS, Inc.).
Axitemortem Observations: No apparent adverse effects occurred after any of
the four
cassette doses.
Bioanalytical Results: Plasnla concentration-time profiles are determined for
all of the
CDK compounds.
Plasma Concentrations are provided in Tables 8-16.
Intravenous Dose: Concentrations of Compounds in plasma could be quantitated
for up to 8 h
postdose. Peak measured concentrations of each conipound in the plasma
occurred at 0.083 h
(the earliest sampling time) postdose.
In the CDK compounds, the mean plasma AUC(0-oo) ranged from 366-2550 ng=h/ml.
The
mean terminal elimination half-life of the Compounds in plasina ranged from
0.7-5.1 h
Table 8. Individual and Mean Concentrations of Compounds in Plasma of Mice
Given
Single
18 mg/kg Intravenous Cassette Doses (Cassette #1).
Tin1e (h) 83 12 85 109 111 MDL
Conc. Cone. Cone. Conc. Conc. 107167
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) Conc.
(ng/ml)
0.083 Mean 1515.7 4109.0 843.3 1693.2 2454.1 512.0
SD 611.8 753.5 124.5 224.3 286.7 97.1
0.25 Mean 217.9 2363.5 341.6 914.8 1085.7 360.0
SD 92.8 124.3 45.1 15.2 129.0 127.8
0.5 Mean 61.3 1094.7 163.8 514.3 587.7 297.2
SD 32.9 36.1 15.7 45.2 29.3 4.4
1 Mean 14.13 465.3 89.0 238.1 334.9 146.1
SD 34.6 21.5 38.7 81.3 12.3
3 Mean 4.1a 74.7 14.3 7.1 30.1 33.8 6.8 20.7 6.4
SD 17.4 8.5
6 Mean 1.6a 27.0 2.7 5.2 1.9 9.5 1.8 10.9 3.0 4.5 0.7
SD
a BLQ= below assay quantification limit; BLQ values represented by a numerical
zero in mean calculations;
standard deviations were not calculated.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
-177-
8 Mean 6.3a 16.9 1.4 3.2 0.8 5.5 0.9 6.0 2.0 2.9 0.6
SD
24 Mean BLQ BLQ BLQ BLQ BLQ BLQ
SD
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
178
Table 9. Individual and Mean Concentrations of Compounds in Plasma of Mice
Given
Single 18 mg/kg
Intravenous Cassette Doses (Cassette #2).
Time (h) 3 81 84 154 MDL 819 MDL
Animal Conc. Conc. Cone. Conc. Cone. 107167
No. (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml) (ngConc.
/ml)
0.083 Mean 3254.9 1772.7 1505.7 4854.1 2774.5 + 471.7
SD 383.6 376.6 794.1 545.8 239.2
1046.2
0.25 Mean 1136.0 394.3 882.7 1126.5 624.5 + 316.7
SD 250.2 141.9 140.2 243.1 110.5 42.3
0.5 Mean 516.3 163.5 446.1 377.4 227.6 + 266.0
SD 80.0 47.2 79.0 73.2 68.4 42.7
1 Mean 234.3 65.3 201.5 126.4 100.6 +_ 132.7
SD 63.5 10.0 37.3 12.3 11.5 21.4
3 Mean 36.9 12.7 27.0 2.4 8.4 3.1 24.4+ 16.1 1.4
SD 8.3 3.4 6.7
6 Mean 9.5 5.4 1.5 6.1 0.8 2.3 1.6 15.3+_ 2.8 0.4
SD 3.2 2.7
8 Mean 5.2 3.5 0.9 2.9 0.2 BLQa 12.4 + 1.6 0.2
SD 1.0 1.9
24 Mean BLQa BLQ BLQ BLQa BLQ BLQ
SD
a BLQ= below assay quantification limit; BLQ values represented by a numerical
zero in mean calculations;
standard deviations were not calculated.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
179
Table 10. Individual and Mean Concentrations of Compounds in Plasma of Mice
Given
Single 15 mg/lcg
Intravenous Cassette Doses (Cassette #3).
Time (h) 87 Conc. 149 112 Conc. 88 MDL 107167
Animal (ng/ml) Conc. (ng/ml) Conc. Conc.
No. (ng/ml) (ng/ml) (ng/ml)
0.083 Mean 1171.4 3114.5 2808.0 1483.3 520.1 69.3
SD 153.4 702.6 271.9 272.5
0.25 Mean 371.9 1696.2 420.9 323.6 32.3
SD 35.9 419.0 69.8 311.7 49.9
0.5 Mean 141.4 133.3 10.2 435.0 48.0 150.2 5.9 209.2 24.1
SD 9.5
1 Mean 65.0 59.8 17.3 175.3 42.4 74.6 16.1 107.8 29.3
SD 14.0
3 Mean 19.2 15.5 4.8 45.0 7.2 24.8 7.4 23.5 6.4
SD 6.0
6 Mean 4.3 0.7 4.1 2.1 17.7 1.7 8.9 1.6 5.0 0.5
SD
8 Mean 3.2 1.6 5.4 0.5 13.6 3.7 5.4 2.0 2.4 1.7
SD
24 Mean BLQa BLQ BLQ BLQ BLQ
SD
a BLQ= below assay quantification limit.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
180
Table 11. Individual and Mean Concentrations of Compounds in Plasma of Mice
Given
Single 15 mg/kg
Intravenous Cassette Doses (Cassette #4).
Time (h) MDL 818 82 89 106 MDL 107167
Animal Conc. Conc.
No. Conc. Conc. Conc.
(ng/ml) (ng/ml) (ng/ml) (ng/ml) (ng/ml)
0.083 Mean 482.0 1458.0 642.0 764.8 64.3 567.3 43.5
SD 65.5 77.4 49.5
0.25 Mean 444.9 7.1 875.3 303.3 396.7 59.2 491.3 32.3
SD 96.7 34.3
0.5 Mean 360.6 369.6 142.4 2.7 184.8 13.0 325.3 13.6
SD 15.7 40.0
1 Mean 146.9 133.7 52.4 4.2 63.3 0.5 145.1 9.5
SD 16.7 16.3
3 Mean 28.5 4.4 37.5 17.0 4.7 21.8 6.1 35.3 8.3
SD 10.7
6 Mean 6.1 0.5 14.5 3.4 3.7 1.0 4.3 0.8 10.1 3.0
SD
8 Mean 1.9 0.4 12.3 2.2 3.8 0.5 BLQa 3.7 0.7
SD
24 Mean BLQ BLQ BLQ BLQ BLQ
SD
The following information is based on a graph of the semi-log of the plasma
concentration in ng/ml versus collection time in hours.
"Cmax" represents the maximum plasma concentration.
"tli2" represents the half-life of the compound.
"AUCo_~" represents the calculated area under the curve.
"AUC% Extrap(obs.)" represents the extrapolated area under the curve.
"Cls" is the clearance rate.
a BLQ= below assay quantification limit; BLQ values represented by a numerical
zero in mean calculations;
standard deviations were not calculated.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
181
Table 12. Mean Pharmacokinetic Parameter Values for Compounds in Plasma of
Mice Given Single
Intravenous Cassette Doses (Cassette #1).
3 mg/kg/compound (18 mg/kg Total Dose)
83 12 85 109 111 MDL
Parameter (units) 107167
Cmax (ng/ml) a 1515.7 4109.0 843.3 1693.2 2454.1 512.0
t1i2, XZ (h) 0.7 2.3 2.3 2.0 2.0 1.7
AUCo,. (ng=h/ml) 449 2550 467 1109 1460 531
AUC% 0.96 2.2 2.27 1.44 1.18 1.36
Extrap(obs.)
(ng=h/ml)
Cls (ml/min/kg) 111.4 19.6 107.1 45.1 34.2 94.1
Table 13. Mean Pharmacokinetic Parameter Values for Compounds in Plasma of
Mice Given Single
Intravenous Cassette Doses (Cassette #2).
3 mg/kg/compound (18 mg/kg Total Dose)
3 81 84 154 MDL MDL
Parameter (units)
819 107167
Cmax (ng/ml) a 3254.9 1772.7 1505.7 4854.1 2774.5 471.7
t112, XZ (h) 1.3 1.7 1.5 0.8 5.1 1.5
AUCo_~ (ng=h/m1) 1489 660 965 1584 1132 467
AUC% 0.66 1.34 0.67 0.16 8.0 0.73
Extrap(obs.)
(ng=h/ml)
Cls (ml/min/kg) 33.6 75.8 51.8 31.6 44.2 107.1
a Highest measured value.
a Highest measured value.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
182
Table 14. Mean Pharmacokinetic Parameter Values for Compounds in Plasma of
Mice
Given Single
Intravenous Cassette Doses (Cassette #3).
3 mg/kg/compound (15 mg/kg Total Dose)
87 149 112 88 MDL
Parameter (units) 107167
Cmax (ng/ml) a 1171.4 3114.5 2808.0 1483.3 520.1
t1i2, XZ (h) 1.6 1.6 2.8 1.9 1.5
AUCo-. (ng=h/ml) 513 1019 1462 642 452
AUC% 1.41 1.22 3.80 2.27 1.15
Extrap(obs.)
(ng=h/ml)
Cis (ml/min/kg) 97.4 49.1 34.2 77.9 110.7
Table 15. Mean Pharmacokinetic Parameter Values for Compounds in Plasma of
Mice Given Single
Intravenous Cassette Doses (Cassette #4).
3 mg/kg/compound (15 mg/kg Total Dose)
818 82 89 106 MDL
Parameter (units) 107167
Cmax (ng/ml) a 482.0 1458.0 642.0 764.8 567.3
t1i2, X. (h) 1.3 3.0 1.8 1.3 1.5
AUC0 _. (ngeh/ml) 585 944 366 440 627
AUC% 0.60 5.66 2.62 1.82 1.32
Extrap(obs.)
(ng=h/ml)
Cls (ml/min/kg) 85.5 53.0 136.5 113.7 79.7
a Highest measured value.
a Highest measured value.
CA 02427338 2003-04-29
WO 02/42303 PCT/US01/44835
183
Table 16. Mean Pharmacokinetic Parameter Values for MDL 107167 (Reference
Standard) in Plasma of Mice Given Single
Intravenous Cassette Doses.
3 mg/kg MDL 107167 in Cassette Doses
Cassette Cassette Cassette Cassette #4
Parameter (units) #1 #2 #3
Cmax (ng/ml)a 512.0 471.7 520.1 567.3
tiizi X, (h) 1.7 1.5 1.5 1.5
AUCo_.,, (ng=h/ml) 532 467 452 627
AUC% Extrap(obs.) 1.36 0.73 1.15 1.32
(ng=h/ml)
Cls (ml/min/kg) 94.1 107.1 110.7 79.7
There are no apparent adverse effects affter administration of any of the four
cassette doses.
Plasma concentration time profiles are determinable for all of the CDK
compounds.
After the intravenous dose, the mean plasma AUC(0-co) ranged from 366-2550
ng=h/ml. Peak
measured concentrations of each compound in the plasma occurred at 0.083 h
postdose.
a Highest measured value.
